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The kidneys play an essential role in the maintenance of hemostasis by their capacity to 
remove metabolic waste products, electrolytes and water from the body. End stage renal 
disease (ESRD) occurs when the function of the kidneys is impaired towards 5-10% of the 
original capacity, defined by a reduction in glomerular filtration rate (GFR), and decreased 
creatinin clearance rate. 
Over the last decades, the prevalence and incidence of ESRD has increased.1 In 2001, a total 
of 9830 patients on kidney replacement therapy (dialysis and renal transplantation) were reg-
istered in the Netherlands. The incidence of patients with ESRD in 2001 was 100 per million, 
increases with age and male individuals are more commonly affected than females (www.
renine.nl). The average survival of 2-, 5- and 10-years in Europe between 1980 and 1999 was 
67, 35 and 11% in dialysis patients.2 The most common causes of ESRD are chronic hyperten-
sion, glomerulonephritis, polycystic kidney disease, renovascular disease and diabetes mel-
litus.1 The pivotal role of the kidneys in human metabolic homeostasis is exemplified by the 
fact that renal failure has been shown to result in anemia, hypertension, neuropathy, thyroid 
dysfunction and reduced libido.3,4 
Patients with ESRD can rely on kidney replacement therapeutic modalities such as hemo-
dialysis (HD), peritoneal dialysis (PD) or renal transplantation (NTx). During HD treatment (in 
2001 one third of the ESRD patients), the blood is filtered by an artificial kidney. Access to 
the circulatory system is obtained through a surgically created arteriovenous shunt. In ad-
dition, erythropoietin is given regularly during the dialysis session and anticoagulants are 
administered. In general, HD treatment is done on a regular basis (performed every two till 
three days for four till five hours). In PD treatment (13% of the ESRD patients), the peritoneal 
membrane of the patients is used as an artificial kidney. Sterile dialysis fluid is introduced 
into the abdominal cavity for several hours, drained and refreshed several times a day (Con-
tinuous Ambulatory Peritoneal Dialysis = CAPD) or continuously at night (Continuous Cycler-
Assisted Peritoneal Dialysis = CCPD). Kidney transplantation is, in general, a more patient 
friendly form of therapy, since the aim is to restore normal function and homeostasis. In the 
Netherlands, the average time for a ESRD patient to undergo renal transplantation is 4.5 year. 
Renal transplant patients (about half of the ESRD patients) receive their allografts from living 
or cadaveric donors. In 2001, 525 kidney transplantations were carried out in the Netherlands 
(364 cadaveric: 161 living donors). Acute and chronic rejection remains a major clinical hurdle 
despite recent advances in immunosuppressive strategies.5 
Although kidney replacement therapies have proven to be successful in prolonging the life 
expectancy of ESRD patients, several limitations and long-term complications exist.6 Since the 
majority of HD patients has no residual urine output, they have to maintain a fluid restricted 
diet to prevent fluid overload and are thus allowed to consume only approximately 500 mL 







occur, which can result in hypertension, acute pulmonary edema, congestive heart failure 
and consequently death.3,7-10 The interdialytic weight gain (IWG) can be used as an indicator 
of compliance to this fluid restricted diet.11,12 IWG is expressed as the excess amount of fluid 
(in kg) removed during the dialysis. 
Apart from the complications described above, PD is potentially complicated by peritoni-
tis, which is a serious and sometimes lethal side effect.13 Although transplantation is a per-
manent solution in 50% of ESRD patients, long term use of immunosuppressive medication 
can lead to side effects, e.g. gingival overgrowth, opportunistic infections and cancer.14,15 In a 
retrospective analysis comprising 918 patients who had undergone a renal transplantation, 
40% of the recipients had developed cancer after 20 years of immunosuppressive therapy.16
SALIVA, ORAL DRYNESS AND THIRST
Human saliva is a unique fluid, secreted by the major salivary glands (parotid, submandibular 
and sublingual glands) and by hundreds of minor salivary glands located in the palate, lip, 
cheek and tongue (Figure 1). Saliva is predominantly produced in the acinar cells of these 
glands divided into serous and mucous cells.17 Saliva from the sublingual, labial and palatal 
glands are rich in high molecular weight mucins, in contrast to the parotid glands, which 
secrete a more watery or serous type of saliva. The submandibular saliva has a more seromu-
cous character. 
Figure 1. Anatomic location of the major human salivary glands. Pal, palatal glands; dPar, ductus parotidea; SL, 
sublingual gland; dSM, ductus submandibularis; Acc, accessory glands; PAR, parotid gland; SM, submandibular gland (Source: collection Oral 
Biochemistry, ACTA)
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Unstimulated whole saliva (UWS) mostly consists of a mixture of saliva largely derived from 
the sublingual, submandibular and minor salivary glands.18 The salivary flow rate of the pa-
rotid glands can be stimulated both by chewing or the application of e.g. citric acid. Saliva 
formed by the various salivary glands differs in biochemical composition. The mean output of 
amylase, for example, is higher by parotid glands compared to that of submandibular glands. 
The composition of whole saliva is therefore influenced by the net flow rate from the dif-
ferent types of salivary glands and by the various types of stimulation. For example, during 
salivary stimulation of the parotid gland, less sodium and bicarbonate will be resorbed in the 
glandular ducts, resulting in a higher sodium concentration.19 
Under physiological conditions, approximately 500-1000 mL of saliva is secreted every 24 
hours, and its main effect is lubricating and protecting all oral tissues.19 In addition, saliva has 
been shown to exert anti-viral, anti-fungal and anti-bacterial capacity.20-24 Salivary proteins 
such as mucins, glycoproteins and the bicarbonate buffer system in saliva all have protective 
functions as depicted in Figure 2.25 
Hyposalivation is the objectively determined reduction of the salivary flow rate (unstimu-
lated salivary flow rate ≤ 0.15 mL/min)26 and can occur due to several reasons. The main rea-
sons are radiotherapy, the presence of an autoimmune disease or the use of multiple medi-
cation.22,27-29 Signs and symptoms of hyposalivation are reduced lubrication, difficulties with 
speaking, swallowing and eating as well as an increased urge for water intake to moisture 
the oral cavity. Due to reduced protection, patients with oral dryness are prone to microbial 







colonization of the oral mucosa, which can result in an increased susceptibility for fungal 
infections and oral inflammations.30,31
Xerostomia has been defined as the subjective feelings of a dry mouth.32 Reduced salivary 
flow rates and xerostomia are not exclusively linked to each other. In most subjects, xero-
stomia will occur when the salivary flow rate decreases to a level below 50% of the normal 
secretory capacity. 33 Xerostomia is known to negatively influence the patients’ quality of life 
(QoL).24,34 Patients with apparently normal salivary flow rates, however, may also suffer from 
xerostomia. This paradoxical finding is likely to be related with alterations of salivary compo-
sition.35,36
Thirst, the urge to drink, can occur as a consequence of both xerostomia and hyposaliva-
tion.37,38 Besides a dry mouth, thirst is affected by many different factors including high con-
centration in plasma of sodium, potassium depletion, vasopressin, acute increases in plasma 
urea as well as psychological factors.39-46
SALIVA, ORAL DRYNESS AND THIRST IN ESRD
In HD patients, reduced salivary flow rate and thirst have been reported to be closely cor-
related.47-53 In the study by Kho and co-workers, salivary flow rates in 22 HD patients and 22 
controls were compared. The salivary flow rate measured on a non-dialysis day of the patients 
was statistically significantly lower than that of the controls (0.30 ± 0.18 versus 0.45 ± 0.25 
mL/min respectively; P < 0.05).49 In another study with 72 dialysis patients, stimulated whole 
saliva was collected before a HD session. The mechanically stimulated salivary flow rate was 
found to be significantly reduced in HD patients, compared with healthy controls (0.69 ± 0.31 
versus 1.64 ± 0.44 mL/min, respectively P < 0.001).54 
It should be noted that the circadian cycle has, under healthy conditions, also a large effect 
on salivary flow rate and dialysis treatment may influence this effect. Therefore, the above 
mentioned studies might be hampered by the moment of collection.55,56 
Besides an effect on the salivary flow rate, it has been shown that renal replacement thera-
py such as HD could also affect the biochemical composition of saliva.47,57,58 However, no large 
scale studies have been carried out to investigate the effect of NTx or PD on the salivary flow 
rates and composition. Patients with renal failure and consequently high urea concentrations 
in serum also display high urea levels in saliva, since urea is passively distributed from serum 
towards saliva.58 Most studies on salivary flow rate and composition in dialysis patients have 
been carried out on a non-dialysis day. The salivary flow rate appeared to be reduced com-
pared to controls.49,50 In addition, a few studies have investigated the effect of dialysis on the 
composition of saliva and revealed a markedly decrease of urea and a small decrease of the 
anti-oxidant status in dialysis patients.47,57 
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In the literature, the prevalence of xerostomia in patients on hemodialysis ranges between 
33 and 76%.12,48,59 Besides xerostomia, thirst is one of the most frequently occurring symp-
toms in ESRD patients.60,61 The combination of the fluid restricted diet, high plasma sodium 
concentration, psychological factors and acute increases in plasma urea may all contribute 
to perceived thirst.39,62,63 No validated thirst assessment test was described in literature at the 
moment of beginning the studies presented in this thesis. We therefore developed a ques-
tionnaire for HD patients: the Dialysis Thirst Inventory (DTI).12
Since ESRD patients have to deal with oral dryness it is conceivable that xerostomia and 
thirst are factors that contribute to the intake of fluid in HD patients and – consequently – to 
the IWG. We hypothesize that oral dryness is associated with the urge to drink or to moisten 
the mouth and throat.12 
ESRD AND ORAL HEALTH
In general, oral health is influenced by many factors. Diet, level of oral hygiene, use of fluo-
ride, presence of commensally microorganisms, genetic factors, ageing, systemic diseases, 
medication and the amount and ‘quality’ of saliva all have been described to play a pivotal 
role in the net state of oral health.21,27,64 In ESRD patients, the oral health could also negatively 
be affected by the underlying pathology, the dialysis treatment, oral dryness or an altered 
salivary composition.47,49,54,65,66 Renal failure is associated with vomiting, oral malodor and 
xerostomia which could all affect the oral health of these patients.60,67 Oral manifestations 
that have been reported include mucosal lesions, oral infections, dental anomalies and bone 
lesions due to secondary hyperparathyroidism, gingivitis, mucosal pallor and lesions, an al-
tered microbiological environment, tooth mobility, malocclusion and an increased risk for 
dental erosion.65-72
Chronic dialysis could retract the attention from oral health towards more important mat-
ters, regarding life and death. Several studies have reported that the oral self care of ESRD 
patients is reduced compared to controls.66,73 On the other hand, maintaining oral health at 
a high level is in any case very important for those HD patients waiting for a renal transplant 
since oral pathologies or infections could jeopardize the success of the transplantation.74-76 
Conflicting data have been reported in literature on the effect of chronic dialysis therapy 
on oral health status.48,66,77,78 In a study, comprising a cohort of 53 hemodialysis patients, the 
number of decayed missing and filled teeth (DMFT) and the Loss of Periodontal Attachment 
(LPA) did not differ from an age- and gender-matched controlgroup.48 In ESRD patients, both 
increased and decreased rates of dental caries have been reported.66,68,79 A study of Bayraktar 
and colleagues showed no difference for the number of decayed, missing or filled teeth be-
tween adult HD patients and controls.54 Increased salivary urea levels could enhance calculus 







leading to lower caries incidence, which has been shown for example in children with chronic 
renal failure (CRF).80 
AIMS AND OUTLINE OF THE THESIS
This thesis comprises a number of studies aiming to provide insight in the acute and long 
term effects of dialysis on oral dryness (salivary flow rate and xerostomia), thirst and oral 
health in ESRD patients. Furthermore, the aim was to assess the relationship between oral 
dryness (defined as reduced salivary flow rates and xerostomia), thirst and IWG in patients on 
hemodialysis, and to investigate potential therapies to reduce oral dryness and consequently 
IWG.
First, the acute effects of HD on the salivary flow rate and composition were studied before, 
during and after a dialysis session (Chapter 2). To unravel the association between oral dry-
ness and fluid-intake in HD patients, we investigated in HD patients the relation between 
IWG, thirst and oral dryness (Chapter 3). 
The oral health of dentate ESRD patients on dialysis treatment was assessed and compared 
to a healthy reference group (Chapter 4). In a two-year follow up study, the oral health, sali-
vary flow rates, thirst and xerostomia were compared of those patients that received a renal 
transplant with those remaining on dialysis (Chapter 5). 
Since it appeared that chewing could stimulate the salivary flow rate in healthy subjects 
(Appendix) and HD patients, we investigated the effect of chewing gum and artificial saliva 
on IWG, salivary flow rate, xerostomia and thirst in a crossover study (Chapter 6). The more 
subjective reports and preferences of the HD patients between chewing gum and artificial 
saliva were explored in Chapter 7. Finally, in Chapter 8, we discuss the results of our studies. 
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Major systemic changes occur during hemodialysis (HD), which could affect the flow rate 
and biochemical composition of saliva. Therefore, the aim of this study was to evaluate acute 
effects of HD on the salivary flow rate, pH and biochemical composition before, during and 
after completion of a dialysis session.
Methods
In 94 HD patients, unstimulated whole saliva (UWS) and chewing-stimulated whole saliva 
(CH-SWS) were collected immediately before, during and after a dialysis session. Salivary flow 
rate, pH, concentration of total protein, albumin, cystatin C and of sodium, potassium and 
urea were measured. 
Results 
Hemodialysis had an acute stimulating effect on the salivary flow rate (UWS before = 0.30 ± 
0.22 mL/min; UWS during = 0.39 ± 0.25 mL/min; P < 0.005). The mean pH of UWS showed a 
small but significant increase during dialysis (pH before
 
= 7.16 ± 0.58 to pH during = 7.31 ± 
0.49; P < 0.005). The concentrations of the biochemical constituents (total protein, albumin, 
cystatin C and S-IgA) in whole saliva changed markedly, but no significant difference in out-
put was found. Also the electrolyte concentration did not change during dialysis. The level 
of urea in CH-SWS declined with 40% (urea before = 25.6 ± 6.4 mmol/L, urea during = 15.3 ± 
4.5 mmol/L). 
Conclusions 
This study shows that HD has significant acute effects on both salivary secretion rate and pro-
tein concentrations in saliva. We conclude that the observed changes in salivary concentra-
tions and proteins are mainly due to an increased watery secretion from the salivary glands. 
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INTRODUCTION
Patients with end stage renal disease (ESRD) have to undergo kidney replacement therapy 
such as hemodialysis (HD), peritoneal dialysis or renal transplantation. The aim of HD treat-
ment is to remove metabolic waste products such as urea, and to remove excess fluid from 
the body of the patients to restore circulatory volume. HD treatment, which is carried out on 
average three times a week during a three till four hours session, has major effects on the 
serum composition and fluid-balance. Furthermore, it had been shown to affect the flow rate 
and biochemical composition of saliva.1-3 
HD patients show reduced unstimulated and mechanically stimulated salivary flow rates 
compared to controls, both before dialysis sessions and on interdialytic days.4-8 In chapter 
3, we will demonstrate that hyposalivation and xerostomia are correlated with thirst in HD 
patients.9 Therefore, it seems feasible to presume that reduced thirst feelings during and after 
HD treatment could potentially be caused by a concomitantly increase of salivary flow rate. 
In addition, several serum components such as albumin or urea are in equilibrium with the 
concentration in saliva. Therefore, saliva can potentially be used to monitor changes in con-
centration of serum proteins and electrolytes.10
However, until now it is still unclear whether a HD session has acute effects on the salivary 
flow rate and composition. Therefore, the aim of this study was to evaluate several salivary 
parameters including flow rate, pH and biochemical composition before, during and after 
completion of a HD session.
MATERIALS AND METHODS
Participants
Ninety-four patients with ESRD undergoing HD treatment were recruited from four different 
dialysis centers. Inclusion criteria were ≥ 18 years old and ≥ three months on HD. The subjects 
were dialyzed three to four times a week for approximately three hours. Each subject signed 
an informed consent and agreed to participate in a follow-up study to investigate the effect 
of HD treatment on saliva and oral health.9 This study was approved by the Medical Ethical 
Committee of the Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
Data collection 
Demographic variables were assessed with a questionnaire, as described in Chapter 3.9 
Clinical data with regard to hemodialysis were retrieved from a database (Diamant®, Diasoft, 
Leusden, the Netherlands) and included the primary renal disease (according to the classifi-
cation of the European Dialysis and Transplantation Association-European Renal Association 









 (removal of urea by dialysis a week). Systolic (SBP) and diastolic blood pressure (DBP) 
was measured before and after the hemodialysis session.
Collection of saliva
Unstimulated whole saliva (UWS) and chewing-stimulated whole saliva (CH-SWS) were col-
lected immediately before a dialysis session (before = baseline), one hour after the start of the 
dialysis (during) and directly after completion of the dialysis session (after). All subjects were 
instructed to refrain from smoking, eating, drinking and tooth brushing for one hour prior to 
the three saliva collection periods. In each patient, the samples were collected during one 
dialysis session.
UWS was collected according to the spitting method12 with small modifications.9,13 Before 
collection, the mouth was rinsed with tap water. The collection started with the instruction to 
void the mouth of saliva by swallowing. Subsequently, saliva was allowed to accumulate on 
the floor of the mouth and the subjects were instructed to spit out into the pre-weighed test 
tubes every 30 seconds. Each saliva collection period was five minutes. 
CH-SWS was collected for five minutes using a piece of parafilm (5 x 5 cm; 0.30 g; Parafilm 
“M”, American National CAL, Chicago, USA). During the saliva collection period, the subjects 
chewed at their own natural pace and stimulated saliva was collected in the same way as the 
unstimulated samples.
The volume of saliva was determined gravimetrically (assuming 1 g = 1 mL) and the pH was 
determined within five minutes after saliva collection (Sentron pH-system 1001, Roden, The 
Netherlands). Hereafter, saliva was homogenized by vigorous shaking for one minute using 
a vortex mixer and centrifuged (10 minutes at 10 000 g, room temperature), to eliminate cel-
lular debris. The supernatant was divided into 500 µL aliquots, frozen at -70 ºC and stored at 
-20 ºC until further analysis. The total time for collection and preparation of the saliva samples 
took approximately 30 minutes, during which the test tubes were kept on ice.
Biochemical analysis of saliva 
The total protein concentration in saliva was determined by the bicinchoninic acid method 
and expressed as mg/L. Bovine serum albumin was used as a standard.14
Albumin, a serum protein present in saliva, was quantified with a sandwich enzyme-linked 
immunosorbent assay (ELISA), as previously described.15 Briefly, high-affinity microtiter plates 
(Greiner, Hannover, Germany) were coated with 1.7 μg/mL of purified immunoglobulins 
against human albumin (Dakopatts, Glostrup, Denmark). Bound albumin was detected using 
peroxidase-conjugated rabbit antihuman albumin (Dakopatts). The optical density at 490 nm 
was measured with an MR 7000 microtiter plate reader (Dynatech, Billinghurst, UK).
The protein cystatin C, present in serum and saliva, was determined in saliva using a sand-
wich ELISA.16 Secretory immunoglobulin A (S-IgA), a protein secreted by the parotid and 
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submandibular salivary glands, was quantified using the method described by Bosch and 
co-workers.13
Sodium, potassium and urea (urea nitrogen) were determined in saliva using an automat-
ed clinical chemistry analyzer (Roche/Hitachi Modular P800, Roche Diagnostics, Mannheim, 
Germany). Sodium and potassium were determined using ion-selective electrodes.17 The test 
principle for the urea determination was an enzymatic procedure using the coupled urease/
glutamate dehydrogenase enzyme system optimized to permit kinetic (fixed time) measure-
ments.18 The electrolyte concentrations were expressed as mmol/L.
All saliva samples were assayed in duplicate. Output of saliva components was calculated 
by multiplying the salivary flow rate (mL/min) with the concentration (mg/mL), resulting in 
mg/min or mmol/min.
Statistical methods
Data are presented as mean ± SD. Since the salivary flow rate and the biochemical con-
stituents showed a skewed distribution, these data were logarithmically transformed (log10) 
before statistical analysis. For readability, the original (untransformed) data are presented. 
Overall differences of the measured variables between the three measurements were ana-
lyzed applying repeated-measures multivariate analysis of variance (MANOVA). We applied 
MANOVA three times; once for the differences between first and second measurement, once 
for the differences between second and third measurement and finally for the difference 
between the first and last measurement. When the multivariate difference showed statistical 
significance, differences between the individual variables were further explored by paired 
t-tests as post-hoc procedures. Data at baseline (before dialysis) were stratified with regard 
to time on dialysis (≤ 24 and > 24 months) and analyzed using analysis of variance (ANOVA). 
Statistical analysis was performed using the statistical software package SPSS (version 10.0, 
SPSS Inc., Chicago, IL, USA). Levels of significance were set at P < 0.05.
RESULTS
Patients demographics
Ninety-four patients with end-stage renal disease (ESRD) undergoing hemodialysis, 64 men 
(mean age 54.8 ± 15.5 years) and 30 women (mean age 59.5 ± 18.7 years) participated in this 
study. The clinical data are presented in Table 1. The mean time of treatment on hemodialysis 
was 35.8 ± 31.0 months, (range 3–188 months) and the Kt/V
week
 was 3.6 ± 1.1. The causes of 
chronic renal failure in the study population were renal vascular disease due to hypertension 
(16.0%), polycystic kidneys adult type (11.7%), glomerulonephritis (10.6%), miscellaneous 







Salivary flow rate and pH
The mean unstimulated salivary flow rate increased significantly with 30% within the first 
hour of dialysis and remained increased after the dialysis session (UWS before = 0.30 ± 0.22 
mL/min; UWS
 
during = 0.39 ± 0.25 mL/min; UWS after = 0.41 ± 0.25 mL/min, P < 0.001), see 
Table 2. The stimulated salivary flow rate (CH-SWS) showed a 17% increase during the first 
hour of dialysis and remained constant thereafter. Salivary flow rates of UWS and CH-SWS 
were well within the range of the normal salivary flow rate values for healthy subjects (refer-
ence value UWS = 0.30 ± 0.20 mL/min; pH = 6.7 ± 0.7).19
At baseline (before), male subjects had significantly higher flow rates of both UWS before 
(0.34 ± 0.22 mL/min) and CH-SWS before (1.21 ± 0.69 mL/min) compared to female subjects 
(UWS before = 0.21 ± 0.21 mL/min; CH-SWS before = 0.74 ± 0.6 mL/min, P < 0.01). 
The mean pH of UWS showed a small but significant increase during dialysis, pH before = 
7.16 ± 0.58 to pH during = 7.31 ± 0.49 (P < 0.005), but dropped to pH after
 
= 6.68 ± 0.54 (see 
Table 2). The mean salivary pH of CH-SWS showed a similar small initial increase (pH = 7.34 ± 
Table 1. Clinical data of HD patients (n = 94)
Mean (SD) Range
Mean age (year) 56.4 (16.7) 20 – 85
Mean time since first dialysis (months) 35.8 (31.0) 3 – 188
Mean IWG (kg) 2.2 (1.3) 0.0 – 5.6
Mean Kt/V 
week
3.6 (1.1) 0.9 – 6.0
Mean SBP
before
 (mm Hg) 146 (22) 90 – 195
Mean DBP
before
 (mm Hg) 81 (13) 50 – 113
Abbreviations are: IWG, interdialytic weight gain; Kt/V, removal of urea by dialysis a week, V, volume of distribution of urea estimated as 55% of 
body weight; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 2. Flow rate and composition of unstimulated (UWS) and chewing stimulated (CH-SWS) saliva before, during and after dialysis (n = 94)
UWS CH-SWS
Before During After Before During After
Flow rate (mL/min) 0.30 (0.23) 0.39 (0.25)a 0.41 (0.25)a 1.05 (0.71) 1.27 (0.83)a 1.23 (0.74)a
pH 7.2 (0.6) 7.3 (0.5)a 6.7 (0.5)a,b 7.3 (0.5) 7.4 (0.9) 6.9 (0.9)a
Total protein (mg/L) 2413 (1080) 1968 (1185)a 1624 (1127)a,b 2215 (1171) 1502 (1108)a 1354 (816)a,b
Albumin (mg/L) 68.1 (60.5) 60.8 (58.5)a 42.9 (45.3)a,b 55.2 (62.0) 37.3 (47.9) 30.9 (30.2)a,b
Cystatin C (units) 1.6 (1.7) 1.3 (1.5)a 1.3. (1.1)a 1.1 (1.0) 0.8 (0.6)a 1.0 (0.6)
S-IgA (mg/L) 385 (293) 320 (266) 216 (168)a 301 (380) 259 (432)a 182 (179)a
Sodium (mmol/L) 14.0 (9.6) 12.6 (8.0) 11.3 (7.5)a 15.8 (11.8) 15.8 (12.5) 13.3 (11.3)a,b
Potassium (mmol/L) 32.2 (11.1) 29.6 (10.7) 26.8 (7.9) 35.0 (11.5) 30.6 (8.5) 29.4 (7.8)
Urea (mmol/L) 24.7 (7.0) 17.4 (5.1)a 10.5 (3.4)a,b 25.6 (6.4) 15.3 (4.5)a 9.6 (3.2)a,b
Data are expressed as mean (SD) before, during and after dialysis (n = 94).
a = significant difference with measurement before dialysis (P < 0.05)
b = significant difference with measurement during dialysis (P < 0.05)
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0.48 before to pH = 7.39 ± 0.90 during dialysis), although no statistical differences were found. 
After dialysis, the salivary pH of CH-SWS was decreased till pH = 6.87 ± 0.86 (P < 0.001). 
The total period on dialysis (≤ 24 months; > 24 months) had no effect on either the salivary 
flow rate or pH of both UWS and CH-SWS (data not shown).
Concentration and output of biochemical constituents
One hour after the start of the dialysis session (during), the concentration of total protein, 
albumin, cystatin C and S-IgA was declined in UWS and remained reduced throughout the 
dialysis session, see Table 2. In CH-SWS, the concentration of total protein, albumin, cystatin 
C and S-IgA declined in the first hour of dialysis and remained declined after dialysis.
However, the output of protein constituents in UWS (total protein, albumin, cystatin C and 
S-IgA) did not differ after one hour from the start of the dialysis treatment. Also no differences 
were observed comparing the protein output before and after dialysis, see Table 3.
The concentration of sodium and potassium in UWS and CH-SWS during HD did not change 
compared to the levels before dialysis. However, after dialysis the sodium concentration in 
both UWS and CH-SWS decreased significantly, see Table 2. On the other hand, the output of 
sodium and potassium did not change in the first hour of dialysis. After dialysis, the output 
was significantly decreased, compared to the levels before dialysis
The average concentration in UWS of urea, a salivary constituent distributed by passive dif-
fusion, decreased significantly by 30%, during dialysis. In CH-SWS the average decline during 
dialysis was even by 40% (urea before = 25.6 ± 6.4 mmol/L, urea during = 15.3 ± 4.5 mmol/L), 
see Table 2. The output of urea in UWS and CH-SWS after dialysis decreased on average with 
60%, compared to the output before.
Table 3. Output of biochemical components of unstimulated (UWS) and chewing stimulated saliva (CH-SWS) before, during and after dialysis 
(n = 94)
UWS CH-SWS
Before During After Before During After
Total protein (mg/min) 657 (464) 663 (472) 575 (403) 1970 (1153) 1537 (991)a 1393 (834)a
Albumin (mg/min) 15.6 (14.5) 17.5 (15.1) 13.8 (14.2)b 39.8 (31.9) 31.9 (26.3)a 29.4 (25.3)a
Cystatin C (units/min) 0.5 (0.7) 0.4 (04) 0.6 (0.6) 1.1 (1.2) 1.1 (1.2) 1.3 (1.3)a,b 
S-IgA (mg/min) 90.2 (76.2) 103.6 (93.0) 79.0 (63.5) 220.9 (3.7) 201.5 (172.0) 171.4 (136.7)a,b
Sodium (mmol/min) 4.4 (4.6) 4.1 (4.3) 3.7 (4.2)a 4.4 (4.4) 4.5 (4.5) 3.7 (4.1)a,b
Potassium (mmol/min) 10.7 (7.8) 9.7 (6.9) 8.9 (6.4)a 9.9 (7.2) 8.9 (6.7) 8.7 (6.7)
Urea (mmol/min) 8.5 (6.5) 5.8 (4.2)a 3.5 (2.7)a,b 7.5 (5.2) 4.5 (3.4) 2.9 (2.3)a,b 
Output (mg/min; mmol/min) is expressed as mean (SD).
a = significant difference with measurement before dialysis (P < 0.05)








To our knowledge, this is the first large-scale study to investigate acute effects of hemodialy-
sis on the salivary flow rate and composition of saliva. It was found that HD treatment had 
an acute stimulating effect on the salivary flow rate. The concentrations of the biochemical 
constituents in whole saliva changed markedly, although the average output in absolute 
terms remained relatively stable.
Only a few studies exist in which saliva of HD patients had been investigated. Unfortu-
nately, two studies which investigated salivary variables before and after HD, did not provide 
salivary flow rate values, so that only concentrations could be compared.10,20 Other studies 
in which saliva was collected before dialysis showed reduced flow rates of CH-SWS in HD 
patients (0.69 ± 0.31 mL/min) compared to healthy controls (1.64 ± 0.44 mL/min).4,5 Citric 
acid (2%) stimulated salivary flow rates in HD patients on interdialytic days also tended to 
be decreased in HD patients compared to controls.8 The findings of Kho and colleagues, who 
investigated the flow rate of UWS on a interdialytic day (0.30 ± 0.18 mL/min), are comparable 
to our findings of UWS before HD treatment (UWS before = 0.30 ± 0.23 mL/min).7 In our study, 
both the unstimulated and chewing stimulated salivary flow rates before dialysis were well 
within the range of normal salivary flow rates of healthy subjects.19
The total protein concentration decreased significantly comparing before and after dialysis. 
This observation is in accordance with the study of Meucci and co-workers in which a trend 
was observed for reduced protein levels after dialysis (3.3 ± 3.9 mg/L) compared to before 
(5.5 ± 6.2 mg/L).20 Although the salivary proteins measured in our study may differ in ori-
gin (serum, serum/saliva and saliva), the protein concentrations in saliva decreased during 
and after HD treatment. The relative contribution of albumin and S-IgA to the total protein 
concentration did not differ before and after dialysis in UWS and CH-SWS (data not shown). 
This illustrates that the level of albumin or S-IgA does not influence the total protein con-
centration in saliva, suggesting that the salivary glands maintain a normal function and no 
basement membrane defect seems to be present in HD patients.2
Under normal physiological circumstances, the composition of saliva differs from that in 
serum with respect to several constituents. Saliva secretion is primarily controlled by the 
mechanisms for sodium and chloride secretion, since fluid transport follows electrolyte 
transport. As the salivary flow rate increases, saliva passes through the striated ducts before 
re absorption of NaCl is complete. Therefore, the sodium and bicarbonate concentrations 
increase with increased flow rates, resulting in a higher salivary pH.19
Table 4 provides reference values for both whole human saliva and serum in healthy indi-
viduals. At all the time points in our study, the potassium concentration in UWS and CH-SWS 
maintained unchanged, which was expected and which is in agreement with an earlier study 
among children on hemodialysis.10 In our study, the increased salivary flow rate did not cor-
relate, however, with an increased salivary sodium concentration. This may be explained by 
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the fact that HD patients are dialyzed against solutions containing sodium bicarbonate or 
acetate solutions, which could have influenced the electrolyte management in the salivary 
glands. Therefore, we conclude that the observed changes in salivary concentrations and 
proteins are mainly caused by the diluting effect of an increased fluid flow during dialysis 
instead of an altered protein secretion during dialysis.
In our study, the urea concentration of saliva was elevated before dialysis (24.7 ± 7.0 
mmol/L), decreased significantly during the HD session and was the lowest after dialysis (10.5 
± 3.4 mmol/L). These changes are in accordance with other biochemical studies measuring 
the urea levels before and after HD treatment.2,10 This illustrates that urea diffuses passively 
from the serum through the salivary glands, suggesting that the decrease in salivary urea 
concentration during HD treatment potentially could be used to monitor the efficacy of HD 
treatment.
Several other mechanisms and underlying factors potentially affecting the salivary flow 
rate could be explored. The salivary flow rate might be influenced by changes in blood pres-
sure during dialysis. Due to an increased extra cellular fluid volume before HD, most patients 
have to deal with hypertension. In patients without chronic renal failure, hypertension per 
se is not related to the salivary flow rate.21,22 During the HD sessions, on average 2.2 liter of 
excess fluid was removed. Under normal conditions, a reduction of plasma volume leads to 
a reduction in the secretion of saliva.23,24 Our results show, however, that the opposite takes 
place during HD treatment.
An alternative hypothesis for the increased salivary flow rate might be an altered aquapo-
rine expression in the salivary glands due to HD treatment. Aquaporines (AQP) are water-se-
lective channels that are responsible for the transport of small uncharged molecules such as 
water through cell membranes. In patients with primary Sjögren’s syndrome, the expression 
of AQP-1 in myoepithelial cells surrounding salivary acini is decreased by 38%, which might 
contribute to the reduced salivary flow rates of those patients.25 The potential role of AQP is 
supported by the observation that changes in plasma osmolality during HD induces AQP-1 
expression on the membrane of intact red blood cells.26 However, an effect in the salivary 
glands was not studied. 
Table 4. Reference values of pooled unstimulated whole saliva (UWS ; n = 10) and plasma
UWS Plasma
Total protein (mg/L) 1057 60000-80000
Albumin (mg/L) 61 35000-55000
Cystatin C (mg/L) 1.1 1.1
S-IgA (mg/L) 138 -
IgA (mg/L) 194 800-3100
Sodium (mmol/L) 12.2 135-145
Potassium (mmol/L) 22.7 4.0







We realize that our results may be biased by several factors. Since acute stress reduces the 
salivary flow rate, it might be possible that due to the relaxation during the hemodialysis 
session the salivary flow rate increased. Reduced flow rates could also be influenced by the 
time of measurement during the day.27 As described in Chapter 3, no diurnal differences in sa-
liva secretion rates were observed between HD patients treated in the morning versus those 
treated in the afternoon.9 
CONCLUSION
This study shows that HD has significant acute effects on both salivary secretion rate and 
protein concentrations in saliva. 
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Patients receiving hemodialysis (HD) have to maintain a fluid-restricted diet. Severe thirst can 
induce non-compliance to this diet, resulting in an increase of interdialytic weight gain (IWG 
= weight predialysis minus postdialysis) associated with poor patient outcomes. Since oral 
dryness may contribute to experienced thirst, we investigated the possible relation between 
thirst, salivary flow rate, xerostomia and IWG. 
Methods
Unstimulated (UWS) and stimulated (CH-SWS) whole saliva were collected from 94 HD pa-
tients (64 men: 54.8 ± 15.5 years; 30 women: 59.5 ± 18.7 years). Secretion rates of saliva were 
determined gravimetrically. Xerostomia was assessed with a validated Xerostomia Inventory 
(XI) and thirst with a newly developed Dialysis Thirst Inventory (DTI). 
Results
Before dialysis, 36.2% of the patients had hyposalivation (UWS ≤ 0.15 mL/min). The XI scores 
had a positive relation with IWG (r = 0.250, P < 0.001). Gender and age differences were ob-
served for thirst, salivary flow rates and xerostomia. The prevalence and severity of thirst and 
xerostomia were greater in younger subjects. Patients with urine-output did not differ from 
those without urine-output with respect to thirst, xerostomia and IWG. Correlations were 
found between thirst (DTI) and both IWG and xerostomia (XI) (r = 0.329, P < 0.001, respec-
tively; r = 0.740, P < 0.001). Other correlations were observed between xerostomia and both 
the salivary flow rate and total number of medications (r = -0.252, P < 0.05, respectively; r = 
0.235, P < 0.05). 
Conclusions
In HD patients, xerostomia (XI) and thirst (DTI) are associated with a higher IWG. Our data 
provide evidence that, in HD patients, xerostomia is related to both salivary flow rate and 
thirst (DTI).
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INTRODUCTION
Patients with end stage renal disease (ESRD) on hemodialysis (HD) have to maintain a fluid 
restricted diet to prevent fluid overload.1 During hemodialysis excess fluid is removed to nor-
malize extracellular fluid volume and blood pressure. For many HD patients, however, it is 
difficult to adhere to this fluid restriction. Chronic fluid overload can result in hypertension, 
acute pulmonary edema, congestive heart failure and premature death.2-6 The interdialytic 
weight gain (IWG) is an indicator of compliance to the fluid restricted diet, and is influenced 
by social and psychological factors, but foremost by physical factors like excessive thirst.3,4,6-8
Thirst or “the urge to drink” is affected by many different factors including sodium intake, 
high plasma sodium, potassium depletion, angiotensin II, acute increases in plasma urea, low 
dry weight (postdialysis hypovolemia) and psychological factors.7-10 Besides thirst, a subjec-
tive feeling of a dry mouth (xerostomia) could also be a potential important stimulus for 
water intake.11-13 Patients with xerostomia caused by radiation therapy, for example, report an 
increased water consumption in order to facilitate eating, articulation and speech.14 Xerosto-
mia has also been reported in patients on HD.15 In addition, other studies showed impaired 
saliva secretion in HD patients compared to healthy controls.16-21 Therefore, it is conceivable 
that xerostomia is one of the factors that contributes to the intake of fluid of HD patients and 
– consequently – to the IWG. The aim of the present study was to establish whether aspects 
of oral dryness, in particular salivary flow rate and xerostomia, are related to thirst and IWG 
in HD patients. 
METHODS
Participants
ESRD patients, undergoing HD for at least three months, were recruited from four different 
dialysis centers. Ninety-four patients on HD gave informed consent for this study, which was 
approved by the Medical Ethical Committee of the Vrije Universtiteit Medical Center, Amster-
dam, The Netherlands. 
Age, gender, level of education, ethnic background, smoking habits, and use of alcohol 
were assessed with a questionnaire. Clinical data with regard to HD were retrieved from pa-
tient files in each participating center and are presented in Table 1. The pathology causing 
the chronic renal failure was classified according to the European Dialysis and Transplantation 
Association-European Renal Association.22 The medication of the patients was categorized as 
potentially causing salivary hypofunction (putatively xerogenic) or not (nonxerogenic).23,24 
Patients were weighed before and after a dialysis session. IWG was defined as the amount of 







assumption that all the weight gained in the previous interdialytic interval was lost during 
the dialysis session.5,25 
Saliva collection
Unstimulated and chewing-stimulated saliva samples were collected before HD. All subjects 
were instructed to refrain from smoking, eating, drinking and tooth brushing for one hour 
prior to the saliva collection.
Unstimulated whole saliva (UWS) was collected according to the spitting method26 with 
some small modifications.27 Several minutes before collection, the participants rinsed their 
mouth with tap water. The collection started with the instruction to void the mouth of saliva 
by swallowing. Subsequently, saliva was allowed to accumulate in the floor of the mouth and 
the subjects were instructed to spit out into pre-weighed test tubes every 30 seconds. The 
saliva collection period was five minutes.
Chewing-stimulated whole saliva (CH-SWS) was collected for five minutes using a tasteless 
piece of parafilm (5 x 5 cm; 0.30 g; Parafilm “M”, American National CAL, Chicago, USA). Dur-
ing the saliva collection period, the subjects chewed at their natural pace. The mechanically 
stimulated saliva was also spitted out into preweighed test tubes every 30 seconds for five 
minutes. 
Saliva volumes were determined gravimetrically (assuming 1 g = 1 mL). Salivary hypofunc-
tion was defined as ≤ 0.15 mL/min UWS.28
Assessment of xerostomia and thirst 
During the dialysis session, all participants completed the Dutch translation of the validated 
Xerostomia Inventory (XI), which consists of 11 items, each with a five-point Likert-scale 
(never = 1 to very often = 5), see Table 2.29,30 Examples of items from the XI are “My mouth 
feels dry”, “I have difficulty in eating dry foods” and “I sip liquids to aid in swallowing food”. 
The responses to the 11 items were summed, which results in an individual XI score for each 
patient that ranges from 11 (no dry mouth) to 55 (extremely dry mouth). 
Table 1. Clinical data (n = 94)
Mean (SD) Range
Mean age (years) 56.4 (16.7) 20 – 85
Mean time since first dialysis (months) 35.8 (31.0) 3 – 188
Mean IWG (kg) 2.2 (1.3) 0.0 – 5.6
Mean Kt/V
week
3.6 (1.1) 0.9 – 6.0
Mean SBP (mm Hg) 146 (22) 90 – 195
Mean DBP (mm Hg) 81 (13) 50 – 113
Mean number of systemic medication (n) 9.8 (3.7) 3 – 18
Mean number of xerogenic medication (n) 1.0 (1.0) 0 – 4
Abbreviations are: IWG, interdialytic weight gain; Kt/V, removal of urea by dialysis a week, V, volume of distribution of urea estimated as 55% of 
body weight; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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The Dialysis Thirst Inventory (DTI) was newly developed and used to quantify the perceived 
thirst. The DTI is a questionnaire with seven items (see Table 2). Each items has a five-point 
Likert type scale (never = 1 to very often = 5). The scores are summed, and provide a DTI score 
ranging from seven (no thirst) to 35 (very thirsty). In order to determine whether the items 
of the DTI represented one construct, a factorial analysis was carried out. This revealed one 
factor with an Eigen value of 3.98, which explained 56.9% of the variance of the items. The 
Chronbach’s alpha for the DTI was 0.87.
When the subjects reported “occasionally” till “very often” on an item from either the XI or 
DTI, it was judged as ‘present’. In all other cases, “never” and “almost never” was judged as 
‘absent’.
Statistical methods 
Data are presented as mean ± SD. UWS and CH-SWS flow rates showed a skewed distribution 
and were logarithmically transformed (log10) before statistical analyses. For readability, the 
original (untransformed) data are presented in Table 3. Normally distributed data (DTI and XI 
score) and the logarithmically transformed data were analyzed with independent Students 
t-tests. Correlations between XI, DTI, IWG and the logarithmically transformed UWS flow rates 
Table 2. Items of the the Xerostomia Inventory (XI), the Dialysis Thirst Inventory (DTI) and the proportion of patients’ answers (%) for each item 
divided in three categories
Xerostomia Inventory Never/
almost never
Occasionally Fairly often/ 
very often
I sip liquid to aid in swallowing food 38.7 29.0 32.3
My mouth feels dry when eating a meal 57.0 21.5 21.5
I get up at night to drink 53.8 24.7 21.6
My mouth feels dry 25.8 44.1 30.1
I have difficulty in eating dry foods 47.8 20.7 31.6
I suck sweets or cough lollies to relieve dry mouth 53.3 21.7 25.0
I have difficulties swallowing certain foods 67.0 22.0 10.0
The skin of my face feels dry 44.0 18.7 37.4
My eyes feel dry 65.6 19.4 15.0
My lips feel dry 30.1 34.4 35.5
The inside of my nose feels dry 62.6 20.9 16.5
Dialysis Thirst Inventory
Thirst is a problem for me 30.4 30.4 39.1
I am thirsty during the day 14.1 38.0 47.8
I am thirsty during the night 43.5 27.2 29.3
My social life is influenced because of my thirst feelings 61.9 15.2 22.8
I am thirsty before dialysis 35.1 23.4 41.6
I am thirsty during dialysis 48.1 27.3 24.7







were subjected to Pearson’s product-moment correlation analysis. To further explore relation-
ships between IWG and both thirst (DTI score) and xerostomia (XI score), partial correlation 
coefficients were calculated after controlling for XI and DTI, respectively.
The main dependent variables (IWG, DTI score, XI score, and salivary flow rates) were sub-
jected to a univariate ANOVA with gender, age (≤ 64 year, > 65 year), alcohol use and smoking 
habits as factors. Potential interactions between these variables were explored using a full 
factorial model (two-way ANOVA). The statistical analysis was performed using the statistical 
software package SPSS (version 10.0, SPSS Inc., Chicago, IL, USA). All levels of significance 
were set at P < 0.05.
RESULTS
Patients demographics
The total sample of this study comprised of 94 HD patients (64 men: age 54.8 ± 15.5 years; 30 
women: age 59.5 ± 18.7 years). The mean time of treatment with HD was 35.8 ± 31.0 months. 






Gender Male 0.34 (0.23)a 1.19 (0.69)a 64
Female 0.21 (0.21) 0.75 (0.64) 30
Age group ≤ 64 years 0.32 (0.25) 1.12 (0.73) 63
> 64 years 0.25 (0.14) 0.92 (0.62) 31
Edentulous No 0.31 (0.24) 1.10 (0.74) 71
Yes 0.26 (0.13) 0.89 (0.54) 22
Diabetic No 0.30 (0.22) 1.09 (0.71) 80
Yes 0.30 (0.26) 0.81 (0.61) 13
Urine output No 0.30 (0.23) 1.06 (0.77) 68
Yes 0.30 (0.21) 1.04 (0.52) 26
Xerogenic medication 0 0.29 (0.19) 1.08 (0.68) 36
1 0.32 (0.26) 1.04 (0.76) 32
2 0.33 (0.26) 1.14 (0.69) 17
≥ 3 0.25 (0.11) 0.90 (0.70)  8
Smoking status Non-smoker 0.28 (0.22) 1.00 (0.69) 73
Smoker 0.38 (0.24) 1.31 (0.77) 17
Alcohol consumption No 0.28 (0.23) 1.09 (0.79) 52
Yes 0.32 (0.22) 1.02 (0.60) 39
Time dialysis ≤ 24 months 0.31 (0.20) 1.19 (0.58) 34
> 24 months 0.29 (0.24) 0.98 (0.76) 59
a P < 0.01.
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The causes of chronic renal failure in the study group were renal vascular disease due to 
hypertension (16.0%), polycystic kidneys adult type (11.7%), glomerulonephritis (10.6%), 
miscellaneous (22.3%) and unknown (39.4%). In total, thirteen patients suffered from diabe-
tes mellitus (type 1 or 2) which was the cause of the chronic renal failure in five individuals. 
The main categories of putatively xerogenic medication used by the HD patients were 
antihistamines (24.2%) and antihypertensives (21.1%). The IWG of the patients was 2.2 ± 1.3 
kg. The average systolic and diastolic blood pressure were 146 ± 22 and 81 ± 13 mm Hg, 
respectively (Table 1). The mean normalized protein catabolic rate was 1.1 ± 0.2 g/kg/day and 
correlated significantly with IWG (r = 0.291, P = 0.033).
Saliva secretion 
The mean salivary flow rates of UWS and CH-SWS were 0.30 ± 0.22 mL/min and 1.05 ± 0.70 
mL/min, respectively. Normal values (0.25-0.50 mL/min) were reported in 34.2% of the pa-
tients, and hyposalivation (UWS ≤ 0.15 mL/min) was found in 36.2% of the cases.28 
Stratified data of the salivary flow rates are presented in Table 3. Male patients had sig-
nificantly higher salivary flow rates than females, both for UWS and CH-SWS (P < 0.001). No 
diurnal differences in secretion rates were observed between patients who were treated in 
the morning versus the afternoon (data not shown). No significant differences in UWS and 
CH-SWS were observed with regard to age, dental status (dentate v.s. edentulous), diabetics, 
urine output, alcohol consumption, smoking, or total time on dialysis. No significant associa-
tion was observed between the number of putatively xerogenic medications used and the 
UWS flow rate (r = -0.018, P = 0.914). 
Xerostomia (Xerostomia Inventory)
The mean XI score of the study population was 28.3 ± 9.1. Significant differences were ob-
served with regard to gender, age and alcohol consumption (Table 4). Women had higher XI 
scores (31.6 ± 9.7) than men (26.7 ± 8.5; P = 0.019). Participants older than 65 years reported 
significant lower XI scores (23.1 ± 7.7) than subjects below the age of 65 years (31.4 ± 9.1; 
P < 0.0005). In 74.2% of the patients a subjective dry mouth was present. A small majority of 
the study population (52.3%) reported to have problems with eating dry food and 61.3% of 
the patients sipped liquids to aid in swallowing food.
The total number of all medications used was positively correlated with the XI score 
(r = 0.257, P = 0.016). However, no significant association was found between the number 
of putatively xerogenic medications used and the XI score (r = 0.039, P = 0.717). A large dif-
ference was observed between female patients who smoked (DTI score = 32.0 ± 4.2) and 








Thirst (Dialysis Thirst Inventory)
The mean DTI score of the patients was 20.3 ± 7.3. Patients over the age of 65 years had 
significant lower DTI scores than subjects younger than 65 years (16.7 ± 7.7 and 22.2 ± 6.5, 
respectively; P < 0.0005), see Table 4. Patients > 24 months on dialysis reported more thirst 
(DTI score = 21.6 ± 7.1) than patients ≤ 24 months on dialysis (DTI score = 18.0 ± 7.4). Table 2 
gives an overview of the scores for each item of the DTI. Of the patients, 39.1% reported thirst 
as a problem (fairly to very often). During daytime, 47.8% of the patients reported to have 
thirst. During the night the proportion of patients with thirst decreased to 29.3%. In 38.1% 
of the study group, social life is influenced by thirst. Before a dialysis session, the perceived 
thirst is much higher (41.6% ‘fairly often’ or ‘very often’) than during dialysis (24.7%) or after-
wards (29.9%).
A nearly significant association was observed between the DTI score and the number of 
medications used (r = 0.212, P = 0.065). Significant two-way interactions for the DTI score 
were observed between gender and smoking [F (1,65) = 4.63, P < 0.05] and between age and 
alcohol [F (1,65) = 5.91, P < 0.05]. A large difference was found between female patients who 






Gender Male 26.7 (8.5)a 19.3 (6.6) 60
Female 31.6 (9.7) 22.2 (8.4) 28
Age group ≤ 64 years 31.4 (9.1)b 22.2 (6.5)b 49
> 64 years 23.1 (7.7) 16.7 (7.7) 23
Edentulous No 29.1 (8.7) 21.0 (6.7) 65
Yes 25.7 (10.1) 18.1 (9.0) 22
Diabetic No 27.7 (8.6) 20.8 (7.7) 76
Yes 31.5 (12.0) 20.2 (7.3) 12
Urine output No 28.8 (9.1) 20.5 (7.3) 64
Yes 26.8 (9.3) 19.8 (7.7) 24
Xerogenic medication 0 28.2 (8.5) 19.9 (7.2) 32
1 28.5 (9.5) 21.3 (7.3) 32
2 26.9 (9.5) 20.0 (8.5) 16
≥ 3 28.6 (13.3) 18.7 (7.4)  7
Smoking status Non-smoker 28.4 (8.8) 20.3 (7.2) 71
Smoker 27.3 (10.8) 20.7 (8.5) 16
Alcohol consumption No 30.0 (10.0)a 21.4 (7.8) 49
Yes 25.9 (7.4) 18.8 (6.7) 38
Time dialysis ≤ 24 months 26.1 (8.3) 18.0 (7.4) 34
> 24 months 29.6 (9.4)  21.6 (7.1)a 54
a P < 0.05; b P < 0.01.
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smoked (DTI score = 32.0 ± 4.2) and non-smoking patients (DTI score = 21.3 ± 8.0). In contrast, 
no difference was observed between male smokers and non-smokers.
Relationships between IWG, thirst, xerostomia, and saliva secretion
A strong positive correlation between thirst and xerostomia was found (r = 0.736, P < 0.0005; 
Figure 1). Thirst and xerostomia are associated with IWG, as shown by the significant correla-
tions of both the XI score and DTI score with IWG (r = 0.376, P = 0.001 and r = 0.250, P = 0.020 
respectively; Figure 2 and 3). Thirst was inversely and significantly correlated with the UWS 
flow rate (r = -0.227, P = 0.049). No significant correlation was observed between UWS flow 









Figure 1. Pearson correlations, between xerostomia (XI score), thirst (DTI score) and flow rate (UWS) and interdialytic weight gain (IWG). 
* P < 0.05, ** P < 0.01
Figure 2. Relationship between interdialytic weight gain (IWG) and xerostomia 
inventory (XI). Pearson correlation (r = 0.250, P < 0.05) 
Xerostomia Inventory (XI 11 - 55)




























Partial correlation coefficients between thirst and IWG remained significant after control-
ling for the XI score (r = 0.253, P = 0.031). After controlling for DTI score, the correlation be-
tween xerostomia and IWG was no longer significant (r = 0.038, P > 0.05). The correlation 
between DTI score and XI score remained high after controlling for IWG (r = 0.700, P < 0.01). 
No significant interactions of gender and age with smoking status and alcohol consumption 
were observed for IWG, thirst, xerostomia, or salivary flow rate. 
DISCUSSION
The present study is the first large scale, multicenter study to investigate whether aspects of 
oral dryness, especially salivary flow rate and xerostomia, were related to thirst and IWG. We 
indeed found significant relationships between a dry mouth (both xerostomia and reduced 
salivary flow rates) and thirst, and xerostomia and IWG. This suggests a possible role of oral 
dryness to explain higher fluid intake between HD sessions, and opens future interventions 
to manipulate dry mouth and/or flow rates to decrease thirst and IWG in HD patients.
A subjective feeling of a dry mouth (xerostomia) in HD patients was assessed using a vali-
dated xerostomia questionnaire (XI) with high scores indicating severe complains of oral dry-
ness. We found that the subjective dry mouth feelings of HD patients (XI = 28.3 ± 9.1) were 
similar to patients receiving radiotherapy for head- and neck cancer two months after the 
initial radiotherapy (XI = 31.4 ± 7.3).29 A relatively large proportion of the HD patients in our 
study reported to have a dry mouth (76.4%). This is in agreement with previous studies on HD 
Figure 3. Relationship between interdialytic weight gain (IWG) and Dialysis 
Thirst Inventory (DTI). Pearson correlation (r = 0.376, P < 0.005) 
Dialysis Thirst Inventory (DTI score 7 - 35 )





















Figure 3. Relationship between interdialytic weight gain (IWG) and Dialysis Thirst Inventory (DTI). Pearson correlation (r = 0.376, P < 0.005)
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patients, in which the percentage of patients reporting a dry mouth ranged between 32.9% 
and 66.7%.17,18 Remarkably, no significant association was observed between the number of 
putatively xerogenic medications used and the XI score. The absence of this association may 
be either the result of the relatively broad classification of putatively xerogenic medication or 
the interaction between multiple medications used by HD patients.31
In our study, the mean XI score of HD patients over the age of 65 years (XI = 23.1 ± 7.7) is 
similar to reports of oral dryness in healthy subjects over 65 years (XI = 20.0 ± 7.0).31 However, 
HD patients under the age of 65 years have much higher XI scores (31.4 ± 7.7), which might 
be explained by a gradual habituation to a dry mouth over the years. It has been suggested 
that younger subjects may also be more likely to experience symptoms of oral dryness when 
salivary flow is low, while in older persons symptoms of dry mouth could be related to a 
more complex constellation of factors where salivary flow is only one component.32 A large 
scale epidemiological survey among an adult population, however, found a strong positive 
correlation between age and reports of a dry mouth.33 Similarly, in our study, age and gender 
differences for the level of xerostomia (XI) and salivary flow rates (UWS and CH-SWS) in HD 
patients were observed. This is consistent with previous studies that men have higher sali-
vary flow rates than women, and women report more xerostomia.31,32,34,35 
The mean salivary flow rates of both unstimulated (UWS) and stimulated saliva (CH-SWS) in 
HD patients were normal and comparable to reference values for healthy subjects.36 However, 
it should be mentioned that the original flow rate date were skewed to the right and had a 
large standard deviation. Many HD patients have low salivary flow rates. The calculated mean 
rates were normal due to a few HD patients with high flow rates. The mean UWS in our study 
was also consistent with the study of Galvada and co-workers, who found an average UWS 
flow rate of 0.26 ± 0.28 mL/min in HD patients compared to controls (UWS = 0.28 ± 0.16 mL/
min).16 Kho and co-workers investigated 22 patients undergoing HD and found an average 
UWS flow rate of 0.30 ± 0.18 mL/min.17 
Our observation that the mean CH-SWS of HD patients was comparable to reference values 
for healthy subjects36 differs from previous studies reporting that the stimulated salivary flow 
rates were significantly reduced in HD patients compared to control groups.15,17,20,21 This could 
be explained by the fact that in our study a tasteless piece of parafilm was used to stimulate 
salivary flow, while previous studies used other mechanical or chemical stimuli like citric acid 
(2%). The altered taste perception of HD patients may also partially contribute to these dif-
ferent findings.37 
The salivary flow rate (UWS) and the perception of a dry mouth (XI) correlated significantly 
(r = -0.298, P < 0.05), which is in agreement with previous studies reporting a correlation be-
tween objective measures of a dry mouth (salivary flow rate) and subjective reports of a dry 
mouth (xerostomia) in patients with rheumatoid arthritis.38,39 Responses to questions related 
to eating (such as ‘my mouth feels dry during eating a meal,’ ‘sipping liquids to aid swallow-







However, a subjective dry mouth is not always necessarily related to a reduced salivary flow 
rate39-41 and other factors including anxiety, depression, and stress might play a role in the 
perception of a dry mouth.35,42 It has been demonstrated that anxiety, depression and stress 
also play a role in the compliance of HD patients to fluid restriction, measured by the IWG.4
For this study a new Dialysis Thirst Inventory (DTI) was developed, focusing on perceived 
thirst. Significantly lower thirst scores were observed in the age group over 65 years, which 
is comparable to reduced complaints of oral dryness (XI) in the older aged HD patients. Our 
findings are also in agreement with diminished feelings of thirst and reduced fluid intake in 
healthy elderly persons.43,44 Older subjects may have a higher osmotic operating point for 
thirst sensation, a diminished response by baroreceptors to volume changes or adaptation 
to the fluid restriction.44
Several investigators have suggested that the salivary glands are directly damaged by ei-
ther uremic involvement or the fluid-restricted diet.15-18,21 In the present study, the salivary 
flow rates are not influenced by the duration of HD treatment. This in agreement with the 
study of Bayraktar and co-workers in which no differences in salivary flow rate were observed 
between patients on HD for more or less than 24 months.21 Also, the large difference between 
the unstimulated and stimulated flow rate in our study indicates that the salivary glands have 
maintained their secretory capacity. This all indicates that the salivary glands are probably 
not damaged by chronic HD treatment. 
Because our study clearly demonstrates that thirst (DTI) and xerostomia (XI) are associated 
with greater IWG, management of thirst and xerostomia is potentially of clinical importance 
in the treatment of HD patients. Patients on daily HD were less thirsty and also showed less 
fluctuation in body fluid volume.45 In addition, xerostomia can be reduced by either stimula-
tion of the saliva secretion (mechanical, gustatory, or pharmacologic) or palliative care using 
mouthwashes or saliva substitutes.46-49 In healthy subjects, gum chewing increases flow rate 
to 187% during the first minute of chewing50 (see Appendix) and gum chewing can, especially 
in those with low salivary function, increase unstimulated flow rates, and might contribute 
to reduced levels of xerostomia.51 Regular use of gum for two weeks resulted even in a long-
term persistent increase in unstimulated salivary secretion rate and showed to be effective in 
reducing xerostomia.52 Also, in patients with advanced cancer, daily use of chewing gum or 
a saliva substitute showed to be effective in reducing xerostomia.48 Use of saliva substitutes 
reduced dry mouth feelings in patients with irradiation-induced xerostomia.53 In a small pilot 
study, use of a saliva substitute in HD patients resulted in a reduction of fluid overload.54 
CONCLUSION
The mean unstimulated and stimulated salivary flow rates of HD patients in this study are 
relatively normal. However, a large proportion of the patients have reduced unstimulated 
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flow rates. Thirst, IWG, and xerostomia are associated in HD patients, indicating a possible 
role of oral dryness to explain higher fluid intake between HD sessions. In other studies, the 
use of saliva stimuli or saliva substitutes showed to be effective in reducing feelings of a dry 
mouth. This might also diminish the urge to drink in HD patients, enhancing compliance 
to the fluid-restricted diet and leading to a decreased IWG and fewer systemic complica-
tions. The potential clinical effect of saliva stimuli and saliva substitutes will be investigated 
in Chapter 6 and 7.
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The aim of this study was to compare the oral health status of chronic renal failure patients 
(CRF) on renal replacement therapy with a matched reference population.
Material and Methods 
In a cross-sectional study, forty-two dentate CRF patients – aged 25-52 years old – were 
matched with a reference group of 808 dentate subjects. The oral health was assessed using 
decayed missing filled (DMF) indices, simplified oral hygiene index (SOHI) and periodon-
tal status. An oral health questionnaire was used to assess self-reported dental problems. 
Students t-tests and chi-square tests were performed to compare the CRF patients with the 
controls.
Results 
All index-scores in the CRF patients were comparable with the controls except for number 
of teeth covered with calculus that was significantly higher (P < 0.05) in CRF patients (4.1 ± 
2.6) than in controls (3.0 ± 2.9). The self-reported oral health questionnaire revealed a trend 
for increased temporomandibular complaints in CRF patients (16.7% vs 5.7% in controls; P = 
0.06) as well as bad taste (31.0% vs 6.8% in controls, P = 0.08)
Conclusion 
For most dental aspects, the oral health of CRF patients is comparable with controls.
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INTRODUCTION
The major function of the kidneys is removal of metabolic waste products, electrolytes and 
water. When this function is impaired towards 5-10% of the original capacity, end stage re-
nal disease (ESRD) can lead rapidly to death, unless renal replacement therapy is started. 
Chronic dialysis therapies, such as hemodialysis (HD) and peritoneal dialysis (PD) have proven 
to be successful in replacing the major functions of the kidney. In HD treatment, an artificial 
extra-corporal device is used to clear the blood of waste products and excess fluid. Access 
to the circulatory system is obtained through a surgically created arteriovenous shunt, and 
anticoagulants are administered during dialysis. HD treatment must be performed every 2-3 
days for 4-5 hours. In PD treatment, the patients’ peritoneal membrane is used as an artificial 
kidney. Sterile dialysis fluid is introduced into the abdominal cavity for several hours, drained 
and refreshed several times during the day (Continuous Ambulatory Peritoneal Dialysis = 
CAPD) or continuously at night (Continuous Cycler-Assisted Peritoneal Dialysis = CCPD). 
Both HD and PD treatment cause systemic changes, oral complications and alterations in 
salivary composition and output.1,2 In addition, vomiting and reduced oral (self ) care could 
also negatively affect the oral health in chronic dialysis patients resulting in more caries, peri-
odontitis and oral lesions.1,2,3 However, conflicting data exist on the effect of chronic dialysis 
therapy on oral health status.4,5,6 Galvada and co-workers reported in a study with 53 HD pa-
tients, that the number of decayed missing and filled teeth (DMFT) and the level of periodon-
tal attachment did not differ from a matched control group.5 Increased salivary urea levels 
could induce calculus formation, but on the contrary also contribute to the remineralization 
of dental enamel, leading towards a lower caries experience in children.7 No differences were 
found for the caries variables between adult HD patients and controls.8 On the contrary, an-
other study reported that the prevalence of periodontitis and caries experience was high in 
dialysis patients, but this study lacked a control group.4 
Therefore, the aim of this cross-sectional study was to compare the oral health status of 




The CRF patients undergoing kidney replacement therapy for at least three months were 
asked to participate. One hundred twenty six dialysis patients (HD, n = 95 ; (C)APD, n = 31) 
gave informed consent to participate in this study, which was approved by the Medical Ethi-
cal Committee of the Vrije Universiteit Medical Center, Amsterdam, The Netherlands. Twenty-







participate in the clinical dental investigation. This resulted in 84 dentate CRF patients avail-
able for matching with a control group of 808 dentate subjects from a dental epidemiological 
study among subjects aged 25-54 years old.9 The CRF patients were matched with the control 
group with regard to age [excluded < 25 years (n = 3) ; > 54 years (n = 39)] and educational 
level. Finally, this resulted in 42 dentate patients aged 25-54 years old, who matched with the 
reference group.
Age, gender and level of education were assessed with a questionnaire and the clinical 
data were retrieved from patient files. The main pathologies causing CRF, classified accord-
ing to the European Dialysis and Transplantation Association- European Renal Association,10 
were IgA nephropathy (9.5%), glomerulonephritis (9.5%), polycystic kidney disease -adult 
type- (7.1%) and renal vascular diseases (7.1%). 
Oral health assessment
The oral health assessment of the dialysis patients took place at a dental clinic nearby one of 
the dialysis centers. Two dentists examined each patient, subsequently. One dentist (JP) was 
involved in the assessment of both the oral health in the ESRD patients and the Dutch epide-
miological caries study, which was carried out in the same year (2002). The data presented are 
based on the consensus reached after the two inspections. The intraclass correlation coeffi-
cient for the DMFT and plaque index was 0.99 and 0.86 respectively, indicating good intratest 
reliability for these variables.11 
The teeth were dried with air and inspected with a standard dental mirror and assessed 
according to the same protocol as used in the reference group.9 This protocol consists of 
several generally accepted oral health indices, such as the DMFT and DMFS, in addition the 
amount of dental plaque was assessed.12,13,14 The periodontal status including pocket depth, 
bleeding on probing (none, minor, moderate and on probing) and presence of calculus was 
assessed using a split mouth model (1st – 3rd quadrant or 2nd – 4th quadrant), to which the 
patients were randomly allocated. A questionnaire was used to assess specific dental issues 
such as problems with ‘caries’, ‘gingiva’, ‘jaw pain’, ‘ulcerations’, ‘bad breath’ or ‘pain’, during the 
preceding year.
Statistical methods
Data are presented as percentages, mean ± SD and the 95% confidence interval (CI) of the 
mean difference. The means of quantitative oral health data from the dialysis patients were 
compared with the matched reference population using independent Student t-tests, chi-
square tests or Fisher’s exact tests when appropriate. All levels of significance were set at 
P < 0.05.
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RESULTS
After matching by age and educational level with a control group of 808 patients (326 men 
and 482 women; mean age 41.3 ± 8.4 years) from a dental epidemiological study, the total 
sample of CRF patients comprised 42 patients (30 men and 12 women; mean age 42.6 ± 9.2 
years). Twenty-eight CRF patients were on HD, eight on CAPD and six on CCPD, see Table 1.
Seven percent had one or more bridges in the maxilla and/or mandible. The amount of 
CRF patients’ wearing a partial denture in the maxilla was comparable with the control group 
(data not shown). Table 2 shows the data regarding the DMF indices. Both the DMFT and 
DMFS scores were comparable in CRF patients (DMFT = 13.3 ± 7.5; DMFS = 37.2 ± 23.7) and 
controls (DMFT = 14.7 ± 6.4; DMFS = 39.1 ± 22.0). No statistically significant differences were 
observed for any of the DMF-indices.
Both CRF patients and matched controls had the same amount of surfaces covered with 
dental plaque (2.4 ± 1.6 vs 2.6 ± 1.4, respectively), see Table 3. CRF patients had significantly 
more teeth covered with calculus (4.1 ± 2.6) than controls (3.0 ± 2.9; P < 0.05). The percentage 
Table 1. Clinical and demographical data of patients with chronic renal failure (CRF) on dialysis (n = 42)
Age (years) 42.6 (9.2)
Male gender (%) 71.4% (n = 30)
Educational level Primary school 33.3% (n = 14)
Secondary school 35.7% (n = 15)
High school or higher 31.0% (n = 13)
Months on dialysis 28.6 (16.9)
Therapy Hemodialysis 66.7% (n = 28)
Peritoneal dialysis: CAPD 19.0% (n = 8)
CCPD 14.3% (n = 6)
Percentages and numbers of clinical and demographic variables. Mean values (SD) are given for continuous variables.
Abbreveations: CAPD, continues ambulatory peritoneal dialysis; CCPD, continues cycler-assisted peritoneal dialysis
Table 2. Decayed Missing Filled index values (mean ± SD) of patients with chronic renal failure (CRF) on dialysis compared to a matched 
reference group
CRF (n = 42) Controls (n = 808) 95% CI mean difference 
Decayed Teeth (DT) 1.4 (1.9) 1.3 (1.8) -0.5 – 0.7
Missing Teeth (MT) 3.7 (5.2) 3.7 (5.6) -1.8 – 1.8
Filled Teeth (FT) 8.1 (5.8) 9.7 (5.6) -0.2 – 3.4
Decayed Missing Filled Teeth (DMFT) 13.3 (7.5) 14.7 (6.4) -0.6 – 3.4
Decayed Surfaces (DS) 1.6 (2.6) 1.6 (2.9) -0.9 – 0.9 
Missing Surfaces (MS) 14.3 (18.7) 14.3 (20.1) -6.3 – 6.3 
Filled Surfaces (FS) 21.3 (16.5) 23.3 (16.3) -3.1 – 7.1
Decayed Missing Filled Surfaces (DMFS) 37.2 (23.7) 39.1 (22.0) -5.0 – 8.8 







of supra- and subgingival calculus was slightly higher in CRF patients (34.4%) than in controls 
(24.6%). A statistically significant association was found between the number of teeth cov-
ered with dental plaque or calculus and the number of elements with bleeding on probing 
(r = 0.543; P < 0.001 and r = 0.568; P < 0.001, respectively).
The periodontal pocket status did not differ between CRF patients and controls. Also, the 
total number of elements with bleeding on probing did not differ. Although the percentage 
of teeth bleeding immediately after probing in CRF patients was higher (21.2%) than in con-
trols (8.2%), and no statistically significant differences were observed. The majority of the CRF 
patients (97.6%) brushed daily (28.6% once a day, 64.3% twice a day, 19.0% more than twice a 
day) which does not differ from of the controls (96.6% brushing daily). During the preceding 
year, 81% of the CRF patients (n = 34) had received professional oral care at least once, which 
is comparable with the reference group.







Dental plaque ( > 2 teeth assessed)
Number of surfaces assessed 5.4 ± 1.0 5.7 ± 0.8 n.s.
Number of surfaces with dental plaque 2.4 ± 1.6 2.5 ± 1.4 n.s.
Score dental plaque (% surfaces): 0 54.1% 56.3% n.s.
1 32.6% 31.6% n.s.
2 , 3 13.3% 12.2% n.s.
Calculus ( > 4 teeth assessed)
Number of teeth assessed 12.3 ± 2.1 12.2 ± 2.2 n.s.
Number of teeth with calculus 4.1 ± 2.6 3.0 ± 2.9 P < 0.05
Calculus (% teeth): no 65.6% 75.4% n.s.
supra or subgingival 34.4% 24.6% n.s.
Pockets ( > 4 teeth assessed)
Number of teeth assessed 12.3 ± 2.1 12.2 ± 2.2 n.s.
Number of teeth with pocket (≥ 4mm) 1.8 ± 2.0 1.6 ± 2.3 n.s.
Pockets (% teeth): ≤ 3.5 mm 95.8% 86.9% n.s.
> 3.5 and ≤ 5.5mm 3.3% 11.5% n.s.
> 5.5 mm 1.0% 1.6% n.s.
Bleeding on probing ( > 4 teeth assessed)
Number of teeth assessed 11.6 ± 3.3 12.2 ± 2.2 n.s.
Number of teeth with bleeding 2.8 ± 2.2 3.0 ± 3.0 n.s.
Bleeding (% teeth): no bleeding 62.1% 66.0% n.s.
minor 12.4% 9.4% n.s.
moderate 1.9% 16.4% n.s.
immediately on probing 21.2% 8.2% n.s.
Students t-tests and chi-square tests were performed, n.s.= no statistical significant difference.
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The association between duration of hemo- or peritoneal dialysis and the various oral 
health variables was investigated, however, no significant associations were found for any of 
these variables.
The self-reported oral health questionnaire revealed that CRF patients did not differ from 
the control group, see Table 4. However, trends were observed for the increased frequency of 
temporomandibular complaints in CRF patients (16.7% vs 5.7% in controls; P = 0 .06) and bad 
taste (31.0% vs 6.8% in controls; P = 0 .08).
DISCUSSION
In this study, the oral health of 42 dentate CRF patients was assessed and compared to a 
matched reference group of 808 healthy subjects. The DMFT and DMFS scores tended to 
be higher in the control group than in the patient group, but the difference was not statisti-
cally significant. These observations are in accordance with previous studies.4,5,6 Galvada and 
co-workers also found no statistically significant difference between the number of carious, 
absent and obturated teeth (CAO) in 105 renal patients on HD treatment (CAO = 14.9 ± 8.7) 
compared to 53 gender matched controls (13.3 ± 7.9).5 
It has been suggested by others that the caries activity in patients on dialysis is lower, as an 
increased urea concentration in saliva leads to higher pH levels.1,15 Higher salivary urea levels 
could potentially protect the teeth from demineralisation but on the other hand enhance 
calculus formation in dialysis patients.16 The higher prevalence of calculus we found, suggest 
that CRF patients received less oral care. This seems not feasible, since almost every partici-
pant had visited an oral healthcare worker during the preceding year. It should be taken into 
Table 4. Self-reported oral health during the preceding year in CRF patients on dialysis compared with healthy controls
CRF (n = 42) Controls (n = 808) P
Caries lesions 41% (n = 17) 25% (n = 203) 0.25
Gingival problems 36% (n = 15) 28% (n = 226) 0.28
Temporomandibular complaints 17% (n = 7)  6% (n = 46) 0.06
Ulcerations 21% (n = 9) 12% (n = 95) 0.12
Problems with eating and drinking 10% (n = 4) 21% (n = 172) 0.19
Missing, moving or broken teeth 17% (n = 7) 21% (n = 166) 0.21
Distortion of teeth position  7% (n = 3) 11% (n = 88) 0.11
Bad breath 24% (n = 10) 12% (n = 96) 0.12
Sharp edges of the teeth 24% (n = 10) 14% (n = 111) 0.14
Bad taste 31% (n = 13)  7% (n = 55) 0.08
Discolouration of the teeth 21% (n = 9) 26% (n = 211) 0.26
Pain 14% (n = 6) 15% (n = 118) 0.15







account that in general, almost everyone (86%) in The Netherlands visits the dentist once or 
twice a year.9 
It might be possible that the effect of a relatively short period of dialysis treatment (28.6 
± 16.9 months) may not be reflected in the DMFT index, which is a measure for the life-long 
caries experience. Long-term dialysis treatment might affect the carious component of the 
DMFT,7,16,17 although studies focusing on the duration of dialysis treatment in relation to oral 
health did not show a substantial effect.4,6 
Our results potentially could have been biased as only relatively healthy and mobile CRF 
patients were able to participate in this study, thus missing those in a very poor physical 
condition.
We found that the number of teeth with calculus was significantly higher in the patient 
group than in controls. This is in accordance with the study by Galvada and co-workers who 
found a significantly higher calculus index in HD patients compared to controls.5 However, 
in contrast to their study, we found no differences between CRF patients and controls with 
respect to the amount of dental plaque. Since in our study the frequency of dental hygiene 
procedures and dental plaque levels were comparable in both groups, it seems feasible that 
other factors such as salivary changes might have contributed to higher calculus deposi-
tion.
A strong correlation between the number of teeth with bleeding and the number of teeth 
covered with dental plaque and calculus was found. This is in agreement with previous stud-
ies on healthy individuals.18,19 An improvement in oral hygiene might reduce the amount of 
dental plaque and calculus, resulting in a reduction of the number of elements with bleed-
ing. However, it should be taken into account that medication of HD patients, such as anti-
coagulant therapy, might mask the effect of an improvement of oral health measures. We 
found support of this concept in our data since the increased prevalence of calculus and 
the higher number of bleeding on probing was not reflected in the severity and number of 
pocket depths (Table 3). This finding also indicates that the increased bleeding on probing 
does not directly reflect the level of inflammation (gingivitis or periodontitis) in CRF patients, 
which is in accordance with findings from Marakoglu and co-workers.6 
In our study, the data of the self-reported oral health questionnaire suggested a trend 
towards an increase of taste disturbances in CRF patients.20-23 Thirty one percent of the CRF 
patients in our study reported to have had a bad taste, in the preceding year. This is in ac-
cordance with another study that showed that 31.7% of HD patients had taste changes.24 
These taste disturbances could be caused by metabolic disturbances, the use of medication, 
a diminished number of taste buds and changes in salivary flow rate and composition.1,21,22,25 
Also, the number of temporomandibular complaints showed a tendency to be higher in 
CRF patients than in the control group. This finding might be related to renal osteodystrophy, 
caused by increased parathyroid functions associated with inappropriate vitamin D, calcium 
and phosphorus metabolism in dialysis patients.26,27
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CONCLUSION
We have shown that most dental aspects of oral health in CRF patients are comparable to a 
well-matched control group. In CRF patients, the number of teeth covered with calculus was 
significantly higher. However, many CRF patients are candidates for renal transplantation and 
need to be kept foci free. Therefore, maintaining good oral health is of major importance 
since oral pathologies or infections could jeopardize the opportunity to receive a successful 
kidney transplant.28
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To compare oral health, salivary flow rate, xerostomia and thirst in end stage renal disease 
(ESRD) patients remaining on dialysis treatment and after renal transplantation.
Material and methods
ESRD patients from dialysis centers in Amsterdam, The Hague and Utrecht, The Netherlands 
were included in a longitudinal observational study. At baseline and after two years, sali-
vary flow rates, xerostomia and thirst were determined in 43 ESRD patients. The number of 
decayed missing filled teeth/surfaces (DMFT/DMFS) was recorded, and periodontal status 
assessed.
Results 
After renal transplantation (n = 20), the salivary flow rate increased significantly from UWS = 
0.30 ± 0.21 mL/min to 0.44 ± 0.29 mL/min (P < 0.001) and the level of xerostomia and thirst 
decreased. After two years, the percentage of bleeding on probing in dialysis patients (n = 23) 
decreased from 29.5 ± 25.4 till 10.3 ± 12.3 percent, (P < 0.050) further oral health differences 
were found between dialysis and renal transplant patients.
Conclusion
DMFT, dental plaque, gingival bleeding and periodontal indices did not change remarkable 
after two years, comparing dialysis and renal transplant patients. Increased salivary flow 
rates, decreased xerostomia and thirst in renal transplant patients are important aspects in 
the quality of life of these patients.
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INTRODUCTION
Over the last decades, the prevalence and incidence of patients with end stage renal disease 
(ESRD) has increased.1 Due to improvements in medical care and prolonged life expectancy, 
patients with renal disorders are increasingly encountered in the dental practice.2
A broad variety of oral manifestations has been reported in ESRD patients including gingi-
vitis, xerostomia, ammonia-like smell, mucosal pallor and lesions, tooth mobility, malocclu-
sion and an increased risk for dental erosion due to frequent regurgitation.3-7 Systemic and 
salivary changes due to chronic renal failure, the use of multiple medication, vomiting and 
reduced oral self care could all potentially affect the oral health in these patients.8;9
The kidneys are essential to remove metabolic waste products, electrolytes and water. 
When the function of the kidneys is impaired towards 5-10% of the original capacity ESRD 
occurs, requiring either hemodialysis (HD) or peritoneal dialysis treatment (PD) or renal 
transplantation (NTx). In HD, an extra-corporal device is used, whereas in PD the peritoneal 
membrane acts as a filter. NTx patients receive their allograft from living or cadaveric donors. 
To prevent allograft rejection, immunosuppressant therapy is required including the use of 
prednisolone, cyclosporine or tacrolimus, which could also affect the oral health.4
Relatively little is known about the long-term effects of dialysis treatment on oral health. 
In addition, most studies on the oral health and salivary flow rate in transplantation patients 
have had a cross-sectional set-up, comparing different renal replacement therapies with 
healthy controls.7;10;11
Therefore, the aim of this study was to longitudinally compare oral health, salivary flow 
rate, xerostomia and thirst in dialysis patients with those ESRD patients who were transplant-
ed during this period.
MATERIALS AND METHODS
Participants
ESRD patients undergoing renal replacement therapy for at least three months were asked to 
participate in a longitudinal study to assess thirst, oral dryness and oral health. One hundred 
twenty six dialysis patients (HD, n = 95; (C)APD, n = 31) gave informed consent to participate 
in this study. Excluded were 29 patients (23%) because they were edentulous, in addition 
thirteen participants (10%) were physically not able to participate in the clinical dental in-
vestigation. This resulted in 84 patients that were enrolled in this study, which was approved 
by the Medical Ethical Committee of the Vrije Universiteit Medical Center, Amsterdam, The 
Netherlands. However, 26 patients died during the two-year study period and fifteen sub-
jects were lost to follow up or withdrew, see Figure 1. After two years, the data of in total 43 







Saliva, xerostomia and thirst
Unstimulated whole saliva (UWS) was collected according to the spitting method12 with 
small modifications, as described previously.13;14 All subjects were instructed to refrain from 
smoking, eating, drinking and tooth brushing for one hour prior to the three saliva collection 
periods. Before collection, the mouth was rinsed with tap water. The collection started with 
the instruction to void the mouth of saliva by swallowing. Subsequently, saliva was allowed 
to accumulate on the floor of the mouth and the subjects were instructed to spit out into the 
pre-weighed test tubes every 30 seconds. Each saliva collection period was five minutes.
Chewing stimulated whole saliva (CH-SWS) was also collected for five minutes using a flat 
piece of parafilm (5 x 5 cm; 0.30 g; Parafilm “M”, American National CAL, Chicago, USA). During 
the saliva collection period, the subjects chewed at their own natural pace and stimulated 
saliva was collected in the same way as the unstimulated samples. The volume of saliva was 
determined gravimetrically (assuming 1 g = 1 mL) and the pH was determined within five 
minutes after saliva collection (Sentron pH-system 1001, Roden, The Netherlands).
A validated xerostomia inventory (XI) was used to quantify the level of xerostomia and 
consisted of 11 items, each with a five point Likert-type scale (never = 1 to very often = 5). 
Examples of the XI are e.g ”My mouth feels dry”, “My lips feel dry” and “I sip liquids to aid in 
swallowing food”. The summed scores provide an individual XI score ranging from 11 (no dry 
mouth) to 55 (extremely dry mouth).14;15
The short-version of the Dialysis Thirst Inventory (DTI) was used to assess the level of thirst. 
The DTI questionnaire has four items, each with a five point Likert-type scale (never = 1 to 
very often = 5) providing a DTI score from 4 (no thirst) to 20 (extremely thirsty). The DTI ques-
tions are: “ Thirst is a problem for me”, “ I am thirsty during the day”, “ I am thirsty during the 
night”, and “My social life is influenced because of my thirst feelings”,16 see Chapter 6.
Oral health assessment
The oral health of the dialysis patients was measured independently by two dentists at a den-
tal office nearby one of the dialysis centers, as described in chapter 4.17 The teeth were dried 
 











Dialysis treatment (n = 84)
DIAL-base 
Dialysis treatment (n = 23)
DIAL-2yr 
Renal transplantation (n = 20)
NTx-2yr
Withdrawn         (n = 15) 
    †       (n = 26) 
Figure 1. Flow chart of the longitudinal study on oral health in chronic renal failure patients during two years
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with air and inspected with a standard dental mirror and oral health was determined with 
several generally accepted oral health indices, such as the decayed, missing, filled teeth index 
(DMFT), the decayed, missing, filled surfaces index (DMFS) and the Simplified Oral Hygiene 
Index (SOHI).18-20 In addition, the periodontal status (bleeding on probing and pocket depth) 
was assessed using a split mouth model.
Statistical methods 
All data are presented as means ± SD. UWS and CH-SWS flow rates showed a skewed distribu-
tion and were logarithmically transformed (log10) before statistical analyses. For readability, 
the original (untransformed) data are presented in Table 1. The patients who remained on 
dialysis treatment (DIAL-2yr) were compared with those who had received a kidney trans-
plant (NTx-2yr). Values of dialysis patients at baseline (DAIL-base) and after two years (DIAL-
2yr), and those who were transplanted (NTx-2yr) were compared with Students t-tests. To 
explore the effects of each treatment modality (DIAL-2yr and NTx-2yr) on the main outcome 
variables, a general linear model of ANOVA (repeated measures design, followed by paired 
t-tests as post-hoc procedure) was performed. The statistical analysis was performed using 
the statistical software package SPSS (version 10.0; SPSS Inc., Chicago, IL. USA). Levels of sig-




UWS (mL/min) 0.31 (.19) 0.31 (.18)
CH-SWS (mL/min) 1.18 (.80) 1.09 (.54)
UWS (pH) 7.28 (.52) 7.10 (.71)
SWS (pH) 7.44 (.43) 7.28 (.57)
XI (11-55) 29.5 (7.5)y 29.0 (9.5)x
DTI
sv
 (4-20) 11.3 (3.8) 11.5 (4.0)x
Renal transplantation
DIAL-base NTx-2 yr
UWS (mL/min) 0.30 (.21) 0.44 (.29)b
CH-SWS (mL/min) 1.12 (.66) 1.38 (.84)
UWS (pH) 7.36 (.49) 6.74 (.40)a
SWS (pH) 7.39 (.42) 7.00 (.24)a
XI (11-55) 24.9 (8.1) 21.4 (7.6)
DTI
sv
 (4-20) 10.6 (4.4) 8.1 (2.6)b
Data at baseline and after two-year follow up of dialysis patients who remained on dialysis (n = 23) and those who were transplanted (NTx; 
n = 20). 
Comparison baseline and after two years is indicated as a = P < 0.001; b = P < 0.050, significant differences between those remaining on 









In total 43 chronic dialysis patients participated in this study, 30 men (mean age 54.0 ± 15.7 
years) and 13 women (mean age 48.9 ± 17.2 years). At baseline, the mean time on dialysis was 
33.0 ± 28.6 months. The main pathologies causing ESRD, classified according to the European 
Dialysis and Transplantation Association-European Renal Association,21 were polycystic kid-
ney disease – adult type – (14.0%), IgA nephropathy (11.6%), glomerulonephritis (7.0%), mis-
cellaneous (27.9%) and unknown (39.5%). After the two-year study period, 20 patients were 
transplanted on average 13.5 ± 7.1 months before the second measurement took place. Two 
NTx patients developed gingival overgrowth after renal transplantation, see illustration 1. 
In total 23 patients maintained on dialysis treatment, awaiting a renal transplant.
Illustration 1. Gingival overgrowth after the use of the use of cyclosporine
Saliva, xerostomia and thirst
The salivary flow rate of patients after renal transplantation (NTx-2yr) increased significantly 
from UWS = 0.30 ± 0.21 mL/min at baseline till UWS = 0.44 ± 0.29 mL/min after renal trans-
plantation (P = 0.002), see Table 1. In the same patients, the salivary pH of UWS decreased 
from pH = 7.36 ± 0.49 till 6.74 ± 0.40 (P < 0.001) A same pattern was observed for CH-SWS. In 
patients who remained on dialysis during the study, the salivary flow rate of both UWS and 
CH-SWS was not altered.
At baseline, the XI values in those who remained on dialysis were higher (XI = 29.5 ± 7.5) 
than those who would receive a renal transplant (XI = 24.9 ± 7.5; P < 0.05), see Table 1. No 
other baseline differences were observed. In NTx patients, the XI scores decreased from 24.9 
± 8.1 till 21.4 ± 7.6, after two years (P = 0.065). No changes were observed for the XI scores 
after two years follow up, in patients who remained on dialysis. Also thirst in NTx patients 
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decreased significantly from DTI = 10.6 ± 4.4 till DTI = 8.1 ± 2.6, (P = 0.020). In patients main-
taining on dialysis, no changes occurred and the DTI score remained high, see Table 1.
Oral health
Although the average DMFS and DMFT values slightly increased after two years, no statisti-
cally significant differences were observed between NTx and dialysis patients (see Table 2). In 
those patients who remained on dialysis, an increase in the number of missing surfaces (MS) 
was found from MS = 18.5 ± 2.9 to MS
 
= 20.6 ± 25.6, after 2 year (P = 0.017). Subsequently, the 
DMFS value of these patients increased significantly, see Table 2.
In both groups, the percentage of teeth without dental plaque remained stable throughout 
the study (Table 3). The average percentage of explored sites that showed immediate bleed-
ing on probing decreased significantly from 29.5 ± 25.4 till 10.3 ± 12.3 percent in patients 
continuing dialysis treatment. Also, in NTx patients, the percentage bleeding on probing 
decreased with 10%, although no statistically significant difference was found. In addition, 
no differences were found between NTx patients and those who remained on dialysis with 
respect to the pocket depth and bleeding measurements.
Table 2. Data at baseline and after two-year follow up of dialysis patients who remained on dialysis (n = 23) and those who were transplanted 
(NTx ; n = 20)
Dialysis treatment
DIAL-base DIAL-2 yr
Decayed Teeth (DT) 1.4 (2.1) 2.1 (3.5)
Missing Teeth (MT) 5.2 (6.9) 5.6 (7.5)
Filled Teeth (FT) 7.1 (6.1) 6.8 (6.3)
Decayed Missing Filled Teeth (DMFT) 13.6 (8.5) 14.4 (8.8)
Decayed Surfaces (DS) 1.8 (2.9) 2.9 (5.8)
Missing Surfaces (MS) 18.5 (23.6) 20.6 (25.6)*
Filled Surfaces (FS) 18.8 (18.5) 18.4 (18.8)
Decayed Missing Filled Surfaces (DMFS) 39.1 (26.9) 41.6 (27.8)*
Renal transplantation
DIAL-base NTx-2 yr
Decayed Teeth (DT) 1.5 (1.6) 2.1 (2.5)
Missing Teeth (MT) 3.3 (4.2) 3.6 (5.0)
Filled Teeth (FT) 10.0 (5.5) 9.6 (5.0)
Decayed Missing Filled Teeth (DMFT) 14.9 (8.1) 15.5 (7.8)
Decayed Surfaces (DS) 1.6 (1.9) 2.4 (2.7)
Missing Surfaces (MS) 12.3 (14.5) 13.8 (16.9)
Filled Surfaces (FS) 27.2 (17.6) 26.9 (17.0)
Decayed Missing Filled Surfaces (DMFS) 41.9 (26.6) 43.1 (25.3)
Comparison between baseline and after two years is indicated as * = P < 0.050. No significant differences between those remaining on dialysis 








To our knowledge, this is the first longitudinal study to compare the course and changes in 
salivary flow rate, xerostomia, thirst and oral health of patients who remained on dialysis 
treatment, with those who received a renal transplant (NTx). It was revealed that oral dry-
ness and thirst decreased after renal transplantation. In patients who remained on dialysis, 
the salivary variables and levels of xerostomia and thirst remained the same throughout the 
two-year study period. This indicates that thirst and oral dryness is a continuing problem in 
these patients. In dialysis patients, a significant increase in the number of MS and DMFS, and 
a reduction of bleeding on probing was found after the two-year observation period.
It was found that the salivary flow rates (both UWS and CH-SWS) increased in the NTx-pa-
tients, while remaining the same in patients on dialysis. Other studies have shown reduced 
salivary flow rates in HD patients compared to healthy controls.7;22-24 Our observation that the 
Table 3. Data at baseline and after two-year follow up of dialysis patients who remained on dialysis (n = 23) and those who were transplanted 
(NTx; n = 20)
Dialysis treatment
DIAL-base DIAL-2 yr
Dental plaque (% surfaces) 0 49.7 (32.0) 49.9 (33.4)
1 27.3 (25.0) 35.9 (30.2)
2,3 18.5 (28.9)  9.6 (15.5)
Bleeding on probing (% teeth) No bleeding 52.8 (29.0) 61.5 (32.4)
Minor 14.9 (16.7) 11.8 (12.6)
Moderate  2.8 (4.4)  2.8 (5.8)
Immediately on probing 29.5 (25.4) 10.3 (12.3)*
Pocketdepth (% teeth) ≤ 3.5 mm 94.3 (7.4) 85.7 (29.5)
> 3.5 – 5.5 mm  3.2 (4.6)  1.9 (3.4)
> 5.5 mm  2.5 (6.0)  3.3 (9.3)
Renal transplantation
DIAL-base NTx-2 yr
Dental plaque (% surfaces) 0 52.4 (33.0) 62.6 (31.3)
1 30.7 (25.8) 23.8 (24.5)
2,3 16.9 (22.2) 13.6 (28.8)
Bleeding on probing (% teeth) No bleeding 57.4 (26.2) 61.5 (38.9)
Minor 11.8 (9.8)  7.2 (11.2)
Moderate  2.0 (2.5)  6.2 (12.0)
Immediately on probing 28.8 (19.2) 19.5 (32.7)
Pocketdepth (% teeth) ≤ 3.5 mm 96.4 (3.2) 96.9 (7.1)
> 3.5 – 5.5 mm  3.2 (3.3)  2.8 (6.5)
> 5.5 mm  0.4 (1.0)  0.1 (.6)
Comparison baseline and after two years is indicated as * =  P < 0.050. No significant differences between those remaining on dialysis and 
those who were transplanted (vertical row) were found at baseline or after two years.
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salivary flow rates increase after renal transplantation does not support the suggestion that 
dialysis treatment affects the salivary glands.25 In the present study, we have shown that the 
reduced salivary flow rates are reversible and restore after transplantation. The salivary flow 
rates in NTx patients might even been underestimated since several studies have indicated 
that long term use of immunosuppressant therapy such as cyclosporine A could suppress the 
salivary flow rate.26;27
A decrease in salivary pH after transplantation is probably due to the reduced concentration 
of urea in saliva which can be hydrolyzed by oral bacteria into ammonia (with a relatively high 
pH).28 A high salivary pH and buffering capacity in dialysis patients could potentially enhance 
remineralization although we could not demonstrate this effect in the present study.29-32 
As initially expected, we have found decreased oral dryness and thirst in patients after 
renal transplantation. After renal transplantation, the physiological function of the kidney 
should restore, which normalizes serum composition, fluid balance, thirst and xerostomia. 
In Chapter 3, we have demonstrated in hemodialysis patients, that salivary flow rate and xe-
rostomia are significantly correlated.14 Therefore, an increase of UWS salivary flow rate after 
renal transplantation could explain a decreased level of xerostomia.33 
The number of MS increased in those who remained on dialysis therapy, and no changes 
occurred in the transplantation group after two years. This might be explained since most 
patients awaiting a renal transplant have to undergo an oral examination to become foci 
free, which is part of the preoperative evaluation.6 In addition, previously we have also found 
no differences for the DMFS, DMFT and periodontal indices between ESRD patients and a 
matched (age and educational status) control group (chapter 4).17 In two patients, markedly 
increased gingival overgrowth was found after renal transplantation – according to their 
medical record – probably due to the use of cyclosporine (see illustration 1). Many other 
studies have reported this phenomenon in ESRD patients after renal transplantation.34;35 
Thomason and colleagues35 reported gingival overgrowth in 30% of transplanted patients 
after the use of cyclosporine. As an alternative, tacrolimus can be used which has shown to 
be successful as an immunosuppressant with less gingival overgrowth.36 
Although two patients displayed gingival overgrowth, the average bleeding scores did not 
increase but slightly decreased in the NTx group, after renal transplantation. In a study with 32 
transplant patients on immunosuppressive therapy, it was found that pocket depths, plaque 
and gingivitis scores did not change significantly before and after renal transplantation.37 In 
our study, the percentage of teeth, which showed bleeding on probing decreased in both 
the dialysis and transplanted patients. A study comparing 36 HD patients with 36 controls 
revealed no statistically significant difference for the periodontal status between these two 
groups.11 The decreased levels of bleeding on probing we have found, illustrate less acute 
inflammation of the gingiva. This might be associated with improved oral hygiene proce-
dures, reduced dental plaque-scores or the immunosuppressive drugs.11;38 The oral hygiene 







the level of dental plaque did not differ between baseline and after two years, which is in 
accordance with Rahman and colleagues10, who found no differences in sulcular bleeding 
index score or gingival index score between healthy subjects, patients on HD or those after 
renal transplantation. 
CONCLUSION
Oral health aspects such as caries, dental plaque, gingival bleeding and periodontal indices 
did not change remarkable after a two-year period in ESRD patients remaining on dialysis 
and those who received a renal transplant. Regular dental examination and instruction in pa-
tients awaiting a renal transplantation is of vital importance to ensure optimal oral health, in 
order to remain foci free to prevent rejection of the allograft after transplantation. Decreased 
levels of xerostomia and thirst were observed in patients after renal transplantation, which 
could add to the quality of life of these patients. 
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Most patients on hemodialysis (HD) have to maintain a fluid restricted diet to prevent a high 
interdialytic weight gain (IWG). The prevalence of xerostomia (the feeling of a dry mouth) is 
higher in HD patients than in controls. Recently, we demonstrated that xerostomia and thirst 
were positively related with IWG in HD patients. Thus, this may play a role as a stimulus for 
fluid intake between dialysis sessions. The aim of the present study was to investigate the 
effect of chewing gum or a saliva substitute on xerostomia, thirst and interdialytic weight 
gain (IWG).
Material and methods 
This study was a randomised two-treatment crossover design with repeated measures. After 
the 2-weeks use of chewing gum or saliva substitute, a washout period of two weeks was 
introduced and hereafter the other regimen was carried out. Xerostomia (XI), thirst (DTI), IWG 
and the salivary flow rates were assessed at baseline and after each treatment period.
Results
Sixty-five HD patients (42 men: 54.6 ± 14.1 years; 23 women: 54.7 ± 16.3 years) participated 
in this study. Chewing gum decreased xerostomia (XI) from 29.9 ± 9.5 to 28.1 ± 9.1 (P < 0.05). 
Chewing gum as well as a saliva substitute reduced thirst significantly (P < 0.05), but no dif-
ferences occurred for the average IWG or the salivary flow rates. 
Conclusion 
The use of chewing gum and, to a lesser extent, a saliva substitute, may alleviate thirst and 
xerostomia in some HD patients.
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INTRODUCTION
Most patients with end stage renal disease (ESRD) on hemodialysis (HD) have to maintain a 
fluid restricted diet in order to prevent fluid overload between dialysis sessions. High fluid 
intake through beverages and food, results in high interdialytic weight gain (IWG) between 
dialysis sessions. Long term non-compliance to the fluid restricted diet can induce complica-
tions such as hypertension, acute pulmonary edema, congestive heart failure and cardiovas-
cular comorbidity.1,2
Several strategies have been advocated to reduce fluid intake and IWG in HD patients, such 
as the administration of an angiotensin-converting enzyme (ACE) inhibitor, dietary measures 
or, ultimately, increasing the frequency of HD sessions.3 In 25 chronic HD patients with fluid 
overload, enalapril (an ACE-inhibitor) modestly decreased interdialytic weight gain (IWG) 
from 0.90 to 0.73 kg per day. Dietary measures, such as the restriction of sodium intake or re-
ducing high protein intake have shown to be effective in reducing IWG in HD patients. How-
ever, compliance to the fluid restriction is also influenced by other factors, such as hormonal 
derangements, social- and psychological changes, thirst (the urge to drink) and xerostomia. 
Xerostomia is a symptom, defined as the subjective feeling of a dry mouth.4 Hyposalivation, 
on the other hand, is the objective measured reduction in salivary flow rate. The prevalence 
of both hyposalivation and xerostomia is higher in HD patients than in healthy controls.5,6 Pa-
tients with xerostomia report increased water consumption to facilitate eating and speech.
Recently, we demonstrated that xerostomia in HD patients was positively associated with 
IWG and thirst and, therefore, could play a role as a stimulus for fluid intake between dialysis 
sessions.4 Besides an effect on fluid intake, oral dryness also has an impact on the oral health 
and on the quality of life of the xerostomic patients.
Xerostomia can potentially be improved by mechanical and gustatory stimulation of the 
salivary glands or by palliative care such as saliva substitutes.7 In a pilot study with seven 
non-compliant HD patients, the use of a saliva-substitute reduced the number of dialysis 
sessions with a high IWG.8 This suggests that saliva substitutes or stimulants could potentially 
be used to decrease xerostomia and thus the urge to drink in HD patients. This may increase 
compliance to the fluid restricted diet and could subsequently result in a decreased IWG and 
an improved quality of life.
The aim of this clinical crossover trial was to investigate the potential effect of the use 









Participants and crossover design
One hundred thirty seven ESRD patients undergoing HD were approached in the participat-
ing dialysis centers. The inclusion criteria were: at least 3 months on HD, 18 years or older and 
mentally and physically being able to participate and complete the study. This study was ap-
proved by the Medical Ethic Committee of the Vrije Universiteit Medical Center, Amsterdam, 
The Netherlands.
During the six-week crossover trial, the patients randomly received either chewing gum 
or the saliva substitute regimen. After a washout period of two weeks, to control for any 
crossover effect between products, the other regimen (chewing gum or saliva substitute) 
was tested.
The low-tack, menthol-containing sugar-free chewing gum was Freedent White™ (Wm. 
Wrigley Jr. Company, Chicago, USA), sweetened with xylitol and sorbitol. To get optimal 
patient compliance, two flavors of this chewing gum (Sweetmint® and Winterfresh®) were 
selected in a study with healthy subjects (see Appendix),9 and a pilotstudy among twenty 
HD patients (data not shown). The participants were instructed to chew one or two pieces of 
gum gently, for at least 10 minutes, six times a day and as desired throughout the day when 
the mouth felt dry or when they were thirsty.
The saliva substitute used in this study was Xialine™ (Lommerse Pharma B.V., Oss, the 
Netherlands), which contains 0.92% xanthan gum and 2 ppm sodium fluoride. Two bottles 
(each with 50 mL artificial saliva) were offered to the participants, who were instructed to use 
the spray at least six times a day and as desired throughout the day when the mouth felt dry 
or when they were thirsty.
Age, gender, ethnic background, denture wearing, smoking habits and use of alcohol 
were assessed with a questionnaire. The causes for the ESRD were classified according to 
the European Renal Association – European Dialysis and Transplantation Association. Clinical 
data at baseline, such as systolic and diastolic blood pressure (SDP, DBP), normalized Protein 
Catabolic Rate (nPCR) and weekly removal of urea by dialysis (Kt/V
week
) were retrieved from 
patient files.
Xerostomia, thirst and Kidney Disease Quality of Life
At baseline, and at the beginning and end of each experimental period, the main parameters: 
xerostomia (XI), thirst (DTI), IWG and salivary flow rates were determined. The Kidney Disease 
Quality of Life (KDQOL) was assessed at baseline of the trial to compare to the study popula-
tion with a reference population.
The Xerostomia Inventory (XI) was used to quantify the perceived xerostomia. The XI is a 
validated questionnaire with 11 items, each with a five-point Likert-type scale (never = 1 to 
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very often = 5). The scores are summed, and provide an individual XI score ranging from 11 
(no dry mouth) to 55 (extremely dry mouth).4,10
Thirst was assessed by using a shortened version of the Dialysis Thirst Inventory (DTI) quan-
tifying the occurrence of thirst before, during and after dialysis and perceived thirst during 
day and night.4 Each item has a five-point Likert-type scale (never = 1 to very often = 5). The 
responses to the five items were summed, which results in a score ranging from 5 (never 
thirsty) till 25 (very often thirsty).
The Kidney Disease Quality of Life (KDQOL) was measured using the short version of the 
validated KDQOL-SF™ based on 36 items that focus on health-related concerns of individu-
als with kidney disease on hemodialysis.11 These items are assigned to three kidney disease 
related dimensions and to two generic dimensions; a) symptom problem list; b) effects of kid-
ney disease; c) burden of kidney disease; d) SF-12 physical health; e) SF-12 mental health. The 
item scores were aggregated without weighting and transformed linearly to a 0-100 range, 
with higher scores indicating better states.
Interdialytic Weight Gain (IWG)
Patients were weighed before and after each dialysis session. IWG was defined as the amount 
of fluid (kg) removed during the session (weight predialysis minus weight postdialysis) with 
the assumption that all the weight gained in the previous interdialytic interval had been lost 
during the dialysis session. The IWG was calculated and expressed as the mean IWG during a 
period of two weeks.4
Saliva collection
Unstimulated whole saliva (UWS) and paraffin chewing stimulated whole saliva (CH-SWS) 
were both collected before dialysis. All subjects were instructed to refrain from smoking, eat-
ing, drinking and tooth brushing for one hour prior to saliva collection. UWS was collected 
according to the spitting method, with some small modifications.4 Before collection, the sub-
jects rinsed their mouth with tap water. The collection started with the instruction to void the 
mouth of saliva by swallowing. Saliva was allowed to accumulate on the floor of the mouth 
and the subjects were instructed to spit into pre-weighed test tubes every 30 seconds. The 
saliva collection period was five minutes.
Paraffin chewing stimulated whole saliva (CH-SWS) was collected for five minutes using 
a tasteless piece of parafilm (5 x 5 cm; 0.30 g; Parafilm “M”, American National CAL, Chicago, 
USA). The chewing stimulated saliva was also spitted out into pre-weighed test tubes every 
30 seconds for five minutes. During the saliva collection period, the subjects chewed at their 








The data at baseline were stratified with regard to gender, age (≤ 64 year; > 64 year), residual 
urine output (yes/no) and full-denture (yes/no) and analyzed with an ANOVA. The period 
effect and the influence of the order in which the subjects received the therapy (treatment-
period interaction) were investigated with two sample t-tests. Since no treatment-period 
interaction was found, we compared the effect of each therapy (chewing gum and saliva sub-
stitute) to the main baseline variables using the General Linear Model of ANOVA – repeated 
measures design, followed by paired t-tests as post-hoc procedure. To explore the effect of 
gender, age, residual urine output and full-denture, these variables were separately imputed 
in the model as between-subject factors. The data of the five dimensions of the KDQOL-SF™ 
were compared with the reference population using paired t-tests. The statistical analysis was 
performed using the statistical software package SPSS (version 10.0, SPSS Inc., Chicago, IL, 
USA). All data are presented as mean ± SD, and levels of significance were set at P < 0.05.
RESULTS
Patients demographics
One hundred thirty seven HD patients were approached to participate in this study. After 
explanation of the aim and design of the study, eighty-nine patients gave informed consent 
for participation and entered the study. Main reasons for not participating in the study were 
no thirst (n = 36), not interested (n = 6) or illness (n = 5). Of the eighty-nine HD patients 
who entered the study, 65 (73%) of the initial sample completed the six-week crossover clini-
cal trial: 42 men and 23 women (mean age 54.6 ± 14.1 and 54.7 ± 16.3 years, respectively). 
Reasons for withdrawal during the trial were holidays (n = 4), language problems (n = 3), no 
xerostomia or thirst (n = 2), transplanted during study (n = 2), illness of the patient (n = 1) 
or other reasons not related to the intervention (n = 12). Causes for the chronic renal failure 
were renal vascular disease due to hypertension (15.4%), polycystic kidneys (12.3%), diabetes 
type 2 (6.2%), miscellaneous (26.1%) or unknown (40%). The clinical and socio-demographi-
cal data at baseline are presented in Table 1.
Baseline: XI, DTI, IWG and KDQOL
At baseline, differences were observed for the XI score, the DTI score and IWG for patients 
younger than 65 and those without residual urine output (see Table 2). The level of xerosto-
mia, thirst and IWG were significantly higher in the younger age group compared to individu-
als over 65 years. Patients with residual urine output had less xerostomia and thirst, and a 
significant lower IWG than those without residual urine output. The baseline values of the 
KDQOL-SF in our study population were comparable to a reference population of 428 HD pa-
tients in The Netherlands12, thus representing a normal Dutch HD population (see Table 3).
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Crossover study: effect on XI, DTI and IWG
A significant treatment effect was observed for xerostomia (P = 0.024) and thirst (P = 0.015), 
see Table 4a. The use of chewing gum decreased the level of perceived xerostomia signifi-
cantly from XI = 29.9 ± 9.5 at baseline to XI = 28.1 ± 9.1 after gum chewing (P = 0.005). Both 
chewing gum and the saliva substitute had a positive overall effect on the perceived thirst 
(DTI score) during the crossover clinical trial. Stratification of preference for the chewing gum 
(Sweetmint®; Winterfresh®) showed no different treatment effect. The IWG during treatment 
with chewing gum or the saliva substitute did not differ from the average IWG measured 
at baseline, see Table 4a. Also the systolic and diastolic blood pressure showed no effect of 
saliva substitute or chewing gum (data not shown). 
Table 1. Demographic and clinical data at baseline (n = 65)
Age (years) (SD) 54.6 (14.8) 
Male gender 64.6% (n = 42)
Diabetes type 1 or 2 15.4% (n = 10)
Residual Urine Output 27.7% (n = 18)
Full denture 32.3% (n = 21)
Current smoker 26.2% (n = 17)
Alcohol use 38.5% (n = 25)
Educational level Primary school 21.5% (n = 14)
Secondary school 35.4% (n = 23)
High school or higher 43.1% (n = 28)
Ethnical background Dutch 60.0% (n = 39)
Indonesian  7.7% (n = 5)
Surinam  6.2% (n = 4)
Maroc  7.7% (n = 5)
Other 18.5% (n = 12)
Time on HD (months) 27.1 (24.0) (n = 4)
HD sessions per week 2  6.1% (n = 4)
3 90.8% (n = 59)
> 3  3.1% (n = 2)
IWG (kg) 2.1 (0.9)
IWG/day (kg/day) 0.94 (0.47)
SBP before (mm Hg) 146.1 (18.9)
DBP before (mm Hg) 80.5 (9.2)
SBP after (mm Hg) 131.3 (19.0)
DBP after (mm Hg) 74.4 (11.0)
Kt/V urea week 4.2 (0.9)
nPCR (g/kg/day) 1.17 (0.31)
Albumin (g/L) 36.0 (4.4)
Mean values (SD) are given for continuous variables. IWG, SBP and DBP are mean values of the dialysis sessions that took place during the 2 
weeks before the baseline measurements. Abbreviations: IWG, interdialytic weight gain; Kt/V week, average removal of urea expressed per 







Gender, age and wearing a full denture had no effect on the response to the different treat-
ment modalities. However, a significant interaction was observed for residual urine output 
with the XI scores. In patients without residual urine output the XI scores decreased signifi-
cantly from 31.9 ± 9.4 at baseline to 29.3 ± 9.1 after gum chewing (P = 0.003) and to 30.6 ± 
9.5, after saliva substitute (P = 0.038), see Table 4b.
In HD patients with thirst, an overall treatment effect of chewing gum and saliva substitute 
on thirst (DTI) and xerostomia (XI) was found (Table 4b). Chewing gum reduced both the XI 
and the DTI score. In patients with thirst, the saliva substitute had no effect on the level of 
xerostomia. Patients with thirst had significantly higher IWG values than those without thirst. 
However, neither gum nor spray did affect the IWG in the ‘thirst group’. No significant differ-
ence was found for the number of patients with diuresis between the ‘thirst’ group and the 
‘no thirst’ group.
In patients with hyposalivation (UWS ≤ 0.15 mL/min), an overall treatment effect was found 
on the XI scores. Gum chewing reduced the XI scores significantly from 33.2 ± 9.1 to 29.7 ± 
8.4 (P < 0.05, see Table 4b). During both treatment modalities, the DTI levels were comparable 
between both groups (see Table 4b) and no overall treatment effect was found. Patients with 
hyposalivation and those with normal salivary flow rates did not differ with respect to the 
IWG. Also, the treatment did not have an effect on the IWG.
Table 2. Xerostomia (XI), thirst (DTI), Interdialytic weight gain (IWG ), unstimulated whole saliva (UWS) and parafilm chewing stimulated 
whole saliva (CH-SWS) at baseline (n = 65)
XI (11-55) DTI (5-25) IWG (kg) UWS (mL/min) CH-SWS (mL/min) n
Gender Male 28.7 (8.5) 16.8 (5.1) 2.2 (1.0) 0.32 (0.28) 0.95 (0.53) 42
Female 32.0 (10.9) 16.4 (5.3) 1.9 (0.8) 0.26 (0.16) 0.90 (0.74) 23
Age group ≤ 64 years 31.7 (9.3)* 17.7 (4.4)* 2.3 (0.9)* 0.32 (0.27) 0.96 (0.62) 46
> 64 years 25.5 (8.7) 14.0 (5.9) 1.6 (0.7) 0.24 (0.16) 0.88 (0.61) 19
Residual Urine Output Yes 24.7 (7.9) 13.9 (5.4) 1.4 (0.8) 0.32 (0.18) 0.96 (0.48) 18
No 31.9 (9.4)* 17.7 (4.7)* 2.4 (0.8)** 0.28 (0.27) 0.93 (0.66) 47
Full denture Yes 30.5 (11.3) 15.5 (6.6) 1.8 (1.0) 0.33 (0.37) 1.00 (0.59) 21
No 29.8 (8.5) 17.4 (4.1) 2.2 (0.8) 0.28 (0.17) 0.90 (0.63) 44
Data were analyzed with an ANOVA, * P < 0.05; * * P < 0.01.
Table 3. Overview of the five dimensions of the Kidney Disease Quality of Life (KDQOL) at baseline compared to a reference population 12
KDQOL dimensions Study (n = 65) NECOSAD (n = 428)
Symptom Problem 77.6 (13.7) 74.8 (15.6)
Effect Kidney Disease 73.0 (17.2) 69.3 (19.4)
Burden Kidney Disease 48.8 (24.0) 45.9 (25.5)
SF-12 Physical 37.1 (11.4) 36.1 (9.8)
SF-12 Mental 47.0 (9.6) 45.8 (10.3)
Data are analyzed with Students t- tests. No significant differences were observed.
NECOSAD = Netherlands Cooperative Study on Adequacy of Dialysis.
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In a subgroup of HD patients (n = 12) without residual urine output, suffering from thirst 
(DTI = 16-25) and hyposalivation (UWS ≤ 0.15 mL/min) the highest mean XI values were ob-
served. A significant reduction of the XI score was observed after the use of chewing gum for 
two weeks from 37.8 ± 7.2 to 32.6 ± 6.6. The use of a saliva substitute, however, did not affect 
the XI score. In this subgroup, no treatment effects were found for the level of thirst (DTI) and 
IWG (data not shown).
Table 4a. The effect of the two treatment modalities (chewing gum and saliva substitute for two weeks) on the main outcome variables in 65 
HD patients 
XI (11-55) DTI (5-25) IWG (kg) UWS (mL/min) CH-SWS (mL/min)
Baseline 29.9 (9.5) 16.6 (5.1) 2.09 (0.9) 0.26 (0.2) 0.89 (0.5)
Chewing gum 28.1 (9.1)* 15.4 (4.8)* 2.07 (0.9) 0.28 (0.2) 0.81 (0.4)
Saliva substitute 29.0 (9.6) 15.5 (5.0)* 2.08 (1.0) 0.30 (0.2) 0.89 (0.5)
Treatment (p) 0.024 0.015 n.s n.s. n.s.




), Interdialytic weight gain (IWG 
kg
), unstimulated whole 
saliva (UWS
mL/min
) and chewing stimulated whole saliva (CH-SWS
mL/min
) are presented. In italics the P-values of the effect of sequence and overall 
treatment (repeated measures MANOVA). The two treatment modalities (chewing gum and saliva substitute) are compared to baseline and 
tested with a GLM-ANOVA, followed by paired t-tests as post-hoc procedures; * P < 0 .050.
Table 4b. The effect of the two treatment modalities (chewing gum; saliva substitute) on the xerostomia (XI), thirst (DTI) and interdialytic 
weight gain (IWG) with regard to residual urine output, hyposalivation and thirst
Residual Urine Output; n = 18 No Residual Urine Output; n = 47
XI (11-55) DTI (5-25) IWG (kg) XI (11-55) DTI (5-25) IWG (kg)
Baseline 24.7 (7.9) 13.9 (5.4) 1.4 (0.8) 31.9 (9.4)# 17.6 (4.7)# 2.4 (0.8)#
Chewing gum 24.7 (8.7) 12.8 (4.9) 1.3 (0.8) 29.3 (9.1)** 16.4 (4.3)# 2.4 (0.7)#
Saliva substitute 24.8 (8.6) 12.2 (5.5) 1.3 (0.8) 30.6 (9.5)*/ # 16.7 (4.3)# 2.4 (0.9)#
Treatment (P) n.s n.s. n.s. P < 0.05 n.s. n.s.
No thirst (DTI 5-15); n = 26 Thirst (DTI 16-25); n = 39
XI (11-55) DTI (5-25) IWG
 
(kg) XI (11-55) DTI (5-25) IWG (kg)
Baseline 22.8 (6.0) 11.4 (3.5) 1.8 (0.9) 34.5 (8.6)$ 20.1 (2.3)$ 2.3 (0.9)$
Chewing gum 22.5 (7.3) 12.2 (4.5) 1.7 (0.9) 31.6 (8.6)**/ $ 17.6 (3.6)**/ $ 2.3 (0.8)$
Saliva substitute 21.2 (5.5) 11.7 (3.9) 1.8 (1.2) 33.8 (8.6)$ 18.0 (4.1)**/ $ 2.2 (0.8)
Treatment (P) n.s n.s n.s. P < 0.05 P < 0.001 n.s.
No hyposalivation ( > 0.16 mL/min); n = 46 Hyposalivation (< 0.15 mL/min); n = 19
XI (11-55) DTI (5-25) IWG (kg) XI (11-55) DTI (5-25) IWG (kg)
Baseline 28.5 (9.4) 15.9 (5.5) 2.1 (1.0) 33.2 (9.1)Φ 18.4 (3.7) 2.1 (0.7)
Chewing gum 27.4 (9.5) 14.8 (4.7) 2.1 (1.0) 29.7 (8.4)** 17.2 (4.6) 2.0 (0.7)
Saliva substitute 27.3 (9.4) 14.8 (5.3) 2.1 (1.0) 33.0 (9.1)Φ 17.2 (3.9) 2.1 (1.0)
Treatment (P) n.s n.s. n.s. P < 0.05 n.s. n.s.




) and interdialytic weight gain (IWG 
kg
). In italics the P-values 
of the effect of the overall treatment (repeated measures MANOVA). The two treatment modalities (chewing gum and saliva substitute) 
are compared to baseline and tested with a GLM-ANOVA, followed by paired t-tests as post-hoc procedure; n.s. = no statistical significance; 
* P < 0.05; * * P < 0.001. Values indicated with (#,$,Φ) in the right column (‘No residual urine output’, ‘thirst’, ‘hyposalivation’) differ statistically 







Saliva secretion: at baseline and effect therapy
UWS and CH-SWS flow rates showed a skewed distribution and were square root transformed 
before statistical analyses. For clarity, the untransformed data are presented. At baseline, the 
mean UWS was 0.26 ± 0.15 mL/min (median = 0.24; range = 0.01-1.80). The CH-SWS was 0.89 
± 0.44 mL/min (median = 0.82; range = 0.18-3.78). Treatment with chewing gum or the saliva 
substitute did not influence the UWS and CH-SWS (Table 4a).
DISCUSSION
Thirst and xerostomia are major problems for patients on hemodialysis.4,6,13,14 Oral-pharyngeal 
factors, such as a dry mouth, have been associated with thirst.4 Therefore it is feasible that 
mechanical stimulation of saliva secretion by chewing gum potentially could reduce thirst.
This study is the first large-scale clinical crossover study to investigate the effect of chew-
ing gum and a saliva substitute on xerostomia (XI), thirst (DTI) and IWG in patients on hemo-
dialysis. Overall, the use of chewing gum during two weeks among HD patients significantly 
reduced both thirst and xerostomia. This is in agreement with other studies that investigated 
the effect of chewing gum on xerostomia in other patient populations, such as rheumatic 
patients15 or in patients with a malignant disease.16 Besides the role of oral dryness, also other 
factors such as sodium intake, high plasma sodium, potassium depletion, angiotensin II lev-
els, rapid increases in plasma urea and psychological factors play role in the multi-complexity 
of thirst and fluid intake among HD patients.4,13,17,18
In this study the use of a saliva substitute by HD patients reduced perceived thirst but had 
no effect on xerostomia. In the literature, conflicting data about the efficacy of saliva sub-
stitutes have been presented. In thirty patients with radiation-induced xerostomia, feelings 
of a dry mouth decreased after the use of a saliva substitute. However, other studies failed 
to show a substantial effect of saliva substitutes after radiation therapy or in patients with 
Sjögren’s syndrome.7,19
Although the effect of the therapy on the XI and DTI score was modest, the majority of 
patients (72.3%) rated chewing gum as a beneficial therapy. Chewing gum was also rated 
best with respect to effectiveness, easiness to use and taste compared to the saliva substitute 
(see Chapter 7). Therefore, chewing gum seems preferable in the reduction of oral dryness 
and thirst among HD patients.
The mean salivary flow rates were normal and comparable, both to reference values for 
healthy individuals and to other studies in HD patients.14 In general, patients with severe 
hyposalivation respond best on saliva substitutes.7 This is in contrast to our study, in which 
gum chewing reduced xerostomia best in the subgroup with hyposalivation (UWS ≤ 0.15 
mL/min). The most plausible reason is that the xerostomia and hyposalivation in other inves-
tigations is of different origin.7,19,20 Since it is likely that salivary glands are not affected by the 
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HD treatment,4 mechanically or gustatory activation by chewing is still possible, in contrast 
to patients suffering from severe Sjögren’s syndrome.
Previously, we have shown that thirst is significantly related to IWG.4 Compliance to the flu-
id restricted diet (500 mL/day) was measured by IWG. Although gum chewing and spraying 
with a saliva substitute significantly reduced thirst, the IWG in HD patients was not affected. 
Several patients indicated that chewing and spraying had a distracting effect and resulted in 
postponing fluid intake, however, the net fluid intake remains the same in the study period. 
This might be explained because the patients know how much weight they are allowed to 
gain between dialysis and thus drink, although no thirst is present. It might also be possible 
that a two-week period is too short to affect the fluid intake and thus the IWG. The contribu-
tion of fluid intake due to the use of artificial saliva was negligible, since the average volume 
of artificial saliva used did not exceed 7 mL/day. 
A potential limitation of this study is the lack of blinding. However, this is unavoidable in 
this crossover design in which the participant received two potential active agents (chewing 
gum and saliva substitute).
CONCLUSION
This crossover clinical trial shows that a saliva stimulating agent (chewing gum) and a saliva 
substitute both induced a modest reduction in the level of thirst (DTI) in HD patients. The 
level of xerostomia (XI) was reduced after the use of chewing gum. However, no evidence of 
reduced fluid intake or weight gain could be obtained. HD patients younger than 65 years 
without residual urine output have to deal most with thirst and xerostomia and could there-
fore benefit from chewing gum or artificial saliva. Therefore, we conclude that the use of 
chewing gum, and to a lesser extent a saliva substitute, may alleviate thirst and xerostomia in 
some HD patients on a fluid restricted diet and thus should be considered as a clinical tool to 
assist HD patients in maintaining to the fluid restricted diet.
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Many patients on hemodialysis therapy (HD) suffer from a dry mouth and xerostomia. This 
can be relieved by mechanical and gustatory stimulation or palliative care. The aim of this 
crossover study was to investigate the effect and preferences of a sugar-free chewing gum 
(Freedent White™) and a xanthan gum-based artificial saliva (Xialine™) in the management of 
xerostomia in chronic HD patients. 
Material and Methods
Sixty-five HD patients participated in a six-week crossover trial. The artificial saliva was rated 
significantly lower than the chewing gum for effectiveness, taste and global assessment. 
Results
No preference differences were found for gender and age, although older subjects rated the 
artificial saliva with a higher mark. Thirty-nine subjects (60%) preferred chewing gum, 15% 
(n = 10) preferred the artificial saliva. 
Conclusion
Both chewing gum and artificial saliva could play an important role in the palliative care of 
xerostomia in HD patients.
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INTRODUCTION
The major function of the kidneys is the removal of metabolic waste products, electrolytes 
and water. If this function is impaired to a fatal level, end stage renal disease (ESRD) occurs 
leading to death, unless renal replacement therapy is started. Chronic dialysis therapy such as 
hemodialysis (HD) has proven to be successful in prolonging the life of these patients. During 
HD treatment, an artificial kidney is used for several hours, three or four times a week, to clarify 
blood of waste products and excess fluid. Patients on HD therapy have several oral complica-
tions among others an impaired salivary flow rate and an increased subjective sensation of 
a dry mouth (xerostomia).1 The prevalence of xerostomia in HD patients ranges between 33 
and 76%.2-4 The patients’ quality of life (QoL) and oral health are negatively influenced by a 
dry mouth.5,6 Besides a direct effect of the HD treatment on the level of xerostomia, also other 
factors such as medication, depression or forthcoming stress from the HD treatment may 
contribute to the perceived xerostomia.7-11
A slight or moderate level of xerostomia can be alleviated by mechanical and gustatory 
stimulation of the salivary glands using chewing gum or lozenges. Severe xerostomia can be 
ameliorated by parasympathetic stimulation (pilocarpine) or palliative care such as artificial 
saliva.12,13 Most studies in this research field focused on either the effect of an artificial saliva 
or a saliva stimulant in patients after radiation therapy in the oral-facial region or in those 
with Sjögren’s syndrome.12,14-17 This is the first study to compare the use of both artificial saliva 
and chewing gum in chronic HD patients.
We aimed to investigate which therapy – sugar-free chewing gum or artificial saliva – was 
preferred most in the management of xerostomia in ESRD patients on hemodialysis.
METHODS
Participants and design of the study
This multi-center study was conducted at the Vrije Universiteit Medical Center (Amsterdam), 
The Rode Kruis Hospital (The Hague) and Stichting DIANET Dialysis Centers (Amsterdam and 
Utrecht). The study protocol was approved by the Medical Ethical Committee of the Vrije 
Universiteit Medical Center, Amsterdam, The Netherlands. 
At the different dialysis centers, one hundred thirty seven ESRD patients, undergoing were 
approached. The inclusion criteria were more than three months on HD, > 18 years of age and 
mentally and physically being able to participate and complete the study. After explanation 
of the aim and design of the study, eighty-nine patients gave informed consent for participa-
tion and entered the study. Sixty-five (73%) of the patients completed the six-week crossover 







The study was a six-week crossover trial. At the beginning and end of each two-week test 
period, the level of perceived xerostomia was measured and the effectiveness of the treat-
ment was assessed. After baseline measurements, patients were randomly allocated to either 
chewing gum or the artificial saliva regimen. A two-week washout period was introduced to 
control for potential crossover effects between products. Subsequently, the other regimen 
(chewing gum or artificial saliva) was tested (Figure 2). 
The chewing gum used in this study was Freedent White™ (Wm. Wrigley Jr. Company, 
Chicago, USA), a low-tack, and menthol-containing but sugar-free chewing gum. To get 
optimal patient compliance, two flavors of the same type of chewing gum (Sweetmint: 






























Approached for the study 
(n = 137) 
Entered the study 
(n = 89) 
Reasons for not participating: 
- too ill    n = 5 10% 
- not interested  n = 7  15% 
- no xerostomia/thirst n = 36 75% 
Completed the study 
(n = 65) 
Reasons for withdrawing during study:
- too ill    n = 1   4.2%
- transplanted   n = 2   8.3%
- no xerostomia/thirst  n = 2   8.3%
- language problems  n = 3   13% 
- holiday during experiment n = 4   17% 
- others       n = 12 50% 
Figure 1. Profile of the study
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Figure 2. Crossover study design: each test period was two weeks. After each test period a questionnaire (Q) was distributed to assess the level 
of xerostomia (XI), the preferences and the effect of the treatment.
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mild; Winterfresh : strong) were selected and given to the patients.18 The participants were 
instructed to chew one or two pieces of gum gently, six times a day for at least 10 minutes 
and as desired throughout the day when their mouth felt dry. The artificial saliva used was 
Xialine™ (Lommerse Pharma B.V., Oss, Holland), based on xanthan gum. The participants were 
instructed to use a dose of three sprays at least six times a day, and as desired throughout the 
day and night when the mouth felt dry.
At baseline and at the end of each therapy, the level of xerostomia was assessed with the 
Xerostomia Inventory (XI). This is a validated questionnaire with 11 items. Each item has a 
five-point Likert type scale (never = 1 to very often = 5) and the scores are summed which 
provides an individual XI score ranging from 11 (no dry mouth) to 55 (extremely dry mouth).19 
At the end of each treatment period, a questionnaire (100mm visual analogue scale = VAS) 
was used to assess the effectiveness, preferences and side effects of the treatment, see 
Table 1.18
Statistical methods
The data of the 65 patients who completed the crossover study were analyzed and are pre-
sented. First, we assessed the potential effect of sequence (chewing gum-artificial saliva vs 
artificial saliva-chewing gum) on the level of xerostomia (XI). Since sequence did not affect 
the XI-level, we investigated the overall treatment effect of each therapy with repeated-
measures multivariate analysis of variance (MANOVA). Hereafter, we investigated the effect 
of each therapy compared to BASELINE for the level of xerostomia using a General Linear 
Model of ANOVA – repeated measures design, followed by paired t-tests as posthoc proce-
dure when appropriate. The differences between the data of the VAS-scales were analyzed 
using non-parametric tests and the other data from the questionnaire were analyzed using 
chi-square tests. Separately, the differences between gender, age (≤ 64 years vs > 64 years) 
and xerostomia (XI score ≤ 33 or > 33) were analyzed. The statistical analysis was performed 
Table 1. Responses to the different items of the questionnaire, concerning the effect of the two therapies (n = 65)
Artificial saliva Chewing gum
Easiness to use the product VAS not easy – very easy 6.7 (2.9) 7.6 (2.3) P < 0.050
Effect on relieving thirst VAS not effective – very effective 3.3 (2.6) 5.5 (2.7) P < 0.001
Effect on relieving dry mouth VAS not effective – very effective 4.3 (2.8) 6.5 (2.5) P < 0.001
Judgment of taste VAS unpleasant – pleasant 6.0 (2.5) 7.3 (2.2) P < 0.050
VAS nasty – delicious 5.5 (2.0) 7.3 (2.0) P < 0.001
VAS mild – strong 2.7 (1.9) 4.5 (2.7) P < 0.001
Global assessment (mark 1-10) 5.6 (2.1) 7.1 (1.6) P < 0.001
The therapy was beneficial 43% (n = 28) 72% (n = 47) P < 0.001
Willingness to use the therapy during a longer time 39% (n = 25) 70% (n = 46) P < 0.001
Data are presented as mean (SD) and were analyzed using non-parametric Wilcoxon tests. Chi-square tests were applied on the reply to the 







using the statistical software package SPSS (version 10.0, SPSS Inc., Chicago, IL, USA). All data 
are presented as mean ± SD and levels of significance were set at P < 0.05.
RESULTS
One hundred thirty seven HD patients were approached to participate in the study. Eighty-
nine patients gave informed consent and entered the study (see Figure 1). Reasons for not 
participating in the study were illness (n = 5), no xerostomia or thirst (n = 36) and not interest-
ed (n = 7). Sixty-five (73%) patients entered the study and completed the six-week crossover 
clinical trial: 42 men and 23 women (mean age 54.6 ± 14.1 and 54.7 ± 16.3 years, respectively), 
which represent the general Dutch population receiving hemodialysis treatment. At baseline, 
the mean time of treatment with HD was 27.1 ± 24.0 months.
Overall, artificial saliva was rated significantly lower than the chewing gum on each item of 
the questionnaire (see Table 1). In the artificial saliva group, the mean VAS score for the effect 
of the therapy relieving a dry mouth (VAS not effective-very effective) was 4.3 ± 2.8 compared 
to 6.5 ± 2.5, for the chewing gum. The taste of the gum was appreciated significantly more 
pleasant and delicious (VAS unpleasant-pleasant = 7.3 ± 2.2) than the artificial saliva (VAS 
unpleasant-pleasant = 6.0 ± 2.5), see Table 1. The global assessment for chewing gum and 
artificial saliva were respectively, 7.1 ± 1.6 and 5.6 ± 2.1. Nevertheless, a subpopulation of the 
patients (15%) preferred the use of artificial saliva. No differences were found between the 
participants and those who initiated but not completed the therapy (data not shown).
The global assessment given by the older patient category (> 64 years) for the artificial 
saliva was significantly higher than the global assessment given by younger patients (mean 
6.6 ± 1.6 and 5.2 ± 2.2, respectively). However, after stratification with regard to gender, age 
and the level of xerostomia (XI) no significant differences were found for the other items in 
the questionnaire, neither for the preferences of chewing gum nor artificial saliva.
Table 2. Differences in preferences between artificial saliva and chewing gum
Artificial saliva Chewing gum
Which therapy do you prefer? 15.4% (n = 10) 60.0% (n = 39) P < 0.001
No preference: 6.2% (n = 4)
None of both: 7.7% (n = 5)
Not reported: 11% (n = 7)
Reason for preference: Effect 60% (n = 6) 92% (n = 36) P < 0.005
Taste 40% (n = 4) 72% (n = 28) n.s.
Easiness to use 80% (n = 8) 74% (n = 29) n.s.
Not much side effect 50% (n = 5) 41% (n = 16) n.s.
Chi-square tests were applied to analyse the differences between artificial saliva and chewing gum.
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A significant difference was found for the number of HD patients who rated the use of chew-
ing gum beneficial (n = 48; 72%) and those who replied that the use of spray was beneficial 
(n = 28; 43%). Twenty-five patients (39%) rated chewing gum as the most beneficial therapy 
in contrast to six patients (9.2%) who chose artificial saliva as most beneficial. Twenty-two 
patients (34%) judged both therapies as equally beneficial, compared to 8 patients (12%) 
who reported that both therapies were not beneficial. Seventy one percent (n = 46) of all the 
patients were willing to use the chewing gum during a longer time, while 39% (n = 25) were 
willing to use the saliva substitute during a longer time.
The preference for the two different tastes of chewing gum were assessed and revealed 
no significant differences, although sweetmint was slightly more preferred (n = 24; 37%) 
than peppermint (n = 18; 28%). Twenty-three patients (35%) had no preference for a specific 
taste.
At the end of the experiment, the overall preferences were assessed. Thirty-nine (60%) pa-
tients preferred chewing gum, while 10 (15%) preferred the artificial saliva. Four patients had 
no preference; five preferred none of both and seven did not report their preference. The two 
main reasons for preference of a specific therapy were the overall effect and easiness to use, 
see Table 2. No difference in preference was found for gender and for age.
Specific side effects related to the therapy were also assessed with a questionnaire (Table 
3). Eighteen patients (28%) reported a bad taste as side effect of the artificial saliva compared 
to six patients (9.2%) after the use of chewing gum. No significant differences were found 
for the other side effects mentioned. Sixteen patients (25%) using chewing gum reported 
fatigue in the jaw muscles after chewing during two weeks. An overview of spontaneously 
given comments, both positive and negative, is presented in Table 4.
Both treatment arms (chewing gum and artificial saliva) demonstrated similar compliance 
during daytime. Ninety five percent (n = 62) used the chewing gum in the afternoon, com-
pared to 83% (n = 54) in the artificial saliva group. In the night, 26% (n = 17) of the patients 
used the artificial saliva compared to 9% (n = 6) in the chewing gum group. Chewing gum is 
used more frequently before (42% ; n = 27) and after (48% ; n = 31) the dialysis session then 
Table 3. Side effects of artificial saliva and chewing gum (n = 65)
Artificial saliva Chewing gum
Unpleasant taste 28% (n = 18) 9.2% (n = 6) n.s.
Nausea 9.2% (n = 6) 4.6% (n = 3) n.s.
Irritation of the oral mucosa 3.1% (n = 2) 4.6% (n = 3) n.s.
Diarrhea 6.2% (n = 4) 9.2% (n = 6) n.s.
Sensitivity of the jaw - - 11% (n = 7) - -
Fatigue of the muscles - - 25% (n = 16) - -
Sensitivity of the teeth - - 6.2 % (n = 4) - -







during (15% ; n = 10). Artificial saliva showed the same pattern, (23% (n = 15); 17% (n = 11); 
7.7% (n = 5), respectively).
DISCUSSION
Patients on hemodialysis (HD) have to maintain a fluid restricted diet to prevent fluid over-
load. Besides that they suffer from thirst and xerostomia, which has a substantial impact on 
the quality of life of severely ill patients and those on chronic renal replacement therapy.6 
Oral effects of long-standing xerostomia are an increased frequency of caries, mucosal sore-
ness and an increased risk of oral inflammation.17 In the management of xerostomia, slight 
xerostomia can be treated by mechanical or gustatory stimulation (chewing gum), while 
more severe xerostomia can be treated with parasympathetic stimulation (pilocarpine or 
Table 4. Overview of comments on the therapies, given spontaneously
CHEWING GUM
Positive Negative
Positive about chewing (n = 2) Pain underneath denture during chewing
Pleasant (n = 3) Pain of muscles in the jaw (n = 2)
Stimulates saliva Naussea (n = 2)
Less oral dryness (n = 4) Dryness and hungry after use
Less thirst (n = 2) Sore gingiva and throat
Pleasant distraction Taste quickly gone (n = 2)
Does not stick to the teeth Sweetmint too sweet
Easier than spray Peppermint too strong
Good alternative for drinking Unpleasant taste
Chewing gum sticks to teeth (n = 3)
Chewing gum too tough
I don’t like chewing
ARTIFICIAL SALIVA
Positive Negative
Oral cavity feels humid Taste not fresh (n = 3)
I don’t drink water in the night anymore Not effective (n = 2)
Spray works when I am very dry, e.g. after speeching Works shortly (n = 4)
Fresh, pleasant spray (n = 2) Taste of spray can be stronger (n = 2)
Gives a good feeling I prefer water
Candy or gum gives more distraction
Nausea (n = 2)
Difficult to press on bottle (n = 3)
Bottles are too big for pocket
The amount of spray is not consistent
Thirsty after use (n = 2)
My throat stays dry (n = 2)
Mouth dryer than before (n = 2)
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cevimeline) or artificial saliva.12,13,18,20 This is the first crossover study among HD patients in 
which the preferences between artificial saliva and chewing gum were compared. It was re-
vealed that, compared with artificial saliva, chewing gum was preferred by the major part of 
the patients in the palliative treatment of a dry mouth.
The efficacy of chewing gum or saliva substitutes as therapy for xerostomia has previously 
been investigated in other patient categories. Only a few clinical trials have been carried out 
in which artificial saliva was tested against the use of chewing gum in a crossover design.14,21,22 
At the end of the trial, 60.0% of the patients (n = 39) preferred the use of chewing gum, 
compared to 15.2% preferring artificial saliva. These results are in accordance with Davies 
and co-workers, who conducted a prospective, randomized, open crossover study among 
forty-one patients with malignancy that experienced from xerostomia.22 In another study, 
one hundred and six subjects with low salivary flow rates and long term xerostomia partici-
pated. Both the saliva substitutes and stimulants relieved the xerostomic feelings to some 
extent, but showed no substantial differences. However, the saliva stimulants V6® chewing 
gum and Salivin® lozenge were ranked as the two best products.14 This is in accordance with 
another crossover study in which patient preferences and product efficacy were assessed in 
eighty subjects with xerostomia and hyposalivation. Although no differences were revealed 
in the efficacy of the various therapies (chewing gum, lemon lozenges, artificial saliva), the 
majority of patients preferred the use of a saliva stimulant (70%; n = 56).21 
In our study we used Xialine™, a saliva substitute based on the natural biopolymer xanthan 
gum.23 Xialine™ improved problems with speech and taste perception in patients treated 
with radiotherapy for head and neck cancer.24 In a crossover study with forty-three Sjögren’s 
syndrome patients, three saliva substitutes (polymer, gum and mucin-based) were equally 
effective in the reduction of xerostomia, compared to placebo.23
The fact that the participants preferred the chewing gum (Table 1 and 2) could have sev-
eral reasons. The effectiveness of gum on relieving thirst and a dry mouth was higher, which 
might be an effect of the saliva stimulating capacity of the gum.18 Artificial saliva probably 
works shorter. Using chewing gum might attract less attention in public than spraying and 
can be carried out easily. In addition, some patients experienced difficulties with pressing 
the bottle. More advanced bottle designs might enhance the easiness to use the spray. Both 
therapies contained menthol flavour, intensity differences of this flavour could have influ-
enced the preferences.
Age has no effect on the preferences, but it has a substantial effect on the global assess-
ment. Older HD subjects rated the artificial saliva higher than the chewing gum. This is in 
accordance with other studies in which older patients preferred use of artificial saliva.26,27 
Several factors may contribute to this observation. It is generally agreed, that the lack of so-
cial acceptance of gum chewing in public plays a role in the aged generation. The prevalence 
of wearing a (partial) denture increases with age, while the amount and density of the jaw 







Since most gum types stick to the denture base, the gum used in this study was a low-tack 
gum which does not stick to a denture and is therefore better accepted in patients with den-
tures or metal appliances.28,29 
In general, chewing gum and artificial saliva are not associated with many side-effects, 
although intense gum chewing can contribute to temporomandibular joint pain.30 In our 
study, respectively 10.8% (n = 7) and 24.6% (n = 16) of the patients reported sensitivity and 
fatigue of the jaw muscles. In a previous study by Davies, among xerostomic patients with a 
malignant disease, fewer side effects after gum chewing were reported.22
Eighteen patients (27.7%) reported an unpleasant taste of the artificial saliva. Therefore, 
acceptance of the artificial saliva may be increased, by offering several choices with different 
tastes. Nausea and diarrhea were also mentioned as side effects of the treatments. However, 
it is not clear if this should be attributed to the therapy only, since HD treatment itself can also 
induce these side effects.31
CONCLUSION
The results of this crossover study show that in HD patients, chewing gum was preferred for 
relief of xerostomia over the use of a saliva substitute. However, a subgroup of HD-patients 
prefers the application of artificial saliva particularly at night. Chewing gum was also rated 
best on every measurement and could thus play an important role in the palliative care of 
xerostomia in HD patients.
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ESRD: THE ORAL COMPONENT
In this thesis, we have described studies of consequences of end stage renal disease (ESRD) 
on several oral parameters. In literature, a high prevalence of bad breath, temporomandibu-
lar pain, neglected oral health and reduced oral self-care were reported in ESRD patients.1-3 
Dissecting the exact role of ESRD in oral health, however, has proven to be elusive since para-
doxical findings have been reported about the numbers of decayed, missing and filled teeth 
(DMFT) in hemodialysis patients (HD).4-6 In order to quantify the role of ESRD, we carried out 
a cross-sectional study, described in chapter 4. In this analysis, we have compared the oral 
health status in a cohort of dentate ESRD patients on hemodialysis (HD) or peritoneal dialysis 
(PD) treatment with a well-defined reference population, matched for age and educational 
status.
Increased levels of urea and the associated high salivary pH (alkaline), increased calculus 
formation and remineralization, are characteristic finding in ESRD patients. The consequences 
of these findings are matter of contention since the net result could potentially have a posi-
tive or negative effect on the oral health.7 The increased salivary pH for example may offer 
protection of the teeth against acids from bacterial and non-bacterial origin such as gastric 
acid.8 
An alternative explanation for our finding of relative good oral health in ESRD patients, 
could be the increased efficacy, adequacy and improved dialysis treatment modalities during 
the last decades for patients with ESRD.9 Since oral and dental foci could jeopardize the suc-
cess of a renal transplant (NTx),5 most patients on the waiting list for a renal transplantation 
underwent a dental examination and treatment before they were included in our study. This 
could potentially have influenced our results.
Our finding of a relatively normal salivary flow rate in ESRD patients was unexpected, since 
most studies have reported reduced flow rates in dialysis patients.8,10-13 Salivary flow rates 
were shown to be significantly increased during HD sessions (Chapter 2). Previous studies 
on saliva either used saliva collected before a dialysis session10,13 or on a non-dialysis day.8 
The variety in collection times in the studies described in literature probably underlies the 
paradoxical findings in prevalence and severity of hyposalivation in ESRD patients. It can be 
hypothesized that after completion of the dialysis session, the salivary flow rate gradually will 
decrease and as a consequence, hyposalivation is present in the post-dialysis episode or in-








Despite the relative normal salivary flow rates, a large proportion of ESRD patients in our 
study reported to suffer from thirst (DTI) and xerostomia (XI), which were the major oral re-
lated complaints in ESRD patients (Chapters 3 and 6). 
Thirst is influenced by many factors including sodium intake, high plasma sodium, potas-
sium depletion, increased levels of angiotensin II, vasopressin, acute increases in plasma 
urea, psychological factors and feelings of a dry mouth.14-21 Almost a century ago, Cannon 
proposed that the first sign of ‘normal thirst’ is the feeling of dryness in the mouth and throat, 
and that thirst can be neutralized by drinking water or stimulating salivary flow with fruity 
acids or chewing gum.22 In the years thereafter, other investigators have also suggested a 
relation between reduced salivary flow rates and thirst.18,23-26 We have shown that oral dryness 
plays an important role in the fluid intake of HD patients and therefore should receive more 
attention in the management of fluid intake in ESRD patients.
At the beginning of our studies, no validated thirst questionnaire had been described in 
the literature. In order to study the clinical impact of thirst in ESRD, we developed the Dialysis 
Thirst Inventory (DTI), as being described in Chapter 3. The DTI has been used to quantify 
thirst before, during and after dialysis, thirst at night, during the day and the impact of the 
fluid restricted diet on the social life.27 In 2002, Welch published the Thirst Distress Scale (TDS) 
for dialysis patients with three conceptual definitions: distress, duration and frequency of 
thirst.28 At the moment, these two thirst-questionnaires are available to measure thirst in di-
alysis patients. For validation purposes, it might be considered worthwhile to compare these 
two thirst-questionnaires in future studies. 
Thirst has been associated with an increased concentration of urea in serum.29 The associa-
tion between thirst and urea is supported by our results. In the study described in Chapter 
2, we have demonstrated that the average urea concentration in saliva (correlating with the 
concentration in serum) decreases during a HD session, which was accompanied by a reduc-
tion in thirst. 
Alterations in the composition of saliva in ESRD patients may have contributed to the feel-
ing of dry mouth. Low visco-elastic properties of saliva has, for example, previously been de-
scribed to result in feelings of a dry mouth.30 Measuring the visco-elastic properties of saliva 
from ESRD patients may provide an answer to this hypothesis. Clearly, more investigation is 
needed to disentangle the role of visco-elastic properties of saliva in thirst in ESRD patients.
The DTI-questionnaire measures subjective aspects of thirst. The underlying mechanism of 
the increased thirst sensation in ESRD, however, is not clarified by our studies. Several aspects 
of HD can be hypothesized to be an explanation for our findings, such as physiological and 
psychological factors.31,32 Therefore, it is of interest to explore the potential relation between 
subjective and more objective physiological parameters. Since in both xerostomic and dialy-
sis patients depression is frequently manifest, the role of depression and other psychological 
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factors influencing water intake in HD patients are a potential explanation for the increased 
thirst sensation as well.33-35
In general, the use of medication is an important cause of xerostomia.36,37 Amongst the 
commonly prescribed medications in ESRD patients are anticoagulants, phosphate binders, 
Ca-antagonists, statines, corticosteroids and vitamins. In general, antihypertensives, which 
have been shown to cause xerostomia, are used in ESRD patients.37 In Chapter 3, we have 
shown, however, that the use of xerogenic medication is not associated with feelings of a dry 
mouth in ESRD patients.
THIRST AND XEROSTOMIA STRATEGIES
It is important for HD patients to comply to the fluid-restricted, since non-compliance is as-
sociated with congestive heart failure and increased mortality. Compliance to the fluid re-
striction could potentially be enhanced by the reduction of thirst by using chewing gum or 
artificial saliva. In Chapters 6 and 7, it was demonstrated that both chewing gum and artificial 
saliva were able to reduce the levels of xerostomia and thirst. In healthy subjects, chewing 
gum stimulates the salivary flow rate during the first minute with 187%, see Appendix. Most 
patients preferred using chewing gum, which also appeared to be most effective in the man-
agement of thirst and xerostomia in HD patients. However, older patients (> 64 years) mostly 
preferred the use of spray, see Chapter 7.38 A few patients complained about the fact that 
the bottle with artificial saliva was difficult to handle. Therefore it may be considered useful 
to develop more ergonomic types of bottles, or other means to administer artificial saliva 
in the oral cavity.39 The use of chewing gum and artificial saliva did not affect directly the 
IWG. Nevertheless, several patients reported to postpone water intake probably due to the 
distracting effect of gum chewing.
The greater part of dialysis patients have developed their own strategy to deal with thirst 
and the limited fluid intake. Drinking tiny volumes, measuring their daily allowed volume, 
sucking on sweets, rinsing the mouth, chewing on ice cubs or distraction are amongst the 
self-care strategies dialysis patients use to reduce their water intake.40,41 Additional informa-
tion about the results and effectiveness of the different strategies being described above are 
therefore of clinical relevance. Finally, the aim is to develop the optimal specific therapeutic 
regimen for each patient.
POTENTIAL BIAS
Our results could have potentially been biased by several factors. The patients participat-







Universiteit Medical Center and the Rode Kruis Hospital) and two private dialysis clinics (Dia-
net Amsterdam and Dianet Utrecht). Although it is possible that the average general health 
status differs between these centers, we could not demonstrate any statistical significant 
differences between the four centers for any of our outcome measures.
The dialysis patients from the centers involved were asked to participate in a study about 
saliva, thirst and oral health. More than half of the patients decided not to participate in this 
study. Major reasons for non-participation were illness or involvement in other clinical trials. 
Also, the absence of thirst or oral dryness was reason for non-participation. This could have 
resulted in an overestimation of the role of thirst and oral dryness in ESRD patients in our 
study. 
Several study designs are described in this thesis: a repeated measurements design (Chap-
ter 2), a cross-sectional design (Chapter 3 and 4), a longitudinal study (Chapter 5) and a 
crossover design (Chapters 6 and 7). It is not possible to measure the effect of chewing gum 
and artificial saliva in a double blind, randomized clinical trial. Therefore, we conducted a 
crossover study (Chapters 6 and 7) with a two-week wash out period, in which no statistically 
significant crossover effect was found. 
Some patients were involved in several parts of the study described in this thesis. Treat-
ment with chewing gum and artificial saliva, for example, could potentially have affected the 
outcome of xerostomia and thirst in HD patients after two years. Although chewing gum and 
the saliva substitute were only used for two weeks each, the possibility exists that subjects 
continued the use of a preferred treatment after completion of the crossover study. Since no 
longitudinal differences were found, this potential effect is probably not present or too small 
to detect.
FUTURE RESEARCH 
Saliva is presently used for the diagnosis of several systemic diseases, since it is easily col-
lected and contains serum constituents.42 Analysis of saliva may be useful for the diagnosis of 
hereditary disorders, autoimmune diseases, malignant and infectious diseases, and endocrine 
disorders as well as in the assessment of therapeutic levels of drugs and the monitoring of 
illicit drug use.42 Maybe, the primary diagnosis of renal failure may also be obtained through 
saliva since it has recently been shown that uric acid in saliva could be used as a biomarker 
of renal function.43 Another potential use of salivary diagnostics may be to monitor the clear-
ance of waste products from the blood during dialysis sessions.
The oral health studies described in Chapters 4 and 5 have focused on general accepted 
oral health indices. Although these indices have been very useful to describe differences and 
similarities between patients and healthy subjects, future studies should also include more 
specific oral health risk factors and oral health related complaints instead of general indices. 
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Specific problems reported in HD patients are calculus, changes in the periodontal status, 
dental erosion, oral dryness and level of oral hygiene. Self-reported complaints in ESRD pa-
tients include halitosis (bad breath), bad taste and temporomandibular complaints. Special 
attention for these specific areas may contribute to an increased – oral health related – qual-
ity of life of patients with ESRD. 
CONCLUDING REMARKS
The aim of this thesis was to provide insight in the role of ESRD on oral dryness, thirst and 
oral health. In Chapter 2, we revealed that HD treatment has an acute stimulating effect on 
the salivary flow rate. In Chapter 4, the oral health of dentate ESRD patients was compared 
with a well-defined reference group. The results indicated that the oral health in our study 
group was relatively well. The long-term effects of ESRD were discussed in Chapter 5. Renal 
transplantation had a major effect on the salivary flow rate, xerostomia and thirst, whereas 
no substantial changes were found for the other oral health variables. Our second aim was 
to unravel the relationship between thirst, xerostomia, salivary flow rate and IWG. In Chapter 
3, we have found that thirst, xerostomia and IWG were statistically significant associated in 
HD patients, indicating a possible role of oral dryness to explain higher fluid intake between 
HD sessions. 
Saliva stimuli and substitutes might diminish the urge to drink in HD patients, enhanc-
ing compliance to the fluid-restricted diet and leading to fewer systemic complications. This 
potential clinical effect was investigated in Chapters 6 and 7. It was found that chewing gum 
could reduce thirst and xerostomia in HD patients effectively. Although the net IWG was not 
affected, chewing gum and artificial saliva could support patients in maintaining their fluid-
restricted diet, resulting in better patient outcomes.
To conclude, this thesis describes the interesting research area of oral health in relation to 
systemic diseases. Increasing awareness of both physicians and dentists for possible relation-
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The kidneys are essential in removing metabolic waste products, electrolytes and water from 
the body. End stage renal disease (ESRD) occurs when the function of the kidneys is impaired 
and reduced towards 5-10% of the original capacity. ESRD patients can receive kidney re-
placement therapy such as hemodialysis (HD), peritoneal dialysis (PD) or renal transplanta-
tion (NTx). During HD and PD treatment, the blood is purified by an extra-corporal artificial 
kidney (HD) or by means of the peritoneum membrane (PD). Most patients have to maintain 
a fluid restricted diet since they have no residual urine output and are allowed to drink at 
maximum 500 mL per day. Since thirst and dry mouth feelings (xerostomia) are among the 
most frequently occurring symptoms, maintaining this fluid restricted diet can be very dif-
ficult resulting in a high interdialytic weight gain (IWG).
Saliva plays an essential role in maintaining an optimal environment in the oral cavity. Sev-
eral proteins are involved in the anti-viral, anti-fungal and anti-bacterial capacity of saliva. A 
close relationship exists between the composition of serum and saliva. Therefore, alterna-
tions in the amount or composition of saliva could potentially influence the oral health. 
The aims of this thesis were:
1) to investigate the acute and long term effects of dialysis treatment on the salivary flow 
rate, xerostomia, thirst and oral health in ESRD patients.
2) to assess the relationship between oral dryness (reduced salivary flow rates and xerosto-
mia) thirst, and IWG in patients on HD.
3) to investigate potential therapies in order to reduce IWG between dialysis sessions.
SALIVA, ORAL DRYNESS, THIRST AND IWG IN HD PATIENTS
In Chapter 2, the acute effects of HD treatment on the flow rate and biochemical composi-
tion of saliva were studied. The aim of this study was to evaluate acute effects of HD on the 
salivary flow rate, pH and biochemical composition before, during and after completion of a 
dialysis session. In 94 HD patients, unstimulated whole saliva (UWS) and chewing-stimulated 
whole saliva (CH-SWS) were collected immediately before, during and after a dialysis session. 
Salivary flow rate, pH, concentration of total protein, albumin, cystatin C and of sodium, po-
tassium and urea were measured. It was revealed that HD treatment had an acute stimulating 
effect on the salivary flow rate (UWS before = 0.30 ± 0.22 mL/min; UWS during = 0.39 ± 0.25 
mL/min; P < 0.05). The mean pH of UWS showed a small but significant increase during hemo-
dialysis (pH before = 7.16 ± 0.58 to pH during = 7.31 ± 0.49 ; P < 0.05). The concentrations of the 
biochemical constituents (total protein, albumin, cystatin C and S-IgA) in whole saliva were 
reduced markedly, but no significant differences in output were found. Also the electrolyte 







(urea before = 25.6 ± 6.4 mmol/L, urea during = 15.3 ± 4.5 mmol/L). We concluded that HD has 
significant acute effects on both salivary secretion rate and protein concentrations in saliva 
and that the observed decrease in salivary concentrations and proteins are mainly due to an 
increased watery secretion from the salivary glands.
In Chapter 3 we described a study to unravel the relationship between oral dryness, 
fluid-intake and IWG in HD patients. Severe thirst, or the urge to drink, is influenced by many 
factors such as sodium intake, high plasma sodium, potassium depletion, angiotensin II, 
vasopressin, acute increase in plasma urea and psychological factors. Thirst can induce non-
compliance to this diet, resulting in an increased interdialytic weight gain (IWG = weight 
predialysis minus postdialysis). Therefore, IWG can be used as an indicator of compliance to 
the fluid-restricted diet and can be associated with poor patient outcomes such as hyperten-
sion, acute pulmonary edema, congestive heart failure, and premature death. Because oral 
dryness (xerostomia and reduced salivary flow rates) may contribute to experienced thirst, 
we investigated the possible relation between thirst, salivary flow rate, xerostomia, and IWG 
in 94 HD patients (64 men, 55 ± 16 years; 30 women, 60 ± 19 years). Unstimulated and chew-
ing stimulated secretion rates of saliva were determined and the level of xerostomia was 
assessed with a validated Xerostomia Inventory (XI). Thirst was measured with a newly de-
veloped Dialysis Thirst Inventory (DTI). It was found that 36% of the patients had hyposaliva-
tion (UWS ≤ 0.15 mL/min), before dialysis. The XI scores were positively related with the IWG 
(r = 0.25, P < 0.001) and the prevalence and severity of thirst and xerostomia were greater in 
younger subjects. It was surprisingly that patients with urine output did not differ from those 
without urine output with respect to thirst, xerostomia, and IWG. Correlations were found be-
tween thirst (DTI) and both IWG and xerostomia (XI) (r = 0.33, P < 0.001, respectively; r = 0.74, 
P < 0.001). Other correlations were observed between xerostomia and both the salivary flow 
rate and total number of medications (r = -0.25, P < 0.05, respectively; r = 0.24, P < 0.05). 
It was concluded that in HD patients, xerostomia (XI) and thirst (DTI) are associated with a 
higher IWG. These data provide evidence that, in HD patients, xerostomia is related to both 
salivary flow rate and thirst (DTI), indicating a possible role of oral dryness to explain higher 
fluid intake between HD sessions. Since other studies haves shown that saliva stimuli or saliva 
substitutes could be effective in reducing feelings of a dry mouth, these therapies might also 
diminish the urge to drink in HD patients, enhancing compliance to the fluid-restricted diet, 
potentially leading to a decreased IWG.
ESRD AND ORAL HEALTH 
At baseline we compared the oral health status of ESRD patients on HD or PD treatment with 
a matched reference population in a cross-sectional study (Chapter 4). Forty-two dentate 
CRF patients – aged 25-52 years old – were matched with a reference group of 808 dentate 
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subjects. The oral health was assessed using decayed missing filled (DMF) indices, simplified 
oral hygiene index (SOHI) and periodontal status. An oral health questionnaire was used to 
assess self-reported dental problems. It was revealed that all index-scores in the ESRD pa-
tients were comparable with the controls except for number of teeth covered with calculus, 
which was significantly higher (P < 0.05) in ESRD patients (4.1 ± 2.6) than in controls (3.0 ± 
2.9). The self-reported oral health questionnaire revealed a trend for increased temporoman-
dibular complaints in patients (17% vs 6% in controls; P = 0.06) as well as a bad taste (31% vs 
7% in controls, P = 0.08). 
The objective of the longitudinal oral health study, described in Chapter 5, was to compare 
the oral health, salivary flow rates, xerostomia and thirst between ESRD patients remaining 
on dialysis treatment with those after renal transplantation. At baseline and after two years, 
oral health, salivary flow rates, xerostomia and thirst were determined in 43 dentate patients. 
The salivary flow rate of twenty patients who were transplanted increased significantly from 
UWS = 0.30 ± 0.21 mL/min towards 0.44 ± 0.29 mL/min (P < 0.001). The level of xerostomia 
and thirst decreased while in dialysis patients no differences occurred. After two years, the 
percentage of bleeding on probing in dialysis patients (n = 23) decreased from 30% till 10%. 
No further oral health differences were found between dialysis and renal transplant patients. 
In conclusion, the DMFT, dental plaque, gingival bleeding and periodontal indices did not 
change remarkable after two years comparing dialysis and renal transplant patients. In dialy-
sis patients awaiting a renal transplant and those who have been transplanted, regular dental 
examinations are important to prevent oral infections, which could jeopardize the success 
of a kidney transplant. Furthermore, increased salivary flow rates and reduced levels of both 
xerostomia and thirst are important aspects and might enhance the oral health related qual-
ity of life.
INTERVENTION STUDY 
The aim of the randomized two-treatment crossover study, as described in Chapter 6, was 
to investigate the effect of a sugar free chewing gum (Freedent White™) and a xanthan gum-
based saliva substitute (Xialine™) on xerostomia, thirst and IWG. HD patients were asked to 
participate in this study and, finally 65 HD patients (42 men: 55 ± 14 years; 23 women: 55 ± 16 
years) participated. After the use of chewing gum or saliva substitute for two weeks, a wash-
out period of two weeks was introduced and hereafter the other regimen was carried out. 
Xerostomia (XI) and thirst (DTI) were determined at baseline and after each treatment period, 
as were IWG and salivary flow rates. The level of xerostomia decreased by the use of chewing 
gum (from XI = 29.9 ± 9.5 to 28.1 ± 9.1, P < 0.05). Chewing gum as well as a saliva substitute 







salivary flow rates. We concluded that the use of chewing gum and, to a lesser extent, a saliva 
substitute may alleviate thirst and xerostomia in some HD patients.
The second aim of the crossover study was to investigate the effect and preferences of a 
chewing gum and a artificial saliva in the management of xerostomia in chronic HD patients. 
Therefore, the more subjective feelings and preferences between the salivary substitute and 
stimulant were further explored in Chapter 7. Artificial saliva was rated statistically signifi-
cant lower than the chewing gum for effectiveness, taste and global assessment. No prefer-
ence differences were found for gender and age, although older subjects rated the artificial 
saliva with higher mark. Thirty-nine subjects (60%) preferred chewing gum and 15% (n = 10) 
preferred the artificial saliva. Although chewing gum was preferred most, both strategies 
(chewing gum and artificial saliva) could potentially play an important role in the palliative 
care of xerostomia in HD patients.
CONCLUDING REMARKS
Dialysis treatment has a direct effect on the composition and amount of saliva. Furthermore, 
we have shown that both oral dryness and thirst are associated with the amount of fluid con-
sumed between dialysis sessions (IWG). Gum chewing increases the salivary flow rates nearly 
twofold in healthy subjects. Therefore, we have investigated the effect of the use of chewing 
gum or artificial saliva on the IWG, oral dryness and thirst, in a group of HD patients. Chew-
ing gum appeared to be the most effective tool to reduce thirst and oral dryness. Especially 
in older patients, artificial saliva was preferred most. Both chewing gum and artificial saliva 
should be easily available to assist in maintaining the fluid restricted diet. Besides, it is of 
major importance to prevent oral infections, which could negatively influence the success of 
the transplantation. Also after renal transplantation, continued attention for the oral hygiene 
is of importance to prevent gingival overgrow, due to the use of immunosuppressive medica-
tion. We have shown that the salivary secretion rates restored after renal transplantation. This 
could contribute to the oral-health related quality of life. Finally, daily dialysis treatment at 






De nieren spelen een essentiële rol bij het verwijderen van metabole afbraakproducten, zou-
ten (elektrolyten) en water uit het lichaam. Wanneer de capaciteit van de nieren gereduceerd 
is tot 5-10% van de oorspronkelijke capaciteit spreekt men van terminaal nierfalen (ESRD: end 
stage renal disease). Verschillende nierfunctievervangende therapieën zijn voorhanden zoals 
hemodialyse (HD), peritoneaal dialyse (PD) of niertransplantatie (NTx). Bij HD behandeling 
wordt het bloed gezuiverd door een kunstnier. Bij PD behandeling wordt gebruik gemaakt 
van het buikvlies als filter. Het merendeel van de dialysepatiënten heeft geen restfunctie van 
de nieren, waardoor geen urine meer kan worden uitgescheiden. De meeste dialysepatiënten 
volgen daarom een vochtbeperkend dieet, waarbij per dag slechts een halve liter vocht ge-
dronken mag worden. Bovendien heeft het overgrote deel van de dialysepatiënten te maken 
met zowel dorst als monddroogte. Het is daarom goed voor te stellen dat het voortdurend 
houden van een vochtbeperkend dieet bijzonder lastig kan zijn.
Speeksel speelt, naast het bevochtigen van de mond, een belangrijke rol bij het handhaven 
van een optimaal, beschermend mondmilieu. Diverse eiwitten in het speeksel dragen bij aan 
de antivirale, antischimmel en antibacteriële eigenschappen. Aangezien een nauwe relatie 
bestaat tussen de samenstelling van bloed (serum) en speeksel, valt het te verwachten dat 
veranderingen in samenstelling van invloed kunnen zijn op de mondgezondheid.
Het in dit proefschrift beschreven onderzoek heeft de volgende doelstellingen:
1) het onderzoeken van acute en lange termijn effecten van dialyse (zowel HD als PD) op 
speeksel, xerostomie, dorst en mondgezondheid bij patiënten met terminaal nierfalen.
2) het bepalen van de relatie tussen monddroogte, dorst en interdialytische gewichtstoe-
name (IWG) in hemodialyse patiënten.
3) het onderzoeken van mogelijke therapieën die het IWG, de dorst en de monddroogte 
kunnen reduceren.
SPEEKSEL, MONDDROOGTE, DORST EN IWG IN HD PATIËNTEN
In hoofdstuk 2 zijn de acute effecten van hemodialyse behandeling op speekselsecretiesnel-
heid en biochemische samenstelling nader beschreven. Het doel van het onderzoek was om 
het effect van hemodialyseren (vóór, tijdens en na dialyse) op de secretiesnelheid, de zuur-
graad (pH) en biochemische samenstelling van speeksel te onderzoeken. Ongestimuleerd 
speeksel (UWS = unstimulated whole saliva) en kauw-gestimuleerd speeksel (CH-SWS = 
Chewing stimulated whole saliva) werden vóór, tijdens en na de dialyse verzameld. Vervol-
gens werd de secretiesnelheid, pH, concentratie van totaal eiwit, albumine, cystatine C en 









Hemodialysebehandeling had een direct effect op de secretiesnelheid (UWS vóór
 
= 0,30 ± 
0,22 ml/min; UWS tijdens = 0,39 ± 0,25 ml/min; P < 0,05). De gemiddelde pH van ongestimu-
leerd speeksel steeg licht tijdens de dialyse, van pH = 7,16 ± 0,58 (vóór dialyse) tot pH = 7,31 
± 0,49 (tijdens dialyse; P < 0,05). De concentratie van zowel totaal eiwit, albumine, cystatine C, 
S-IgA als het zoutgehalte (elektrolyten) in speeksel daalde ten gevolge van de dialyse. Echter, 
de uitscheiding per minuut (= output) bleef gelijk. De concentratie ureum in speeksel (CH-
SWS) nam tijdens de dialyse af met maar liefst 40% (ureum vóór
 
= 25,6 ± 6,4 mmol/l; ureum 
tijdens
 
= 15,3 ± 4.5 mmol/l). Hemodialysebehandeling heeft dus een direct effect op zowel de 
secretiesnelheid als de eiwitconcentraties van speeksel. Zeer waarschijnlijk zijn de gevonden 
concentratieverschillen in het bijzonder veroorzaakt door een toegenomen waterige secretie 
uit de speekselklieren.
In hoofdstuk 3 wordt de relatie tussen speeksel, monddroogte, dorst en IWG in HD 
patiënten beschreven. Dorst of ‘de behoefte om te drinken’ wordt beïnvloed door allerlei 
factoren zoals zoutinname, een hoge zoutconcentratie in het bloed, kalium, angiotensine 
II en vasopressine. Bovendien spelen, naast een snelle toename van de hoeveelheid ureum 
in het bloed, psychologische factoren een rol. Dorst kan, bij patiënten zonder restfunctie (= 
urine productie), van invloed zijn op het niet volgen van een vochtbeperkend dieet. Dit kan 
uiteindelijk leiden tot een toename in IWG. Grote interdialytische gewichtsverschillen gedu-
rende langere tijd kunnen gepaard gaan met een hoge bloeddruk, hartfalen en vroegtijdig 
overlijden.
Verminderde speekselsecretie en monddroogte spelen mogelijk een rol bij het dorstgevoel. 
Daarom werd de relatie tussen dorst, monddroogte en IWG onderzocht bij 94 HD patiënten 
(64 mannen: 54,8 ± 15,5 jaar; 30 vrouwen: 59,5 ± 18,7 jaar). Zowel UWS als CH-SWS werd 
opgevangen. De mate van monddroogte werd bepaald met behulp van een gevalideerde 
‘xerostomie vragenlijst’ (XI). Tot slot werd de mate van dorst gemeten met een nieuw ontwik-
keld instrument, de zogenaamde ‘dialyse- en dorstvragenlijst’ (DTI). Voor aanvang van de dia-
lyse was bij 36% van de patiënten sprake van hyposalivatie (UWS ≤ 0.15 ml/min). Bovendien 
werd gevonden dat de mate van monddroogte (XI) samenhangt met de hoeveelheid vocht 
die men tussen de dialyses tot zich nam (r = 0,25, P < 0,001). Patiënten jonger dan 65 jaar 
rapporteerden meer monddroogte en dorst dan ouderen. Een opmerkelijke bevinding was 
dat de mate van dorst (DTI), monddroogte en IWG gelijk was bij patiënten met restfunctie en 
degene zonder restfunctie. Dorst (DTI), IWG en monddroogte (XI) hingen nauw met elkaar 
samen (DTI en IWG: r = 0,33, P < 0,001; DTI en XI: r = 0,74, P < 0,001). Daarnaast werd een 
statistisch significant verband gevonden tussen de mate van monddroogte, de speekselse-
cretiesnelheid (r = -0,252, P < 0,05) en het totale aantal gebruikte medicijnen (r = 0,235, P < 
0,05). Dat een toename in de mate van monddroogte of dorst bij HD patiënten gepaard gaat 
met een hogere IWG, suggereert dat monddroogte mogelijk een rol speelt bij de behoefte 
– tussen de dialyses door – vocht tot zich te nemen.
Samenvatting 117
Eerder onderzoek heeft aangetoond dat bevochtiging van de mond, door kauwgom of 
kunstspeeksel, effectief werkt tegen monddroogte. Daarnaast zouden deze interventies mo-
gelijk als therapie bij HD patiënten kunnen worden toegepast, om de behoefte om te drinken 
te verminderen. Hierdoor zou men zich beter kunnen houden aan het vochtbeperkend dieet, 
hetgeen uiteindelijk zou kunnen leiden tot een verlaging van de IWG. 
NIERFALEN EN MONDGEZONDHEID 
De mondgezondheid van HD en PD patiënten werd in een cross-sectioneel onderzoek verge-
leken met een controlegroep (hoofdstuk 4). Tweeënveertig dentate (= eigen tanden en kie-
zen) patiënten met terminaal nierfalen werden vergeleken met een op leeftijd en opleiding 
overeenkomende controle groep tussen de 25-52 jaar, (n = 808). Het aantal vervallen (D), ver-
loren (M) en gevulde (F) gebitselementen (DMFT) werd vastgelegd. Tevens werd de mate van 
mondhygiëne en de conditie van het tandvlees bepaald. Met behulp van een mondgezond-
heidsvragenlijst werden aanvullende gegevens over eventuele gebitsproblemen vastgelegd. 
De mondgezondheid van ESRD patiënten bleek vergelijkbaar met die van de controlegroep. 
Alleen het aantal gebitselementen met tandsteen was in de patiëntengroep hoger (4,1 ± 
2,6) dan in de controlegroep (3,0 ± 2,9, P < 0,05). Zeer waarschijnlijk hangt dit samen met de 
verhoogde concentratie ureum in het speeksel, hetgeen leidt tot een hogere pH in de mond 
en het neerslaan van speekselzouten op de gebitselementen. Uit de mondgezondheidsvra-
genlijst bleek dat het aantal ESRD patiënten met kaakgewrichtsklachten (16,7%) groter was 
dan in de controlegroep (5,7%; P = 0,06). Daarnaast rapporteerden ERSD patiënten vaker 
een slechte smaak (31,0%) dan de controlepatiënten (6,8%; P = 0,08). Ook dit hangt mogelijk 
samen met een verhoogde concentratie ureum in speeksel, dat onder invloed van bacteriën 
omgezet kan worden in ammoniak.
De longitudinale veranderingen in de mondgezondheid bij ESRD patiënten zijn beschreven 
in hoofdstuk 5. Doel van dit onderzoek was om gedurende twee jaar de mondgezondheid, 
speekselsecretiesnelheid, mate van xerostomie (XI) en dorst (DTI) van dialyserende ESRD 
patiënten te vergelijken met een groep patiënten die in dezelfde periode waren getransplan-
teerd. Bij aanvang van het onderzoek werd de mondgezondheid, speekselsecretiesnelheid, 
mate van monddroogte (XI) en dorst (DTI) vastgesteld bij 43 dentate patiënten. Het aantal 
DMFT, de hoeveelheid tandplaque, en de conditie van het tandvlees verschilden niet tus-
sen beide groepen. De ongestimuleerde speekselvloed (UWS) van twintig getransplanteerde 
patiënten steeg van 0,30 ± 0,21 ml/min naar 0,44 ± 0,29 ml/min, P < 0,001. De mate van 
monddroogte en dorst daalde in deze groep, terwijl bij de dialysepatiënten geen verschil op-
trad. Het aantal gebitselementen met bloeding na sonderen daalde in een periode van twee 
jaar, van 29,5% naar 10,3% in de groep dialysepatiënten (n = 23). Verder werden geen an-








patiënten. Blijvende tandheelkundige begeleiding, van zowel dialysepatiënten op de wacht-
lijst voor een niertransplantie als reeds getransplanteerde patiënten, is van eminent belang 
om orale ontstekingen te voorkomen. Daarnaast spelen een toegenomen hoeveelheid 
speeksel en verminderde monddroogte een belangrijke rol bij een verbeterde kwaliteit van 
het leven in getransplanteerde patiënten.
INTERVENTIE STUDIE
Het doel van de cross-over studie beschreven in hoofdstuk 6, was het effect van kauwgom 
en kunstspeeksel (spray) op dorst (DTI), monddroogte (XI) en IWG bij HD patiënten te onder-
zoeken. Vijfenzestig HD patiënten (42 mannen: 55 ± 14 jaar; 23 vrouwen: 55 ± 16 jaar) deden 
mee aan dit onderzoek. De patiënten werden willekeurig in een groep ingedeeld om ge-
durende twee weken kauwgom (suikervrije Freedent White™) of kunstspeeksel (Xialine™) te 
gebruiken. Na twee weken kauwen of sprayen, werd gedurende twee weken geen therapie 
gegeven, zodat het effect van de ene therapie op de andere geminimaliseerd werd. Vervol-
gens kreeg de eerste groep kunstspeeksel en de andere groep kauwgom aangeboden. De 
mate van monddroogte (XI), dorst (DTI) en IWG werden vóór en na iedere behandelperiode 
bepaald. De mate van monddroogte daalde door het kauwgomgebruik van XI = 29,9 ± 9,5 
tot XI = 28,1 ± 9,1 (P < 0,05). Zowel kauwgom als kunstspeeksel gaf een significante verlaging 
van het dorstgevoel (P < 0,05). De gemiddelde ongestimuleerde speekselsecretiesnelheid 
en de gemiddelde IWG veranderden echter niet. Geconcludeerd werd dat het gebruik van 
kauwgom en – in mindere mate – kunstspeeksel zowel dorst als monddroogte kunnen ver-
minderen bij HD patiënten.
Het tweede doel van de cross-over studie was het effect van en de voorkeur voor kauwgom 
of kunstspeeksel bij de behandeling van xerostomie nader te onderzoeken. De resultaten 
van het vragenlijstonderzoek naar voorkeur en beleving van kauwgom en mondspray zijn 
beschreven in hoofdstuk 7. Voor zowel de effectiviteit, smaak als de totaalbeoordeling werd 
kunstspeeksel significant lager beoordeeld dan kauwgom. Geslacht en leeftijd hadden geen 
effect op de voorkeur. Oudere onderzoeksdeelnemers beoordeelden kunstspeeksel wel met 
een hoger gemiddeld eindcijfer. Zestig procent van de mensen (n = 39) gaf de voorkeur aan 
kauwgom en vijftien procent (n = 10) gebruikte liever kunstspeeksel bij het verlichten van 
monddroogte. Hoewel kauwgom de voorkeur genoot kunnen beide strategieën, afzonderlijk 




Dialyseren heeft een direct effect op de samenstelling en hoeveelheid speeksel. Daarnaast 
hebben wij aangetoond dat zowel monddroogte als dorst samenhangen met de hoeveel-
heid vocht die tussen de dialyses wordt geconsumeerd (IWG). Het kauwen op kauwgom kan 
de speekselsecretiesnelheid bijna doen verdubbelen bij gezonde personen. Daarom werd in 
een groep HD patiënten onderzocht wat het effect van kauwgom en kunstspeeksel was op 
het IWG, de monddroogte en het dorstgevoel. De deelnemers aan het onderzoek vonden 
het gebruik van kauwgom het meest effectieve middel om dorst en droogte te verminderen. 
Vooral oudere patiënten hadden ook baat bij het gebruik van kunstspeeksel. Deze thera-
pieën zouden voor alle dialysepatiënten voorhanden moeten zijn, zodat het houden van een 
vochtbeperkend dieet dragelijker en gemakkelijker zou kunnen worden. Daarnaast is het van 
belang de mond van dialysepatiënten ontstekingsvrij te houden in verband met het slagen 
van een eventuele niertransplantatie. Ook na de transplantatie is blijvende aandacht voor de 
mondhygiëne van belang om de kans op gingivale overgroei door het gebruik van immuno-
supresiva te verminderen. Uit ons onderzoek bleek tevens dat de hoeveelheid speeksel na 
transplantatie volledig genormaliseerd was, wat mogelijk een positieve bijdrage kan leveren 
aan de mondgezondheid gerelateerde kwaliteit van het leven. Tot slot zou de steeds vaker 
toegepaste (dagelijkse) HD thuisdialyse mogelijk een belangrijke bijdrage kunnen leveren 
aan een vermindering van monddroogte en dorst.
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Chewing gums have been studied for clinical use to stimulate the salivary flow rate in healthy 
and diseased individuals. However, differences in preferences of chewing gums may influ-
ence patient compliance during long-term use. Therefore, we compared the effect of several 
chewing gums on the flow rate of whole saliva and pH, and investigated the preferences of 
these gums.
Material and methods
Eighty-three healthy subjects participated in the first part of the study. Both parafilm-stimu-
lated and chewing gum-stimulated whole saliva from eight different chewing gums was col-
lected and salivary flow rate and pH were determined. In another group of 112 healthy sub-
jects, we investigated the preferences for the chewing gums with a 10-item questionnaire. 
Results
All gums had comparable effects on salivary flow rate and pH. The average increase in flow 
rate was 187% during the first minute of chewing compared with parafilm stimulation. After 
10 minutes of gum chewing, the amount of saliva was equal to parafilm stimulation. The 
questionnaire showed differences in preferences for the chewing gums, which were related to 
taste and gum shape. Gender interactions were observed for sparkling taste (P = 0.019), glob-
al assessment (P = 0.047) and the willingness to use the gum for several weeks (P = 0.037).
Conclusions
Although all chewing gums stimulated the salivary flow rate equally, the observed differ-
ences in preferences may influence long-term compliance. Therefore, we recommend that 
chewing gums are tested before the start of clinical studies, to identify the most appreciated 
chewing gum for specific groups of patients.
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INTRODUCTION
Salivary gland hypofunction, which results in reduced salivary flow rates, is often caused by 
medication.1 It has also been observed in patients who received head and neck radiotherapy,2 
those on hemodialysis3,4 and in those with autoimmune disorders e.g. Sjögren’s syndrome.5 
To some extent, oral dryness and related complaints can be relieved by saliva substitutes and 
saliva stimulants, such as lozenges and chewing gum.6,7,8,9,10
Chewing gum and lozenges both stimulate the activity of the salivary glands and as a 
consequence the salivary flow rate in healthy and most diseased individuals.10,11 In contrast, 
saliva substitutes provide a passive moistening of the oral tissues. Almost 69% of patients 
with advanced cancer preferred gum to artificial saliva for the management of xerostomia,9 
or the feeling of having a dry mouth.12,13 Limited daily use of chewing gum for eight weeks 
elevated the unstimulated salivary flow rate by 16% in healthy subjects. After termination 
of the experiment, the salivary flow rate remained elevated for an additional two months.14 
Also xerostomia patients with salivary hypofunction had persistent increased flow rates after 
eight weeks stimulation by chewing gum.6,15
Although different chewing gums produced only slight differences between saliva secre-
tion rate and pH,16 varying patient group preferences have been reported for saliva stimu-
lants such as chewing gum and lozenges.9,17 Because such differences may influence patient 
compliance during long-term clinical studies with saliva stimulants, we compared the effect 
of several chewing gums on the salivary flow rate and pH and investigated differences in 
preferences for these saliva stimulants.
MATERIALS AND METHODS
Participants
Eighty-three dental students (41 men: 25.6 ± 4.2 years; 42 women: 24.1 ± 3.2 years) partici-
pated in the first part of the study. None of the students were using medication, except for 
the use of oral contraceptives in most women. Pregnant women were excluded from the 
study. The procedures were approved by the Medical Ethical Committee of the Vrije Univer-
siteit Medical Center, Amsterdam, the Netherlands. 
Saliva collection
Subjects were instructed to abstain from smoking, drinking and eating one hour before saliva 
was collected. Saliva was collected by means of the “spitting method”.18 Sampling took place 
at room temperature between 8.30 and 10.30 AM. Before collection, participants were asked 
to rinse their mouth with water. After a 15 minutes break, before the collection started, the 








saliva was collected during five minutes using a 5 x 5 cm flat piece of tasteless wax (Parafilm 
“M”, American National CAL, Chicago, USA). During the saliva collection period, the saliva was 
spitted out in a pre-weighed test tube every 30 seconds. After another 15 minutes pause, 
each participant received randomly a piece of one of the chewing gums (for characteristics 
of the eight sugar-free chewing gums, see Table 1). The participants were allowed to chew 
at their own natural pace.19 Stimulated whole saliva was collected at intervals of 0-1, 1-2, 4-5 
and 9-10 min after the start of chewing. The volume of saliva was determined gravimetrically 
(assuming 1 g = 1 mL) and the pH was measured within five minutes after saliva collection 
(Sentron pH-system 1001, Roden, The Netherlands).
Study design and questionnaire
To identify which chewing gum was preferred, another group of 112 dental students (61 men: 
23.2 ± 4.1 years; 51 women: 24.1 ± 3.2 years) participated in the second part of the study. 
After a uniform instruction to use the gum freely during the next two days, the subjects ran-
domly received one package of chewing gum (see Table 1). At the third day, a taste-question-
naire with 10 items was completed. The preferences for the different chewing gums were 
measured with several 100mm visual analogue scales (VAS) (see Table 2). Next, the volunteers 
randomly received a package of another chewing gum. This way, each individual tested three 
of the eight different chewing gums.
Statistical methods
The statistical analyses were carried out using SPSS (version 10.0, SPSS Inc., Chicago, IL, USA). 
First, we assessed the overall effect of the chewing gums on salivary flow rate and pH with re-
peated-measures multivariate analysis of variance (MANOVA). Next, we investigated the effect 
of each individual chewing gum on salivary flow rates and pH with the General Linear Model of 
ANOVA using a repeated measures design, followed by paired t-tests as post-hoc procedure.
Differences in preferences for the gums were analyzed with ANOVA, followed by Tukey mul-
tiple comparison tests when appropriate. Effects of gum taste and gum size (see Table 1) and 
Table 1. Characteristics of the eight chewing gums investigated
Name Shape Weight (g) Manufacturer
WF-S Orbit Winterfresh Stick 2.7 A
WF-T Extra Winterfresh Tab 2.0 A
WF-P Freedent Winterfresh Pellet 1.5 A
PM-S Orbit Peppermint Stick 2.7 A
PM-T Extra Peppermint Tab 2.0 A
PM-P Freedent Peppermint Pellet 1.5 A
SM-P Freedent Sweetmint Pellet 1.5 A
LO-P Liquorice Original Pellet 1.3 B
A = Wm. Wrigley Jr. Company (USA), B = Stimorol Dandy A/S (Denmark)
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the potential interaction between chewing gum and gender were explored with multivariate 
analysis of variance (MANOVA) followed by LSD pairwise comparisons when appropriate. All 
levels of significance were set at P < 0.05.
RESULTS
We investigated the potential effects of eight different chewing gums on the salivary flow 
rate and pH. MANOVA showed no statistical significant differences between the tested chew-
ing gums with regard to the salivary flow rate, presented in Figure 1 and Table 3. All chewing 
Table 2. Chewing gum questionnaire
1. How many pieces of chewing gum did you use?
2. On average, how many minutes did you chew on one piece of gum?
3. Consistency VAS (soft – firm)
4. Stickiness VAS (sticky – not sticky)
5. Taste I VAS (unpleasant – pleasant)
Taste II VAS (flat – fresh) 
Taste III VAS (nasty – delicious)
Taste IV VAS (mild – strong)
6. How long does the gum maintain its taste? VAS (short – long) 
7. What was the stimulated saliva like? VAS (watery – slimy)
8. For how many weeks would you be willing to chew this gum, six times a day?




































gums stimulated the flow rate significantly during the first minute of chewing, compared 
with parafilm stimulation. The average increase was on average 187% (range 116 to 228%). 
Most chewing gums showed a sustained increase in flow rate during the second minute (av-
erage 86%, range 56 to 111%). After 10 minutes of gum chewing, the amount of saliva was 
equal to the saliva stimulation by tasteless parafilm.
The data on salivary pH are presented in Table 4. MANOVA demonstrated no statistical 
significant differences between the chewing gums with regard to the pH. The salivary pH 
showed a small increase during the period of 10 minutes chewing. This increase in pH, how-
ever, only reached statistical significance for WF-T, PM-S and SM-P.
To identify which chewing gum had the highest preference, we tested the chewing gums 
in a crossover study in another group of 112 subjects. Each subject tested three different 
chewing gums during two days and was asked to complete a chewing gum questionnaire for 
each gum. In total 306 questionnaires were returned, representing a response rate of 91%. 






Chewing gum stimulated (mL/min)
0-1 min 1-2 min 4-5 min 9-10 min
WF-S* 10 1.57 ± 0.75 4.82 ± 1.30§ 3.31 ± 0.71§ 2.03 ± 0.46 1.74 ± 0.61
WF-T* 12 1.66 ± 0.48 5.24 ± 1.08§ 3.33 ± 0.65§ 2.28 ± 0.68# 2.08 ± 0.53#
WF-P* 11 1.58 ± 0.78 4.15 ± 1.48# 2.55 ± 0.81§ 1.51 ± 0.65 1.52 ± 0.78
PM-S* 16 1.60 ± 0.49 4.87 ± 1.32§ 3.03 ± 1.09§ 1.80 ± 0.56 1.68 ± 0.59
PM-T*  7 1.43 ± 0.60 4.70 ± 0.84# 3.00 ± 0.81# 1.97 ± 0.67 1.68 ± 0.57
PM-P*  8 1.55 ± 0.33 4.65 ± 1.10# 2.88 ± 0.76 1.75 ± 0.58 1.80 ± 0.83
SM-P*  9 1.98 ± 0.56 4.27 ± 1.05§ 3.08 ± 1.09 1.84 ± 0.60 1.59 ± 0.65
LO-P*  9 1.44 ± 0.61 3.74 ± 1.07# 2.53 ± 0.50# 1.38 ± 0.37 1.16 ± 0.52
Data are expressed as mean ± SD (n = 7-16). General Linear Model of ANOVA using a repeated measures design: * P < 0.05. Paired t-test vs 
parafilm stimulated saliva: § P < 0.01, # P < 0.05
Table 4. pH of chewing gum stimulated saliva at different time points, compared with the pH of parafilm stimulation
Chewing gum n Parafilm
stimulated
Chewing gum stimulated
0-1 min 1-2 min 4-5 min 9-10 min
WF-S 10 7.2 ± 0.4 7.4 ± 0.1 7.4 ± 0.2 7.7 ± 0.4 7.7 ± 0.3
WF-T* 12 7.1 ± 0.2 7.3 ± 0.2 7.5 ± 0.2# 7.6 ± 0.2§ 7.6 ± 0.2§
WF-P 11 7.2 ± 0.3 7.3 ± 0.2 7.5 ± 0.3 7.7 ± 0.3 7.7 ± 0.3
PM-S* 16 7.3 ± 0.2 7.4 ± 0.2 7.6 ± 0.2# 7.8 ± 0.2§ 7.7 ± 0.3§
PM-T  7 7.1 ± 0.1 7.4 ± 0.2 7.5 ± 0.1 7.5 ± 0.1 7.6 ± 0.1
PM-P  8 7.2 ± 0.1 7.4 ± 0.2 7.7 ± 0.3 7.8 ± 0.4 7.9 ± 0.4
SM-P*  9 7.1 ± 0.2 7.3 ± 0.1 7.5 ± 0.2 7.7 ± 0.3# 7.7 ± 0.3
LO-P  9 7.1 ± 0.3 7.4 ± 0.3 7.5 ± 0.2 7.7 ± 0.3 7.6 ± 0.3
Data are expressed as mean ± SD (n = 7-16)
General Linear Model of ANOVA using a repeated measures design: * P < 0.05
Paired t-test vs pH of parafilm stimulated saliva: § P < 0.01, # P < 0.05
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The results from the questionnaire revealed statistical significant differences in use and pref-
erences for the chewing gums (Table 5).
A significant difference was observed for the average time the subjects chewed on a gum. 
The PM-S gum was used longer than any other gum, whereas the WF-T was used shortest. The 
global assessment showed that the subjects preferred the PM-S and SM-P gums significantly 
to the WF-S and LO-P gum. This preference is also demonstrated by the high scores of PM-S 
and SM-P with regard to Taste I (unpleasant – pleasant) and Taste III (nasty – delicious), in 
contrast to the low scores of WF-S and LO-P on these VAS scales.
With the use of MANOVA, we compared the overall differences between peppermint fla-
vored gums (PM-S, PM-T and PM-P) and Winterfresh chewing gums (WF-S, WF-T and WF-P). 
This revealed that the PM gums were considered more pleasant than the WF gums (Taste I 
= 6.1 ± 2.5 and 4.7 ± 2.7, respectively, P < 0.001) and more delicious (Taste III = 5.9 ± 2.4 and 
5.1 ± 2.5, respectively, P = 0.010). Also the global assessment of the PM gums (6.7 ± 1.4) 
was significantly higher than that of WF gums (6.1 ± 1.6, P = 0.001). The subjects chewed 
significantly longer on PM than on WF gum (38.5 ± 29.7 vs 29.8 ± 24.4 minutes, P = 0.012) and 
were willing to use this gum six times a day for a longer period of time (2.8 ± 2.7 vs 2.0 ± 2.4 
weeks, P = 0.014).




















WF-S 47 4.9 ± 2.4 35.5 ± 30.3 5.0 ± 2.8 3.9 ± 2.6 5.1 ± 2.3 4.5 ± 2.4 5.7 ± 1.6
(a) (a) (a,b) (a) (a,b,c) (a) (a)
WF-T 39 4.9 ± 2.1 26.8 ± 20.3 5.1 ± 2.8 4.9 ± 2.8 4.9 ± 2.4 5.3 ± 2.8 6.2 ± 1.6
(a,b) (a) (a,b) (a,b) (a,b) (a,b,c) (a,b)
WF-P 26 7.1 ± 2.9 27.0 ± 16.5 5.0 ± 2.0 6.0 ± 2.2 5.6 ± 1.9 6.0 ± 2.2 6.7 ± 1.4
(b,c) (b) (a) (a,b,c) (a,b,c) (a,b,c) (a,b)
PM-S 36 6.1 ± 1.3 48.3 ± 38.3 4.1 ± 2.6 6.6 ± 2.5 5.2 ± 1.8 6.2 ± 2.5 7.2 ± 1.4
(b,c) (b) (a) (b,c,d) (a,b,c) (b,c,d) (b,c,d)
PM-T 47 5.2 ± 1.6 35.7 ± 23.6 5.0 ± 2.4 5.9 ± 2.4 4.4 ± 1.9 5.9 ± 2.4 6.6 ± 1.4
(a,b) (a) (a,b) (b,c,d) (a) (b,c) (b,d)
PM-P 53 6.6 ± 2.8 33.6 ± 25.0 5.2 ± 2.4 6.0 ± 2.6 6.0 ± 2.3 5.8 ± 2.5 6.6 ± 1.5
(b,c) (a) (b) (b,c,d) (b,c) (a,b,c) (b,d)
SM-P 23 7.0 ± 2.6 31.2 ± 31.0 5.0 ± 1.9 6.7 ± 2.5 5.1 ± 2.1 7.1 ± 1.8 7.2 ± 1.2
(b,c) (a) (a,b) (b,c,d) (a,b,c) (b,c,d) (b,c,d)
LO-P 35 6.7 ± 3.5 26.9 ± 21.5 4.7 ± 2.3 4.9 ± 3.3 4.8 ± 2.1 5.2 ± 2.9 5.8 ± 2.1
(b,c) (a) (a,b) (a,b) (b,c,d) (a,b) (a)
Data are expressed as mean ± SD. * ANOVA P < 0.05, followed by Tukey multiple comparison tests. Chewing gums sharing a common 
character (a, b, c or d) in a vertical column do not differ significantly with regard to that item of the questionnaire. Only items from the 








Potential effects of the shape of the gums were also explored with MANOVA. This showed 
that the pellet-shaped gums (PM-P and WF-P) were consumed significantly more (6.7 ± 2.9 
pieces consumed, P < 0.001) than stick or tab-shaped gums (stick-shaped: 5.4 ± 2.1; tab-
shaped: 5.1 ± 2.0). The subjects chewed significantly longer on the stick-shaped gums (41.1 
± 34.3 minutes, P = 0.013) than on the tab or pellet-shaped gums (30.9 ± 22.5 and 30.7 ± 24.8 
minutes, respectively). The taste of the pellet-shaped gums was considered more fresh (Taste 
II: 5.4 ± 2.2, P = 0.039) than that of stick or tab-shaped gums (5.1 ± 2.1 and 4.6 ± 2.1, respec-
tively). Saliva produced by chewing pellet-shaped gums was considered more slimy (3.5 ± 
1.8, P = 0.049) than that produced by sticks or tabs (2.9 ± 1.9 and 3.1 ± 1.9, respectively). 
A statistical significant gender interaction was revealed for Taste II (dull – sparkle, P = 0.019). 
Women considered the WF-S more sparkling than male subjects, while the opposite was ob-
served for WF-P. A gender interaction was also seen for the global assessment (P = 0.047): 
male subjects appreciated WF-P more, whereas the SM-P was preferred more by women. 
Finally, a gender interaction was shown for the number of weeks that the subjects were will-
ing to use a gum (P = 0.037). Men expressed that they were willing to use PM-S for a longer 
time, whereas women reported longer times for WF-P. 
DISCUSSION
In this study, we compared eight different sugar-free chewing gums with regard to effects on 
the salivary flow rate, pH and differences in preferences. All investigated gums stimulated the 
salivary flow rate significantly during the first minute, followed by a progressive decline of the 
flow rate (Figure 1 and Table 3). 
A positive relation between the weight of the chewing gum and the salivary flow rate has 
been reported.11 In our study, no significant differences in stimulating salivary flow rates were 
observed between the gums, which differed in weight from 1.3 to 2.7 gram (see Table 1). This 
result is in agreement with a previous study on other gums,16 and suggests that the stimula-
tion of the flow rate by chewing gum is not related to differences in gum taste, size, shape 
or weight. 
The initial increase in flow rate is probably induced by a gustatory stimulus by the chew-
ing gums. Within 39 seconds, the intensity of taste showed a peak value.20 Therefore, the 
observed decline in flow rate during the continued chewing of the gum could be related to 
loss of flavour. However, during chewing a gum also softens and reduces in size.11 This might 
lead to a reduced stimulation of periodontal mechanoreceptors,21 which may also contribute 
to the decrease in flow rate.
When the subjects used the chewing gums freely, the average chewing time for each piece 
of gum was 33 minutes, which is comparable with the mean value for the U.S. population 
(36 minutes).22 Between the various gums, however, significant differences in chewing time 
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were observed, as well as in the willingness to use it for several weeks. These differences 
seem to be related to both taste and size. The mean chewing time and the willingness to use 
were significantly higher for peppermint-flavoured gums (PM), which were also rated more 
pleasant than the winterfresh (WF) gums. The subjects also used the larger stick-shaped 
gums longer than the smaller tab or pellet-shaped gums. As a result, the chewing gum that 
combines peppermint taste with a stick shape (PM-S) was used longer than any of the other 
gums (Table 5). 
The questionnaire revealed significant gender effects for several taste items as well as for 
the willingness to use chewing gum for several weeks. This gender effect on taste preferences 
seems at variance with other studies, reporting no gender differences in taste perception 
of sweetness23,24 and threshold sensitivity to basic tastes.25 The gender effect in the present 
study was not related to the different gustatory thresholds of pregnant women,26 since these 
were excluded from the study. 
Several investigators suggested the clinical use of chewing gums for the relief of patients 
with xerostomia or hyposalivation.6,7,9,10,15 Although all chewing gums investigated in our 
study stimulated the salivary flow rate equally, the observed differences in preferences prob-
ably may influence compliance during long-term use. Therefore, factors like taste, shape and 
size should be taken into account in the design of clinical studies, which investigate the effect 
of chewing gums in specific groups of patients.
In real life, most people will use several different brands of chewing gums. The results of 
this study apply to patient cohorts whose gum use is supervised. In addition, the selected 
criteria (flow rate and pH) represent just two of a multitude of biological parameters that 
could be used to rank chewing gums for potential use in patients with xerostomia.
Our study has been limited to dental students without systemic diseases, having a good oral 
health and normal salivary flow rates.27 An altered taste has been reported in elder individu-
als,25 patients with reduced salivary flow rates,28 diabetics,29 and in patients on hemodialysis.30 
This might have influenced the preferences for the chewing gums. Taste preferences may 
also vary among populations due to environmental, behavioural, demographic and other 
reasons. Therefore, we recommend that the preferences for chewing gums are tested in pa-
tients before the start of long-term clinical studies, in order to identify the most appreciated 
chewing gum for each specific group of patients and to get optimal patient compliance.
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Onderzoek doen is boeiend, verrijkend en leuk. Mijn vreugde over het verloop en de afron-
ding van dit project is, mede gezien het multidisciplinaire karakter, dan ook groot. Dit proef-
schrift, op het grensvlak van geneeskunde, tandheelkunde en biochemie, is tot stand komen 
dankzij de blijvende inzet en het enthousiasme van een grote en diverse groep mensen die 
ik daar dan ook in het bijzonder voor wil bedanken. 
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onderzoek. Wellicht had je als nefroloog nooit kunnen denken ooit promotor te zijn van een 
tandarts. Je waardevolle bijdrage uit de nefrologie, scherpe blik, open karakter en Amster-
damse verkoopmentaliteit worden zeer gewaardeerd.
Dr. B.M. van Amerongen, copromotor. Beste Barbara, een bijzonder moment voor ons bei-
den. Je was de onmisbare schakel bij het tot stand komen en opzetten van dit toch wel grote 
en veelkleurige project. Schakel tussen de nefrologie en de tandheelkunde en tegelijk ook 
tussen de tandartsen en biochemici. Je doorzettingsvermogen, kritische blik, nauwgezetheid, 
blijvende inzet en betrokkenheid heb ik zeer gewaardeerd. Op de juiste momenten stuurde 
je bij. Waar je ook in de wereld was, je stond altijd voor me klaar. Hartelijk dank daarvoor.
Dr. H.S. Brand, copromotor. Beste Henk, honderden uren zaten we naast elkaar. Soms stil-
zwijgend, ijverig aan het werk voor ‘het bureau’, ‘het gesticht’ of ‘gene zijde’. Je was altijd flui-
tend, zingend, neuriënd, opgewekt, luid typend, vol goede moed en stimulerend aanwezig. 
Zonder jouw pragmatische aanpak, doeltreffende schrijfwijze en ijver had dit proefschrift 
er ongetwijfeld anders uitgezien. Dank voor je vriendschap, persoonlijke betrokkenheid en 
openheid.
Prof. dr. E.C.I. Veerman, (dr. V.) Beste Enno, jouw brede belangstelling, onnavolgbare inte-
resse en biochemische inzichten waren verrijkend en boeiend, zowel voor de inhoud van dit 
proefschrift als voor mijzelf. Je leerde me scherp, compact, kritisch en ‘to-the-point’ formule-
ren. Het is me een genoegen dat ik je mocht leren kennen.
Mevr. M. Valentijn-Benz, paranimf. Lieve Marianne, mensen zoals jij zijn schaars en moeten 
gekoesterd worden. Altijd opgewekt, positief, vrolijk, betrokken, enthousiast, stimulerend, 
betrouwbaar, nauwkeurig en systematisch. Op de meest uiteenlopende tijden van de dag 
moest soms gewerkt worden, en je was er, altijd. Om 7:00 uur ’s morgens in de weer met vers 
speeksel en zonder probleem om 23:00 uur ’s avonds nog in het donkere lab. Jouw inzet en 
betrokkenheid zijn essentieel geweest voor het doen slagen van dit project. Je was als een 







Dr. G.K. Hovingh, paranimf. Beste Kees, in gedachten ga ik terug naar de voorbereidingen 
voor het eindexamen scheikunde. Samen in een witte labjas op zolder studeren om zo dicht 
mogelijk bij het scheikundige gevoel te komen. Een vertrouwd gevoel om dan nu samen dit 
proefschrift te mogen verdedigen. Je Groningse nuchterheid, levensvisie, sportieve krach-
ten, rijke woordenschat maar bovenal warme vriendschap waardeer ik zeer. Marije, Hidde en 
Dees, jullie hebben een supervent en -papa.
De heren prof. dr. F. Lagerlöf, prof. dr. E.C.I. Veerman, prof. dr. A. Vissink, dr. ir. P.D. Bezemer, 
dr. J.H.G. Poorterman en dr. R.M. Valentijn wil ik allen hartelijk dank zeggen voor hun betrok-
kenheid bij het onderzoek en de bereidwilligheid zitting te nemen in de promotiecommis-
sie. Hej Folke, actually you stood at the initial step of my academic career. It was a pleasure 
to be in Stockholm at the Karolinska Institutet and to work with you. You have shown that 
enjoying life and research fits perfectly. Folke, tack so mücke. Beste Arjan, ‘speekselgoeroe uit 
het Noorden’ dank voor je constructieve commentaar op het manuscript en je enthousiasme 
over dit onderzoek. Dick, jouw epidemiologische adviezen op cruciale momenten van het 
onderzoek waren onontbeerlijk. Beste Jan, collega, ‘mental-coach’ en vriend. Betrouwbaar, 
loyaal, analyserend, relativerend en hartelijk. Dank voor je prettige aanwezigheid, klinische 
blik en inzicht. Het is vertrouwd en goed te weten dat iemand altijd voor je klaar staat. Je 
advies dat er belangrijkere zaken in het leven zijn dan werken aan een proefschrift heb ik 
zeker ter harte genomen. Rob, dank voor je waardevolle commentaren én voor het lenen van 
‘je meisje’.
Grote dank gaat uit naar alle patiënten die, ondanks de veelal moeilijke omstandigheden, 
trouw deelgenomen hebben aan dit onderzoek gedurende de afgelopen jaren. In het bijzon-
der wil ik stilstaan bij hen die onbaatzuchtig een bijdrage wilden leveren voor de toekomsti-
ge generatie patiënten, maar vroegtijdig zijn overleden. Werken en onderzoek doen in deze 
omstandigheden was regelmatig zwaar en maakt je bewust van je kwetsbaarheid als mens. 
De nefrologen, dialyseverpleegkundigen, het secretariaat en facilitair personeel van Dianet 
Amsterdam, Dianet Utrecht, de dialyseafdelingen van de Vrije Universiteit Medisch Centrum 
en het Rode Kruis Ziekenhuis wil ik danken voor hun aandeel in het project en de dagelijkse 
inzet voor de patiënten. Zonder jullie support en positieve houding zou het onmogelijk ge-
weest zijn ingang te vinden bij de dialysepatiënten. Ingrid Keur, Joost Bijlsma, Pieter Vos, 
Menno Kooistra in het bijzonder dank voor jullie medewerking en inbreng tijdens het gehele 
onderzoek. Ook dank ik de dialyseafdelingen van het Medisch Centrum Alkmaar en het Uni-
versitair Medisch Centrum Utrecht voor hun gastvrijheid.
Het verhaal gaat dat op grote hoogte, tijdens een intercontinentale vlucht, de kiem voor 
dit onderzoek is gelegd. Ik dank Paul Stevens en Piet ter Wee dan ook hartelijk voor het plan-
ten van het onderzoeksidee in goede aarde. De Nierstichting wil ik danken voor de mogelijk-
heid om dit onderzoek te starten. Prof. dr. J.M. ten Cate, beste Bob, hartelijk dank voor het 
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de uitvoering van dit onderzoek. Dank voor de warmte en liefde die jullie geven. Ik hoop dat 
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ACE Angiotensin Converting Enzyme
ACTA Academic Center for Dentistry Amsterdam
AQP Aquaporines
CAPD Continuous Ambulantory Periotoneal Dialysis
CCPD Continuous Cycler-Assisted Periotoneal Dialysis
CH-SWS Chewing stimulated whole saliva
CRF Chronic Renal Failure
DBP Diastolic Blood Pressure
DIAL Dialysis
DMFS Decayed Missing Filled Surfaces
DMFT Decayed Missing Filled Teeth
DS Decayed Surfaces
DT Decayed Teeth
DTI Dialysis Thirst Inventory
EDTA-ERA European Dialysis and Transplantation Association-European Renal 
Association
ELISA Enzyme-Linked Immunosorbent Assay





IOT The Netherlands Institute for Dental Sciences
IWG Interdialytic Weight Gain
KDQOL Kidney Disease Quality of Life
KDQOL-SF Kidney Disease Quality of Life- Short Version
Kt/V Removal of urea by dialysis a week
LO-P Liquorice Original
LPA Level of Periodontal Attachment
MS Missing Surfaces
MT Missing Teeth






QoL Quality of Life










SBP Systolic Blood Pressure
SD Standard Deviation
S-IgA Secretory Immunoglobulin A
SM-P Freedent Sweetmint
SOHI Simplified Oral Hygiene Index
SWS Chewing Stimulated Whole Saliva
TDS Thirst Distress Scale
UWS Unstimulated Whole Saliva
VAS Visual Analogue Scale
VUMC Vrije Universiteit Medical Center
WF-P Freedent Winterfresh
WF-S Orbit Winterfresh
WF-T Extra Winterfresh
XI Xerostomia Inventory
